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SUMMARY 
Cells sense the mechanical environment, actively or passively, through membrane 
embedded proteins named mechano-receptors. The binding force is generated once 
the mechano-receptor engages its immobilized ligand. The received mechanical signal 
propagates along the structure of the receptor and across the membrane, which is 
often accompanied and realized by local or global conformation changes of the 
receptor. Usually through allosteric mechanisms, which are not fully understood, this 
signal is converted into intracellular chemical signals – a procedure termed 
mechanotransduction – which then generates an elaborate response that mediates cell 
survival, proliferation, differentiation, migration and other physiological or 
pathological functions, thereby completes the whole mechanosensing process. 
Integrins form a superfamily of adhesion mechano-receptors. Their 
mechanotransduction functions are realized by the various conformational changes, 
which enables bidirectional transduction of signaling, and the regulation of integrin 
binding kinetics. On platelet surface, multiple types of integrins are expressed, 
including αIIbβ3, αVβ3, α5β1, αMβ2 and more. They enable platelet communication 
with the adjacent extracellular matrix and cells by binding to their respective 
counterparts, which involves probably subsequent conformational changes. Thus, 
studying the binding kinetics and molecular dynamics of integrins enables deep 
inspection of the linkage between their molecular structure and physiological 
functions. 
XXI 
The mechanosensing of platelets play a critical role in the proceeding hemostasis 
and thrombosis, especially in the arterial environments where shear forces become 
large, and soluble stimulating molecules can be easily dissipated by high-speed flow. 
In this context, two mechano-receptors - GPIbα and integrin αIIbβ3 - mediate the early 
and mid-stages of platelet adhesion and activation through mechanotransduction. The 
mechanosensing involves a cascade of molecular and cellular reactions in response to 
the force, which finally realize: 1) enhanced binding capacity of the receptors; and 2) 
signal transduction that leads to the activation of platelets via intracellular signaling. 
However, how platelets distinguish mechanical signals received from GPIbα and 
integrin αIIbβ3 and respond accordingly and precisely largely remain unknown. 
In this thesis, I describe my Ph.D. researches on integrin dynamics and platelet 
GPIbα and integrin αIIbβ3 mechanosensing. I put myself in the shoes of an engineer, 
and regarded the platelet and its receptors as delicate machinery to addressed four 
questions: 1) how integrin conformational changes are associated with its binding 
kinetics and activities; 2) how is the mechanical signals in different waveforms 
deciphered and converted into corresponding chemical signals by platelets, and what 
is the required mechanical signal for GPIbα and integrin αIIbβ3 mechanosensing? 3) 
what is the underlying molecular mechanisms for the signal to propagate through the 
cell membrane and realize mechanical-to-chemical transfer? and 4) what is the 
difference in the results of GPIbα and integrin αIIbβ3 mechanosensing as compared to 
platelet activation by soluble stimulus? My studies were carried out surrounding the 
XXII 
above questions, which brought us new biomechanical insights on integrin dynamics 
and platelets adhesion and signaling: 
1) Integrin conformational dynamics and binding kinetics: using a cutting-edge 
force spectroscopy, biomembrane force probe (BFP), it was discovered that 
integrin αVβ3 undergoes bending and unbending conformational changes in a 
dynamic fashion. This process does not require energetic or signaling support 
from a cell. The probability, rate and speed of these bending and unbending 
conformational changes are regulated by mechanical force, ligand, integrin 
genotype, cation and purified/cellular environment. In somewhat 
disagreement to conventional perspective that unbending is associated with 
integrin activation, force-enabled αVβ3 unbending does not reinforce the 
strength of its binding in the physiological Ca2+/Mg2+, but does in Mn2+. 
2) GPIbα-mediated mechanotransduction: Using an upgraded, 
fluorescence-enabled BFP which manipulated a single human platelet, we 
showed the ability of a single GPIbα-VWFA1 binding event to trigger platelet 
intracellular Ca2+ flux. A positive correlation was found between the binding 
duration (lifetime) and the intensity of the Ca2+ signal, so that the signaling is 
stronger triggered by WT VWF-A1 (A1WT) at higher forces because of its 
catch-bond behavior, but weaker by a Von Willibrand disease (VWD) mutant 
R1450E which manifest a slip-bond. This suggests a new concept about VWD: 
signaling deficiency. Unfolding of two domains of the GPIbα structure, 
lucine-rich-repeat (LRRD) and mechanosensitive (MSD) domains, mediates 
XXIII 
the signal transduction in that, LRRD unfolding prolongs the binding lifetime 
and analogously enhances signaling intensity, whereas MSD unfolding 
digitally affects the fluxed Ca2+ type. Abolishment the binding of a 
cytoplasmic molecule 14-3-3ζ to GPIb complex depleted most of the α-type 
Ca2+. The strong correlation between mechanical force, structural 
conformational changes and molecular association of GPIbα, and the 
amplitude and type of the resulted Ca2+ signal suggested that GPIb together 
with its functionally adjacent molecules form a molecular mechanosensor. 
3) GPIbα-triggered platelet activation: I invented a new dual-BFP approach that 
studies the adhesion molecules’ inter-talk on platelet surface. It was found 
that the mechanotransduction of GPIbα leads to an intermediate level of 
integrin αIIbβ3 activation, P-selectin expression and phosphatidylserine 
exposure as compared to ADP and thrombin, two soluble platelet activators, 
which suggests that GPIbα triggers platelets into an intermediate activation 
state. The intermediate up-regulation of αIIbβ3 is unstable and transient, but is 
important in that it opens the pathway of integrin mechanotransduction 
mediated outside-in signaling, so that the αIIbβ3 can be further activated 
through repeated binding and pulling of ligand. This defines cooperation 
between integrin inside-out and outside-in mechano-signaling. On the other 
hand, ADP-activated αIIbβ3 can also be further activated via outside-in 
mechano-signaling to a hyperactive state. Overall, my study discovered a 
four-stage regulation of platelet αIIbβ3 by bidirectional signaling. 
XXIV 
These studies altogether accomplished a step forward in the field of biomechanics 
and biophysics, and provide mechanistic insights in platelet physiology and 
mechanobiology. The technical innovations I made including micro-space 
temperature controlling, which allows BFP experiments to be done in a physiological 
thermal environment, and dual BFP, which can study inter-talk of heterogeneous 
receptors on the same cell during mechanosensing, should facilitate the future 
development of single-cell mechanobiology. 
Finally, I extended my research to tentatively investigate atherothrombosis in 
type I and II diabetes. I found that platelet hyperreactivity in diabetes is closely 
associated with enhanced adhesive capacity and exaggerated mechano-signaling of 
GPIbα and integrin αIIbβ3. These results imply the medical importance of my research, 




CHAPTER 1: INTRODUCTION 
1.1 Specific aims 
Platelets are a key player in both hemostasis (the physiological process of blood 
cessation after blood vessel injuries) and thrombosis (pathological blood clotting). 
Upon a vascular injury, the platelets adhere to the sub-endothelium and attach to each 
other, so as to form an aggregation to block the injury site and stop the bleeding. 
Meanwhile, the adhesion of platelets through surface adhesion receptors triggers 
signals in a force-dependent fashion, which is transmitted into the cell and stimulates 
platelet activation, a process termed platelet mechanosensing. Specifically, two 
platelet receptors - GPIbα and integrin αIIbβ3 - mediate the early to mid-stages of 
platelet adhesion and activation, especially in the arterial environments and under 
pathological conditions where shear rates are high. Glycoprotein Ibα (GPIbα) is a 
major part of the GPIbα-V-IX complex that constitutes the receptor for von 
Willebrand factor (VWF). Its binding to VWF at the A1 domain (VWF-A1) enables 
rolling (translocation) of platelets on the sites of vascular injury. Integrin αIIbβ3, also 
known as glycoprotein IIb/IIIa, allows for platelet stable adhesion to VWF on the 
surface of sub-endothelium and promotes the expansion of the platelet aggregates by 
cross-linking via ligands like soluble fibrinogen and fibronectin. Both GPIbα and 
αIIbβ3 has been reported to trigger outside-in platelet-activating signals under forces 
via ligation, which suggests that both molecules are involved in the platelet 
mechanosensing. In my Ph.D. works, I studied platelet surface GPIbα and αIIbβ3 in 
2 
the context of adhesion and signaling. The goal is to figure out the respective 
mechanisms of GPIbα- and αIIbβ3-mechated platelet mechanosensing and their 
physiological and pathological importance in the context of platelet functioning. I 
conducted single-molecular level experiments with a fluorescence biomembrane force 
probe (fBFP) to systematically correlate mechanically dependent GPIbα and αIIbβ3 
ligation with readouts of platelet activation including platelet intracellular Ca2+ signal, 
integrin up-regulation, P-selectin expression, phosphatidylserine (PS) scrambling on 
the plasma membrane. Following three aims were formed:  
Aim 1: Characterize integrin binding affinity regulation and bending/unbending 
conformational changes.  
Integrins are a family of adhesion molecules that are able to adopt multiple 
conformational states, which allows regulation of their affinity in ligands binding. 
Under this aim I used purified αVβ3 – another β3 integrin that has a high structural 
similarity to αIIbβ3 – to gain insights in its molecular basis for dynamically 
transitioning between multiple affinity states and conformational states, which were 
hypothesized to be determined by the flexible structure and affected by the 
environmental conditions. We used a BFP and a HS-AFM to conduct the experiments 
in the following steps: 
i) Use a BFP to analyze the single-bond lifetime of αVβ3-fibronectin interaction 
in two cation conditions: Ca2+/Mg2+ (physiological-mimicking) and Mn2+ (artificially 
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activating). Also, study the impact of WOW-1, an antibody that specifically blocks 
the binding of activated αVβ3, on the binding kinetics. 
ii) Use a BFP to observe the bending/unbending conformational changes of αVβ3 
under a tensile force. The conformational changes were characterized by the 
bending/unbending distance, time-to-bend/extend and switch time under all forces. 
Results from Ca2+/Mg2+ and Mn2+ were compared to render the impact of integrin 
activation to the conformation regulation. The lifetime-after-bend/extend was 
collected to reflect how the bending/unbending of the integrin affects its binding 
capacity. 
iii) Use a HS-AFM to observe the bending/unbending conformational changes of 
αVβ3 under zero-force. By seeding the integrin molecules onto a mica surface and 
scanning with a super-sensitive cantilever tip, HS-AFM allows real-time imaging of a 
single integrin with high temporal and spacial resolutions, and for the first time 
directly revealed the dynamic integrin conformational changes. Parameters collected 
from this section, including the bending/unbending distance, time-to-bend/extend and 
switch time were used as an extrapolation of the BFP results at zero-force, which is in 
benign agreement with the BFP results. 
Besides, another integrin, αMβ2 (MAC-1), was also used in a collaborative 
lupus-associated project that measures its conformation and binding, and the impacts 
of mutations. 
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Considering that integrin adhesion and conformation could be used as solid 
readouts of integrin activity, the research in this aim provide critical fundaments for 
the following studies and add significance to the overall thesis. 
Aim 2: Investigate the GPIbα-mediated platelet mechanotransduction.  
GPIbα is the primary adhesion receptor that enables initial platelet recruitment to 
the vascular injury site by binding to immobilized VWF multimers. This binding also 
initiates a platelet signaling that leads to transient intracellular Ca2+ flux and αIIbβ3 
up-regulation. The studies under this aim intended to correlate GPIbα adhesion to its 
mediated platelet signaling. Several key questions were addressed: 
i) In GPIbα mechanotransduction, what attributes are meaningful in the input 
mechanical signal in the sense that they can be distinguished by the platelet and affect 
the output chemical signal? To answer this question, we consider the GPIb signaling 
pathway as fine machinery, which receives certain input signals and precisely 
produces corresponding output signals. fBFP was used in this study. By manipulating 
the GPIbα binding on a single-molecular level and using intraplatelet Ca2+ flux as 
readout of signaling, it was discovered that GPIbα triggers outside-in signaling in a 
force-, bond duration (lifetime)- and ligand- dependent manner. Among them, durable 
force pulling is indispensable for activating signaling, while in the presence of 
lifetime, force amplitude positively correlates with signaling strength. 
ii) How is the GPIbα mechanotransduction realized in the molecular level? 
Specifically, how could a molecule complex read the information contained in a 
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mechanical stimulation and translates it into a chemical signal? Of note, previous 
publications have suggested that certain domains of GPIbα may act as a signal 
transducer. In our investigation, we discovered that the unfolding of GPIbα 
mechano-sensitive domain (MSD), and the direct binding of a cytoplasmic molecule, 
14-3-3ζ, to the tail of GPIbα and GPIbβ mediate the transduction of GPIb signaling. 
Aim 3: Investigate the downstream consequence of GPIbα-mediated platelet 
mechanotransduction.  
What is the physiological significance of GPIbα mechanotransduction? GPIbα 
signaling has been suggested to be trivial as compared to GPIV, another receptor that 
mediates initial platelet recruitment and signaling. However, scientific evidences also 
show that lack of GPIbα signaling results in drastic hemostatic deficiency in vitro and 
in vivo. In this section I studied the platelet activation consequence of 
GPIbα-mediated mechano-signaling. Using a BFP, we found that GPIbα 
mechanotransduction leads to several critical signs of platelet activation, which 
defines a new activation state of platelets: 
1) Integrin αIIbβ3 up-regulation. The activation of αIIbβ3 by GPIbα signaling has 
been observed and acknowledged for long, but no work has quantified this activation 
in a single molecular level. Integrins could adopt multiple ligand binding states. For 
example, αLβ2 possesses at least three dissociation rate states. Based on functional 
studies, people conventionally believe that αIIbβ3 only possesses two states, an 
inactive state and an activated state. Surprisingly, our investigation discovered a new 
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intermediate state that exists in αIIbβ3, which is not simply realized by the mixture of 
the two conventionally acknowledged states, but has its independent molecular 
conformation, ligand binding affinity and regulatory mechanisms. The αIIbβ3 
up-regulation by GPIbα signaling, ADP or thrombin stimulation is realized by the 
shift of the equilibrium among all three states to different extent, which realizes varied 
overall binding capacities. 
2) P-selectin expression. The expression of P-selectin following GPIbα 
mechanotransduction is an unexpected discovery, because GPIbα signaling is 
conventionally believed trivial and not powerful enough to trigger α-granule release. 
What is more puzzling is that the binding strength of the expressed P-selectin decayed 
over time, suggesting this process might be reversible. 
3) Phosphatidylserine (PS) exposure. The PS exposure has been shown to 
strongly rely on the action of shear force onto platelets. Agreeing with that, force 
pulling on GPIbα could trigger PS exposure.  
1.2 Background and significance 
1.2.1. Hemostasis and thrombosis 
The primary physiological role of platelets is to facilitate hemostasis, namely, to 
prevent hemorrhage after injury by preserving vascular integrity1-3. Upon 
sub-endothelium exposure due to blood vessel injury, circulating platelets embark on 
a cascade of well-coordinated events including adhesion and aggregation on the 
exposed sub-endothelium and ultimately result in stable thrombus formation to repair 
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the damaged blood vessel and stop bleeding. Thrombosis describes the formation of a 
blood clot (thrombus) inside a blood vessel, obstructing the flow of blood through the 
circulatory system. It occurs either together with hemostasis as triggered by a vascular 
injury and bleeding, or independent of injuries under certain pathological conditions. 
Certain diseases including diabetes, obesity and hypertension have high risks of 
severe thrombosis, which produces thrombus’s that are significantly large enough to 
reduce the blood flow to a tissue or even completely occlude the whole blood vessel. 
This may lead to myocardial infarction and ischemic stroke, claiming one in each four 
deaths worldwide. As the two sides of the coin, platelets play a critical role in 
hemostasis, but also contribute significantly to pathological thrombosis2,4,5.  
1.2.2. Platelets in shear-dependent hemostasis 
In the early and mid-stages of hemostasis, multiple receptor-ligand interactions 
function to recruit and attach platelet onto the injury site (Fig. 1-1). The early stage 
adhesion is mediated by the platelet receptors GPVI and GPIb-IX-V in parallel (Fig. 
1-1). Depending on the amplitude of the shear force in the blood vessel, one or the 
other of them will play a primary role6,7. In veins and small arteries where blood flow 
is relatively slow (< 500 s-1), the initiation of platelet recruitment cascade majorly 
mediated by GPVI-collagen interaction, which realizes stable adhesion at low forces6. 
However, under high shear rates (> 800 s-1), which are usually present in arteries and 
arterioles or at pathological situations such as restricted lumen in atherosclerosis, 
GPVI-collagen interaction becomes too weak to resist the high shear force. Instead, 
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the adhesive interaction between platelet surface GPIbα-IX-V and the collagen- and 
endothelium-bound VWF strings enables platelet rolling (translocation) on the 
exposed sub-endothelium6,8. Both the GPIb-VWF interaction and GPVI-collagen 
interaction trigger outside-in signaling across the cell membrane, inducing 
downstream activation effects like cytoplasmic Ca2+ intensity increase and integrins 
activation9-11. This activation promotes multiple integrins from a non-adhesive 
low-affinity state to a high-affinity state, which becomes able to mediate firm 
arrestment and aggregation10,11. 
1.2.3. GPIb-IX-V and VWF 
The GPIb-IX-V complex is composed of four glycoproteins - GPIbα, GPIbβ, 
GPIX, and GPV with a ratio of 2:4:2:1 (Fig. 1-2 A)12,13. GPIbα is covalently 
connected with the two GPIbβs with a disulfide bond at the membrane-proximal end 
of the ectodomain, while GPIX and GPV are noncovalently associated with the 
complex14. By interacting with sub-endothelium-bound VWF through its major 
ligand-binding subunit GPIbα, it enables slow rolling of platelets on the surface of 
injured arteries and the initiation of platelet activation. This interaction also transmits 
mechano-signal that activates integrin αIIbβ3. 
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Figure 1-1. A model of primary hemostasis in blood flow. Platelets are firstly recruited 
through the specific interactions of GPVI and fibrillar collagen as well as GPIb-IX-V 
complex and collagen-bound VWF. Stable platelet adhesion occurs through the binding of 
platelet GPVI to fibrillar collagen6. These early stage adhesions stimulate platelets to 
undergo a series of biochemical changes that induce integrins activation, leading to their 
high affinity interactions with adhesion proteins, which include α2β1-collagen interaction6, 
α5β1-fibronectin interaction (not shown in this illustration)15, 
αVβ3-fibronectin/fibrinogen/VWF interactions (not shown in this illustration)15, and most 
importantly, the interactions between αIIbβ3 and fibronectin, fibrinogen and VWF15. These 
adhesive interactions are indispensable in the ability of platelets to form stable aggregates 
with other activated platelets and promote thrombus growth. 
GPIbα is a 145 kDa membrane surface protein that is composed of an ectodomain 
(489 amino acids (a.a.)), a transmembrane domain (21 a.a.) and a cytoplasmic domain 
(100 a.a.). Its ectodomain includes a Lucine Rich Repeat domain (LRRD) which 
contains the binding site for its ligand VWF-A1, and a long stalk (macroglycopeptide) 
that connects it to the transmembrane domain (Figure 1-2 B)16. Lack of GPIbα causes 
a congenital bleeding disorder – Bernard-Soulier syndrome, as well as severe defects 
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in both hemostasis and arterial thrombosis mouse models, claiming its 
indispensability in platelet function17,18. GPIbβ is a transmembrane protein much 
shorter than GPIbα with 121 extracellular, 25 transmembrane and 34 cytoplasmic 
amino acids, which are comparable to GPIX. No ligand binding site is found on the 
ectodomain of GPIbβ and GPIX, and no evidence has directly shown their 
functionality in the cell behavior. It is postulated that GPIbβ facilitates GPIb-IX-V 
mechano-signaling by juxtamembrane domain motional change16,19. Nonetheless, 
their absence causes complete elimination or severe reduction of GPIbα expression on 
platelet surface, which results in phenotypes of Bernard-Soulier syndromes14. This 
indicates that GPIbα forms a complex with GPIbβ and GPIX before expressed on cell 
surface.  
VWF is a disulfide bonded multimeric glycoprotein that circulates in the blood 
stream. It is secreted by both endothelial cells and activated platelets. Its 
multimerization is realized by disulfide bond linkage on both termini homogeneously 
in an N-N and C-C manner. Endothelial cells initially secrete ultralarge forms of 
VWF (ULVWF), which are hyperactive and has exaggerated capacity in binding to 
platelet GPIbα. ULVWF is quickly cleaved by the plasma protease ADAMTS13 at 
the A2 domain to yield smaller and less active plasma VWF (pVWF) (Fig. 1-2 C), 
whose molecular weight typically exceeds 1,000 kDa20. Each monomer of VWF 
consists of a number of functional domains, of which the A1 domain binds to both 
GPIbα and collagen, the A3 domain only binds to collagen, and the C1 domain binds 
to β3 integrins (Fig. 1-2 C). In the platelet recruitment cascade, VWF acts as an 
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essential cross-linker between platelets and the sub-endothelium by interacting with 
GPIbα and β3 integrins on platelet surface and interacting with collagen on the 
sub-endothelium or endothelial cells adjacent to the injury site6,8,21.  
The behavior of adhesions is mainly determined by kinetics (on-/off-rate 
constants) of its receptor-ligand systems. The binding between GPIbα and VWF-A1 
features fast on-rate (kon) and off-rate (koff), resulting in rapid bond formation, but also 
rapid breaks. Because of its relatively low affinity (as calculated by Ka = kon / koff), this 
binding does not support firm adhesion but translocation on the sub-endothelium22-24; 
nonetheless, it is the only adhesion capable of slowing the platelets down while 
resisting the high shear forces in the arteries by inactive discoid platelets 6. 
1.2.4. Integrin αIIbβ3 and its ligands 
Integrin, cadherin, selectin and Ig CAM superfamily are the four adhesion 
receptor families in human. They play central roles in cellular interactions with 
neighboring cells and the extracellular matrix25. Members of the integrin family 
primarily act as receptors for extracellular matrix (ECM) proteins15,25,26, but could 
also form adhesions with hetero-species cells15,27-30. Each integrin is a heterodimer 
composed of an α and a β subunit; each subunit has a large extracellular domain, a 
single membrane spanning region, and a short cytoplasmic domain (except for the β4 
subunit)25,31. The integrin receptor family of vertebrates includes at least 18 distinct α 
subunits and 8 β subunits, which creates a total of 24 different combinations that have 
been identified to date at the protein level 15,32. Among them, platelets constantly 
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express integrins αVβ3, α2β1, α6β1, α5β1, and most abundantly, αIIbβ3 on their 
surface33-37. In addition, activated but not resting platelets have been reported to 
express αLβ2 (LFA-1) and αLβ2 (Mac-1), two integrins that mainly function in the 
adhesion and migration of leukocytes i.e. monocytes and neutrophils38.  
 
Figure 1-2. GPIb-V-IX complex and VWF. (A) Scheme of the GPIbα-V-IX complex 
arrangement on a cell membrane surface. GPIb-IX-V complex is composed of four 
glycoproteins - GPIbα, GPIbβ, GPIX, and GPV. Solid blue lines indicate interactions 
between the members; dashed blue lines indicate potential interactions. (B) Scheme of a 
GPIbα inserted into a membrane bilayer. The binding epitopes for VWF-A1 and antibodies 
are indicated on the protein structure. The portions of the ectodomain that correspond to LRR 
and MP are indicated by green square brackets. (C) Domain organization of a VWF 
monomer. VWF contain a triplicate repeat sequence of A domains in the central portion of 
the 2,050-residue mature subunit (D’-D3-A1-A2-A3-D4-B-C). 
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Integrin αIIbβ3 (also known as glycoprotein IIb/IIIa, GPIIb/IIIa) is found mainly 
on platelets, which composes of an integrin αIIb subunit and an integrin β3 subunit 
(Fig. 1-3). Like other β3 integrins and all β1 integrins, αIIbβ3 is in lack of an αI 
domain at the top of its α subunit β-propeller domain, which can be seen in all β2 
integrins, and its epitope for ligand binding resides in between of the β-propeller and 
βI domain. Other than VWF, its ligands also include plasma proteins fibrinogen and 
fibronectin15. On inactive and discoid platelets, it remains in a low-affinity state which 
barely binds to its ligands. Upon activation, it becomes highly adhesive and plays a 
dominant role in platelet firm arrest and aggregation39. αIIbβ3 could be activated by 
both inside-out signaling, which involves binding of talin and kindlin to the β3 
cytoplasmic domain and the separation of the αIIb and β3 at the transmembrane and 
cytoplasmic domains, and outside-in signaling, which requires ligation of an agonist 
at its headpiece and the downward signal transmission in a structurally allosteric 
fashion36,40-44. The primed αIIbβ3 can also be suppressed by certain anti-platelet agents 
(e.g., Rap1 and PI3 kinase inhibitors)45. Evidence has been found that αIIbβ3 
activation/inactivation accompanies global conformational changes of its own 
structure41,46-48. The activity of αIIbβ3 also mediates heterotypic cell-cell interactions 
of other cell species like tumor and endothelial cells 49. 
Fibrinogen is the primary ligand of αIIbβ3 in the process of platelet aggregation. It 
exists in the blood stream, and is secreted by activated platelets. It has a dimerized 
structure, containing two sets of intertwine of three chains (α, β and γ). Each 
monomeric fraction of fibrinogen bears three sites for integrin binding: two RGD 
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sequences in the Aα chain which applies to the binding of αIIbβ3, αVβ3 and α5β1, and 
one AGDV sequence in the C-terminus of γ chain which is specific for αIIbβ350. The 
symmetric structure of fibrinogen with multiple binding sites together with a 
molecular length of ~50 nm makes it perfect glue to crosslink platelets to form an 
aggregate. 
 
Figure 1-3. Structures of β3 and β1 integrins (A), fibrinogen (B) and fibronectin (C). (A) the 
extracellular fraction of α subunit is composed of β-propeller, thigh, genu, calf-1 and calf-2, 
while that of β subunit is composed of βI, hybrid domain, PSI, EGF1, EGF2, EGF3, EGF4 
and βTD (all indicated). (B) One fibrinogen molecule is made up from two sets of α, β and γ 
chains. The epitopes for integrin binding (RGD and AGDV a.a. sequences) are indicated. (C) 
Each fibronectin contains four classes of domains (FN1, FNII, FNIII and IIICS). The 8th, 9th 
and 10th module of FNIII (FNIII8-10) bear all the epitopes that are important for interacting 
with integrins (all indicated). 
Fibronectin is a glycoprotein of the extracellular matrix with a molecular length 
of ~15 nm. Just like fibrinogen, it exists both in the blood stream and the α-granules 
of platelets. Fibronectin is a physiological ligand for multiple integrins, which, except 
for hemostasis, also plays a critical role in the cell-ECM interactions and focal 
adhesion. Specifically, FNIII10 contains the RGD sequence26,51,52; FNIII9 bears a 
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synergy site that reinforces the α5β1-FNIII10 interaction, but seems to have no effect to 
the anchorage of β3 integrins (Fig. 1-3 C)53. Fibronectin binds to fibrinogen at the 
Aα221−391 region only when the fibrinogen is converted by thrombin to fibrin54. 
During platelets aggregation, blood plasma fibronectin molecules attach to the 
activated platelets on the aggregate surface, and act as a cross-linker to attract more 
inactive platelets55,56. 
 
Figure 1-4. Sketches of the three global conformational changes that integrins may undergo: 
ectodomain bending/extending (A), cytoplasmic domain closing/opening (B) and hybrid 
domain swing-in/out (C). 
1.2.5. Integrin affinity and conformational changes 
Integrins adopt different functional states under different conditions. In the 
inactive state, integrins have extremely low affinities for ligand binding, which will be 
drastically up-regulated upon activation. So far, this multi-affinity property have been 
verified in integrin α5β1, αLβ2 (LFA-1), and αIIbβ3 in single molecular level26,29,57,58. 
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In the meanwhile, owing to the flexible molecular structure, integrins adopt multiple 
global conformations, including a bent /extended ectodomain, a closed/opened tail 
and swing-in/out of the β chain hybrid domain, which were observed by EM47,59,60, 
crystallography59, and antibody mapping61,62 (Fig. 1-4). In these studies, the integrin 
conformation was strongly affected by the cation conditions, talin-head binding and 
certain activating antibodies which all affect integrin binding capacity, indicating that 
integrin conformation has strong correlation with function. Among them, talin 
recruitment is one of the two major physiological manners of cell surface integrin 
activation, which docks in between of the integrin transmembrane domains and causes 
tail unclasping via steric effects, and in turn results in extodomain extension by 
allosteric effects40,46. In parallel, a pulling force through ligand binding also induces 
integrin activation and conformational changes via allosteric effects. A recent 
research from our lab observed and characterized integrin LFA-1 ectodomain 
bending/unbending conformational change in real-time, which for the first time 
revealed this process in a dynamic manner and confirmed that: 1) integrins under bent 
or extended conformations have diverse binding affinities and 2) force breaks the 
bending/unbending equilibrium and facilitates extension63. However, the mechanistic 
details of integrin conformational change are still missing, among which two 
intriguing questions are raised: 1) can integrins undergo conformational change 
without support from the cell, and 2) how do force and cell signaling trigger integrin 
conformational change respectively. To answer these questions, the proposed project 
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will characterize the real-time bending/unbending behavior of integrins in cell-free 
and cell-surface systems. 
1.2.6. Platelet activation 
Platelets can be activated through multiple signaling pathways: 
1) Mechano-signaling pathways: the activation of platelets via mechano-signaling 
relies on the surface receptor molecules. According to current views, the primary 
receptors that initiate mechano-signaling are GPIbα and GPVI. Through binding to 
their respective ligand (VWF and collagen) against force (see Section 1.2.2), GPIbα 
transduces intracellular signals that activate integrin αIIbβ3, while GPVI activates 
integrin α2β1, both involving the release/mobilization of the intracellular calcium 
storage (Fig. 1-5). Activated integrins adopt high-affinity association with their 
ligands, and initiate a secondary nonetheless stronger wave of mechano-signaling that 
leads to activation of other integrins (for example, αIIbβ3 adhesion is a sufficient and 
necessary pre-requisite for activating α2β164), platelet cytoskeletal deformation, α- and 
dense-granule release and more2. 
2) Chemo-signaling pathways: these include activation pathways by soluble 
agonists. The engagement of ADP (with receptors P2Y1 and P2Y12)65,66 and thrombin 
(with PAR1 and PAR4)67 both trigger strong activation, including integrin 
up-regulation, cytoskeletal remodeling, granule release, degranulation and cell death 
2,5,68.  
Several hallmarks of platelet activation are well-accepted by the field: 
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1) The activation of αIIbβ3 is a sign of platelet deriving strong adhesiveness and 
the capacity to mediate firm attachment and crosslinking. It can be detected by active 
αIIbβ3 specific antibody PAC-143, or the binding strength against ligands like 
fibrinogen and fibronectin. Similarly, the activation of other integrins like αVβ3 and 
α5β1 is also informative on the platelet activation extent. 
 
Figure 1-5. A map of platelet activation pathways. Adapted and modified from (Jackson, 
2011)2. 
2) The α- and dense-granule releases are realized only when platelets are 
substantially activated. Among the released substances, P-selectin is an easily 
detectable subject since it will be expressed on the platelet surface instead of released 
to the extracellular environment69. It adds an additional platelet-endothelium 
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interaction by binding to PSGL-1, and also allows crosstalk between platelets and 
leukocytes. 
3) Phosphatidylserine (PS) exposure. Phospholipids in the platelet membrane 
have PS enriched in the inner leaflet but not in the outer leaflet. During platelet 
activation, cytoplasmic Ca2+ intensity increases induces lipid scrambling, by which 
the PS are exposed in the outer leaflet70,71. This allows blood coagulation factors to be 
recruited to the platelet surface and convert pro-thrombin into thrombin72,73, the 
importance of which is implicated by the lipid scrambling deficiency in Scott 
syndrome74,75. It is argued in previous studies that GPVI is the major receptor that, 
upon binding to collagen under flow, induces PS exposure, while GPIbα and αIIbβ3 
only facilitate this process76. 
1.2.7. Platelet mechano-signaling 
Mechano-signaling is a process that cells rely on to sense the mechanical 
environment and react. In adhesion-mediated mechano-signaling, a specific adhesion 
receptor-ligand interaction is required. It is initiated by the cell-surface receptors 
binding to the ligand on an opposing surface (of a cell or extracellular matrix), 
followed by a tensile force exerted on to the receptor-ligand complex, which could be 
either an external force like flow shear stress or produced by the cell body 
deformation. The force acts onto the receptor as a mechanical signal, which is 
transduced across the membrane and converted into a chemical signal. After reaching 
the cytoplasm, the signal induces a series of intracellular signaling events, finally 
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resulting in certain mechanical and/or chemical reactions of the cell. A 
mechano-signaling process can be divided into four steps, taking GPIbα an example: 
1) mechanopresentation: the receptor binding domain A1 is exposed by structural 
changes in VWF induced by elongational flow and collagen immobilization77; 2) 
mechanoreception: GPIbα receives the force signal via engaging A1 to tether the 
platelet against shear stress; 3) mechanotransmission: force is propagated from the 
A1-binding GPIb N-terminal leucine rich repeat domain (LRRD) through the 
mucin-like macroglycopipetide (MP) stalk region and the juxtamembrane 
mechanosensitive domain (MSD) across the membrane to the supporting structures 
inside the platelet78; 4) mechanotransduction: force induces mechanical and 
biochemical changes, eliciting intraplatelet Ca2+ mobilization and integrin 
activation9-11. Of these, the previous three have been substantially studied, while the 
investigations on mechanotransduction in platelet molecules are still in their infancy. 
Intriguingly, how the binding kinetics manipulates signaling, and how this 
manipulation is realized by merely several cooperative molecules? This shapes up the 
central question of this thesis. 
Many platelet receptors are involved in mechano-signaling. The proposed project 
only focuses on two: GPIbα and αIIbβ3. GPIbα is the primary mechano-receptor 
during platelet activation, which is further amplified by soluble agonists (e.g., 
adenosine diphosphate (ADP) and thromboxane A2 (TXA2)) released during the 
primary activation79. Signaling through GPIbα via binding to VWF-A1 can activate 
αIIbβ3 independently of other receptors, in which Ca2+ plays an important role9. GPIbα 
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mediates transient Ca2+ concentration elevations released from the intracellular 
storage, which are designated as type α/β Ca2+ based on the pattern: type α Ca2+ 
manifest a sharp onset and a quick fading, while type β is smoother. Type α/β signals 
could be derived independently by GPIbα interacting with VWF-A110. Inhibition of 
the first stage Ca2+ release from intracellular storage by membrane permeable Ca2+ 
chelators prevents platelet firm adhesion, suggesting that Ca2+ is an obligatory 
signaling molecule on the pathway to αIIbβ3 activation10,11,80,81.  
Activated integrin αIIbβ3 initiates outside-in signaling when binding to its ligands, 
which triggers a secondary but more robust and sustained Ca2+ signal (type γ), and 
induces phosphorylation of downstream kinases (including Akt and FAK) and platelet 
spreading10,82,83. 
Previous studies have given beautiful mechanistic answers to many 
mechano-signaling systems in human cells, for example hair cells, in which force 
induces lateral motion of the hair along the cell membrane and controls the 
open/closing of ion channels84-87. In the platelet system, however, mechano-sensing 
remains poorly studied, probably due to the limitations in techniques: in previous 
studies, the activation of platelets in mechano-signaling is detected in low spatial and 
temporal resolution, and the mechanical stimulation cannot be well-controlled. With 
our unique technique Biomembrane Force Probe (BFP)88,89, we will be able to control 
receptor-ligand bond formation to single-molecular level and characterize multiple 
aspects of platelet activation with high spatial and temporal resolution, which makes it 
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a perfect weapon for observing platelet mechano-triggering. The technical details of 
BFP will be introduced later in the corresponding section. 
1.2.8. Significance 
The outcome of this project will provide knowledge about mechanical and kinetic 
regulation of platelet signaling and activation by platelet adhesion, and thus advance 
our understanding on hemostasis and blood coagulation on molecular level. Overall, 
this research has scientific and clinical significance. 
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CHAPTER 2: MATERIALS AND METHODS 
2.1 Proteins and reagents 
Recombinant WT and MTs R1450E, R1306Q and V1279I monomeric VWF 
1238-A1 (residues 1238–1471) was a generous gift from Dr. Miguel A. Cruz 
(Department of Medicine, Baylor College of Medicine, Houston TX) and was 
generated by E.coli as previously described90. Recombinant WT and MT I1309V 
monomeric VWF 1208-A1 (residues A0742-17/21) and dimeric VWF 1208-A1 
(residues A0742-17/21) were generously provided by Dr. Zaverio Ruggeri (The 
Scripps Research Institute, La Jolla, CA). GFP-lact-C2 and anti-GPIbα antibody 
WM23 were gifts from Dr. Renhao Li (Emory University, Atlanta, GA). Human 
plasma fibrinogen and VWF were generous gifts from Dr. Shaun Jackson (The 
University of Sydney, Australia). Hexa-His tagged recombinant αVβ3 ectodomain was 
a gift from Dr. Junichi Takagi, Osaka University, Japan47. Biotinylated fibronectin 
module III, domain 7-10 (FNIII7-10) and 9-10 (FNIII9-10) were generous gifts from Dr. 
Andres Garcia (Georgia Tech). Antibodies 10E5 (anti-αIIbβ3) and 7E3 (anti-β3) were 
generous gifts from Dr. Barry Coller (Rockefeller University, New York, NY). The 
antibodies AP3 and AP5 were generous gifts from Dr. Peter Newman (Blood Center 
of Wisconsin). The antibody 6D1 (anti-GPIbα) was a gift form Dr. Michael Berndt 
(University of Curtings, WA, Australia). Peptides mP6, Ser mP6, mP13, Ser mP13, 
MPαC and MPcsC were provided by Dr. Xiaoping Du (UIC, Chicago, Illinois). 
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CBRM1/29, CBRLFA1/2 and CBRLFA1/7 were a generous gift from Dr. Timothy 
Springer (Children’s Hospital, Harvard University, Boston, MA).  
All commercialized reagents purchased from companies are listed below: 
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2.2 Functionalization of beads 
The functionalization of beads by proteins was described in previous literature in 
detail91. In general, glass beads were first incubated with MPTMS (Section 2.1) to be 
thiolated. MAL-PEG3500-NHS linker was used to mix with the protein of interest 
and then the thiolated glass beads so as to link a certain protein onto the bead surface. 
Streptavidin (SA)−Maleimide (Section 2.1) was used to incubate with thiolated glass 
beads to derive SA beads. For proteins (segments) that were already biotinylated, they 
were simply incubated with SA beads to attach onto the beads surface. All beads after 
incubation were washed with and resuspended in phosphate buffer (27.6 g/L 
NaPhosphate monobasic (NaH2PO4 • H2O), 28.4 g/L Anhy. NaPhosphate dibasic 
(Na2HPO4)) and stored in 4°C. 
2.3 Red blood cells 
The preparation of RBCs was described in previous literature in detail. In general, 
8-10 μl of blood was obtained from finger prick abiding an Institutional Review 
Board approved protocol, and RBCs were purified by centrifugation and then 
incubated with Biotin-PEG3500-NHS linker (Section 2.1) solution. Biotinylated 
RBCs were incubated with nystatin (Section 2.1) to be swollen to the desired 
osmolarity. 
2.4 Platelets 
To obtain fresh discoid human platelets, whole blood was drawn slowly from a 
healthy donor’s vein to fill in a 3ml syringe preloaded with 0.43ml ACD buffer (6.25 
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g sodium citrate, 3.1 g citric acid anhidrous, 3.4 g D-glucose in 250 ml H2O, pH 6.7). 
The whole blood was centrifuged at 300g for 10min without brake at 37℃ . 
Platelet-rich plasma was extracted, diluted by platelet washing buffer (PWB, 4.3 mM 
K2HPO4, 4.3 mM Na2HPO4, 24.3 mM NaH2PO4, 113 mM NaCl, 5.5 mM D-Glucose, 
10 mM Theophylline, 0.5% bovine serium albumin (BSA), pH 6.5) with a 1:2 ratio, 
and centrifuged at 900g for another 10 min. The platelet pellet was finally 
resuspended into Hepes-Tyrode buffer (134 mM NaCl, 12 mM NaHCO3, 2.9 mM 
KCl, 0.34 mM sodium phosphate monobasic, 5 mM HEPES, and 5 mM glucose, 1% 
BSA, pH 7.4) for BFP experiments. For the Ca2+ imaging experiments, isolated 
platelets were incubated with Fura2-AM (Section 2.1) at 30 μM for 30 min. 
2.5 Cell lines 
CHO cell lines and Jurkat cell lines expressing MAC-1 and FcγRIIA are provided 
by Dr. Tanya Mayadas lab (Harvard Medical School) by cell transfection techniques. 
Mouse lung endothelial cells expressing human integrin αVβ3 were provided by 
Dr. Martin Schwarz lab (Yale University). 
2.6 BFP experiments 
2.6.1 System setup 
The procedure of BFP experiments were described in detail in a previous paper91. 
Generally speaking, a BFP system is built up by an inverted microscope, an 
experimental chamber, three micropipette manipulators with a piezo-mover 
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supporting one of them (target), and three water reservoir systems. The experimental 
chamber was made up by two parallel pieces of coverglass, in the gap between which 
is experimental buffer filled. Three micropipettes are respectively mounted onto the 
three manipulators and inserted into the experimental buffer (Fig. 2-1A,B), which are 
respectively connected with the three water reservoir systems. By adjusting the 
reservoir height, one can control the inner pressure of the micropipettes so as to 
aspirate or blow away items. RBCs, probes beads and target cells/beads are separately 
injected into the experimental buffer at different areas. 
Among the three micropipettes, the probe pipette aspirates a RBC, the helper 
pipette aspirates a probe bead and the target pipette aspirates a target cell/bead (Fig. 
2-1B).  
 
Figure 2-1. BFP experiment setup. Photo of the BFP chamber and micropipette setup (A), the 
placement of the three pipettes under the microscope (B) and a demonstration of the probe 
pipette grabbing a RBC and the helper pipette grabbing a glass bead (C). Adapted from 
(Chen et al, 2015)91 
BFP uses this micropipette-aspirated biotinylated RBC as a force transducer (Fig. 
2-2 A). On the apex of the RBC is a glass probe bead attached via SA-biotin 
interaction (Fig. 2-2 A). The placement of the probe bead onto the RBC is realized by 
the helper pipette (Fig. 2-1 C). The probe bead is also functionalized by certain 
ligand(s) to suit experimental purpose (Figure 2-1 A insert, using T-cell receptor and 
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peptide:MHC as an example, the bead is coated with peptide:MHC). Another 
opposing micropipette grabs a target cell/bead that expresses/immobilizes the receptor 
under investigation (Fig. 2-2 A insert, T-cell receptor). 
 
Figure 2-2. Introduction of BFP experiment. Take T-cell receptor and peptide:MHC 
interaction as an example, modified from (Chen 2015)91. (A) The BFP photomicrograph. A 
bead was attached to the apex of a micropipette-aspirated red blood cell (RBC, left) to form a 
force probe. The probe was aligned against a T -cell (target cell, right) aspirated by an 
apposing micropipette. Insert: BFP functionalization. The probe bead was pre-coated with 
peptide:MHC. The T-cell expressed T-cell receptor. (B) The intensity profile of the bead edge 
in (A). The ROI region in the x-direction is plotted as x-axis (in pixel number) and the light 
intensity (in gray scale value) averaged by binning 30 pixels along the y-direction. (C) The 
deflection of the RBC and the position of the bead and the target (T-cell) in a test cycle of 
force clamp assay. The vertical and horizontal dashed lines indicate the zero-force position of 
the RBC apex and the time course, respectively. The line edge tracker of the RBC deformation 
is shown in blue in each panel. The same yet less steps are adopted in adhesion frequency 
assay (which lacks the steps of “clamp” and “dissociate”) and thermal fluctuation assay 
(which lacks the step of “dissociate”). (D-F) Exemplary time-force raw data curves of a 
no-adhesion event (D), a rupture force event (E) and a lifetime event (F). 
The interface between the probe bead and the RBC is tracked (Fig. 2-2 B). By 
judging from the deformation of the RBC, one can derive the force exerted onto it. 
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During the experiment, the target cell/bead is driven by a piezo movement to 
repeatedly contact with the probe bead, hold for a certain time and retract (Fig. 2-2 C). 
If the bead detaches from the cell surface readily, it indicates no adhesion, while an 
adhesion event would be manifested by a tensile force signal (Fig. 2-2 D-F)91. 
2.6.2 Force spectroscopy assays and data analysis 
In BFP, several experimental modes (assays) can be chosen to suit different 
purposes:  
2.6.2.1 Force-ramp assay 
Force-ramp assay ruptures all bonds without holding, which enables the 
collection of each bond’s ramping and rupture signature. The characteristics of this 
signature, like the slope, rupture force and sometimes the existence of kinks, contain 
much information about this bond, which will be discussed in detail in later sections. 
Force-ramp assay is sometimes simplified to adhesion frequency assay, which 
does not calibrate the force but simply record the probability of adhesion over touches 
(Fig. 2-2 E)92. 
By counting the probability of adhesion in repeated touches (termed adhesion 
frequency) under a whole range of contact time, one can plot the “adhesion frequency 
vs. contact time”92. If only one association mode exists between the receptor and 
ligand, this plot should adopt a hyperbolic shape. A 2-D kinetics model was deduced 
previously to fit this data, which, together with the information of the probe’s and 
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target’s site densities (see Section 2.7), is able to quantitatively calculate the binding 
kinetics parameters including the on-rate, off-rate and thus the affinity of this 
interaction92,93 by using the Equation 2-1: 
𝑃𝑃𝑎𝑎 = 1 − 𝑒𝑒𝑒𝑒𝑒𝑒�−𝐴𝐴𝑐𝑐𝑚𝑚𝑟𝑟𝑚𝑚𝑙𝑙𝐾𝐾𝑎𝑎�1 − exp (−𝑘𝑘𝑜𝑜𝑜𝑜𝑜𝑜𝑡𝑡)��            (Equation 2-1) 
in which Pa is the adhesion frequency, Ac is the contact area between the probe and 
the target. mr and ml are the site densities of the receptor and the ligand, respectively. 
Ka and koff are the two-dimensional affinity and off-rate, respectively, in the absence 
of force, and t is the contact time. 
However, if more than one association modes exist, the above model does not 
apply, and more complicated analysis will be required. 
2.6.2.2 Force/distance clamp assay 
Force/distance clamp assay clamps the tensile force at a certain level, and 
measures the bond lifetime in single molecular level (Fig. 2-2 F)29,91. The molecular 
site densities of the probe/target pair are titrated to ensure infrequent adhesion, which 
guarantees most probably single-molecular interactions between the two surfaces29. 
The average clamping force and lifetime are extracted from each lifetime event. 
Plotting an “average lifetime vs. force” curve is one common way to present 
force/distance clamp assay result, which is produced by binning the lifetime data pool 
into different clamping force regimes (commonly 5-10 pN in width). The curve 
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reflects the binding strength under force, given that the lifetime is the reciprocal of the 
off-rate. 
2.6.2.3 Thermal fluctuation assay 
Thermal fluctuation assay pauses the retraction phase of the BFP cycle at 0 pN, 
so that the probe and target surfaces loosely contact with each other. The oscillation 
of the signal is measured and the decrease and increase of the thermal fluctuation 
level are distinguished, which is a measure of the bond formation and dissociation in 
single molecular level89,91,94. The rationale of this assay is that when the probe bead is 
free of binding with an opposing surface, it has more freedom of motion, and thus has 
a higher level of thermal fluctuation, whereas once a bond forms, the bead’s position 
will be better constrained94. 
The time lengths of each interval with high and low thermal fluctuation level 
were collected, which reflect the off- and on-state of the bond association, 
respectively. The time length of the former is an indicator of on-rate, while the latter 
an indicator of off-rate under zero-force. 
2.6.2.4 Spring constant measurements 
In the BFP rupture-force signature (Figure 2-2E) or the lifetime event signature 
(Fig. 2-2 F), the retraction phase data can be used to derive the overall spring constant 
of the biological system with all elements in series. In the compressive force fraction 
(negative to zero force), the biological system includes the RBC, the probe bead 
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(which is regarded as a rigid body and neglected) and the target bead/cell (Fig. 2-3 A), 
while in the tensile force fraction (zero to positive force), the molecular complex in 
association between the two surfaces will also be taken into consideration (Fig. 2-3 B). 
This is because when the force is compressive, the molecular complex will lay 
horizontally between the two opposing surfaces and avoid being compressed, while 
under tensile force they will be stretched due to the separation of the two surfaces and 















                  (Equation 2-2) 
Which is also shown in Fig. 2-3 A,B. In Equation 2-2, ktarget, kmol, and kRBC are 
respectively the spring constants of the target bead/cell, the molecular complex and 
the RBC. Slope1 and Slope2 are the overall spring constant of the system in the 
compressive and tensile force fractions of retraction, which are derived from the BFP 
signals. Shown in Fig. 2-3 C is an example of the BFP retraction phase signal 
signature. The insert is the original signal, while in the main figure the x-axis “Time” 
is converted to “Displacement” by multiplying it with the pre-set retraction rate, vret, 
which by default is 3333.33 nm/s. After conversion, we are able to derive the 
relationship between the force increase and the extension of the overall system, which 
reflects the rigidness of the system, in other words, the spring constant. The linear 
fitting slopes of the compressive and tensile force fractions are respectively Slope1 
and Slope2. 
34 
From Equation 2-2, we are able to calculate the spring constant of the target 
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 If the target is a bead, which we can regard as a rigid body considering its much 
higher stiffness when compared to cells and molecules, ktarget ->∞. So the Euqation 



















Figure 2-3. Illustration of the spring constant calculation under a compressive and tensile 
force (A,B) and an exemplary BFP signature of the retraction phase that shows the slope 
different in the compressive and tensile force fractions (C). In Panel C, the “Force vs. Time” 
signal (insert) was converted to “Force vs. Displacement”, so that the linear fitting slopes 
directly reflect the spring constant of the biological systems. The Slope1 and Slope2 in Panel 
C correspond to the terms with the same names in Panels A and B. 
2.6.2.5 Fitting adhesion frequency to derive average number of bonds 
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The average number of receptor-ligand bonds formed during each cell-bead 
contact, <n>, is derived as92,95: 
𝑃𝑃𝑎𝑎,𝑚𝑚𝑎𝑎𝑚𝑚 = 1 − exp (−< 𝑛𝑛 >)                 (Equation 2-4) 
Assuming a single homogeneous population for both the receptors and ligands.  
If more than one receptor population is involved: 
𝑃𝑃𝑎𝑎,𝑚𝑚𝑎𝑎𝑚𝑚 = 1 − exp(< 𝑛𝑛 >𝑡𝑡𝑜𝑜𝑡𝑡𝑎𝑎𝑙𝑙)               (Equation 2-5) 
where <n>total is the total average number of bonds. 
2.6.2.6 Calculation of average effective affinity 
Continuing from Section 2.6.2.5, remember the definition: 
< 𝑛𝑛 >= 𝑚𝑚𝑟𝑟𝑚𝑚𝑙𝑙𝐴𝐴𝑐𝑐 < 𝐾𝐾𝑎𝑎 >= 𝑚𝑚𝑟𝑟𝑚𝑚𝑙𝑙 < 𝐴𝐴𝑐𝑐𝐾𝐾𝑎𝑎 >, 
in which mr, ml and <Ka> are respectively the receptor and ligand site density and 
average effective affinity. Thus: 
< 𝐴𝐴𝑐𝑐𝐾𝐾𝑎𝑎 > =
<𝑛𝑛>
𝑚𝑚𝑚𝑚𝑚𝑚𝑡𝑡
                         (Equation 2-6) 
2.6.2.7 Lifetime multi-state analysis 
The multi-state analysis assumes that the collected lifetime events under a certain 
force f are from a mixture of multiple receptor-ligand binding states with different 
dissociation rates under force. The survival frequency of lifetime t, defined as the 
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fraction of lifetime events longer than t, were fitted with the multi-state model that 
assumes superposition of exponential decays 29: 
ln(𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆 𝑓𝑓𝑆𝑆𝑒𝑒𝑓𝑓𝑆𝑆𝑒𝑒𝑛𝑛𝑓𝑓𝑓𝑓) = ln{∑ 𝑤𝑤𝑖𝑖𝑒𝑒𝑒𝑒𝑒𝑒[𝑘𝑘𝑖𝑖(𝑓𝑓) ∗ 𝑡𝑡]𝑛𝑛𝑖𝑖=1 }          (Equation 2-7) 
in which t is lifetime, wi and ki are the fraction and off-rate of the ith state, 
respectively. The sum of all wi equals to 1. Two-state (n = 2) and three-state (n = 3) 
models were tested. 
The derived off-rates of each state were then plotted against force, which was 
fitted to the Bell’s model – the average lifetime of single-state binding decays 
exponentially with force 96: 
k(𝑓𝑓) = 𝑘𝑘0𝑒𝑒𝑒𝑒𝑒𝑒(𝑆𝑆𝑓𝑓/𝑘𝑘𝑅𝑅𝑇𝑇)                    (Equation 2-8) 
in which f is force, k0 is the off-rate under zero-force, a is the reactive compliance, kB 
is Boltzmann constant, and T is absolute temperature. 
2.7 Measurement of molecular site density 
The deduction of 2-D binding kinetics parameters from BFP results need the 
information regarding the molecular site densities of the target cell/bead and probe 
bead (Section 2.6.2.1). 
To measure the molecular site density, the cells or beads are incubated with a 
fluorescently tagged monoclonal antibody against the molecule of interest at 10μg/ml 
at room temperature for 30 minutes and washed for 3 times. The fluorescent 
37 
intensities of the cells or beads are measured by a BD LSR flow cytometer (BD 
Biosciences), and compared to standard calibration beads (Section 2.1) to determine 
the total number of molecules per cell or bead. Then the site density is calculated by 
dividing total number of molecules per cell or bead to the cell or bead surface area27,92. 
The surface area was calculated from the radii measured with a customized LabView 
(National Instrument) program. 
2.8 Fluorescence BFP experiment 
The Fluorescence BFP (fBFP) experiment adds in the concurrent intracellular 
Ca2+ monitoring of the target cell. This is realized by pre-loading the cell with 
Fura2-AM, a fluorescent Ca2+ indicator, exciting this indicator with 340/380 nm 
wavelength light and detecting the emission signal via a fluorescence camera. The 
emission intensity triggered by 340 nm light indicates the Ca2+-bound Fura2 
concentration, while that triggered by 380 nm indicates free Fura2 concentration. A 
340/380 intensity ratio reflects the Ca2+ concentration.  
During an fBFP experiment, a regular BFP experiment is performed, while the 
alternating fluorescence images were produced in a ~1 Hz frequency91. 
The data analysis of the fluorescence results is based on a customized Labview 
program, which reviews the images frame by frame, and calculates the intensity ratio 
between the two channels automatically. 
2.9 Switch BFP assay 
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Cell surface receptor cross-talk and cooperativity is always an important and 
intriguing problem in cell biology and biomechanics, for example, GPIbα and integrin 
αIIbβ3 on platelets, or selectins and β3 integrins on neutrophils. In these systems, the 
ligand engagement with the first receptor initiates a mechano-signaling into the cell, 
which then leads to the activation of the second receptor in a time scale of tens of 
seconds or a couple of minutes. Studying receptor cross-talk has the difficulty due to 
the fact that it requires the sequential presentation of two sets of ligands that 
potentially interact with two receptor systems, which in most systems cannot be 
fulfilled. 
 
Figure 2-4. Switch BFP demonstration using platelet GPIbα and integrin αIIbβ3 inter-talk as 
an example. (A) Switch BFP setup before switch. The platelet was aligned with and driven to 
repeated touch Probe I that presented VWF-A1, until a lifetime event was observed. Then the 
platelet aspirating pipette will be moved upward. (B) Switch BFP setup after switch. The 
platelet was aligned with and driven to repeated touch Probe II that presented FNIII7-10 or 
fibrinogen to test αIIbβ3 integrin activity. 
The switch BFP concept was first described in Dr. Lining Ju's thesis, attaching 
two ligand bearing beads onto one RBC probe. The switch mechanism was realized 
by manual rotation. The limitations of this method are low throughput and high failure 
rate. The new switch BFP technique was designed and built by myself with the help 
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of my colleague, Ms. Zhou Yuan. Besides the original probe pipette, a second pipette 
was added into the system that is able to realize sequential interrogation of the cell 
surface. With the capability of almost seamlessly sequentially presenting two sets of 
ligands to a single cell, it is a powerful tool to study cell surface receptor cross-talk. 
Normally, only one force probe will be needed to fulfill the experiment. However, 
the switch assay which observes the inter-talk between cell surface receptors requires 
the addition of a second probe. In a switch assay, the added probe will act as Probe I, 
which is in charge of priming the signal-initiating mechano-receptor, e.g., GPIbα, by 
providing ligand for association (Fig. 2-4A). The original force probe acts as Probe II, 
which interrogates the platelet for signaling readouts, e.g., αIIbβ3 up-regulation (Fig. 
2-4B). During the experiment, the platelet will first be aligned and repeatedly touch 
with Probe I for GPIbα-ligand engagement (Fig. 2-4A). Once the 
mechanotransduction is triggered, the platelet-aspirating micropipette will be moved 
upward to start interrogation by Probe II (Fig. 2-4B). The switch time, defined as the 
interval between the platelet interacting with Probe I and with Probe II, could be as 
short as ~30 seconds. 
2.10 Temperature controlling system for BFP 
The temperature controlling system was the second add-on of the BFP system 
designed and realized by myself. It enables in vitro BFP experiments under a 
physiological mimicking temperature, which is important in cell signaling studies, 
40 
considering that many cell signals could only be triggered under physiological 
temperature. 
This temperature controlling system integrates a commercial temperature 
controller, Fuji PXR Temperature Controller (Part No.: PXR3-NAY1-4V0A1), and is 
composed of two electric circuits: the heating circuit and the controlling circuit, which 
are linked through a reed relay (Fig. 2-5). The system takes advantage of 
heat-electricity effect to heat up the experimental chamber, and to realize that, the top 
coverglass will have to be replaced by a piece of conductive glass (resistance: 240Ω). 
In the heating circuit, heating of the conductive glass is via the heat effect of the 
currency flowing through the conductive glass provided by an 18V DC power supply. 
Since the resistance is distributed in the glass evenly, heat is also evenly generated all 
over the glass surface, which assures a relatively uniform temperature distribution 
throughout the glass covering area. One 500Ω rheostat is used as an adjustment of the 
heating speed, and also reduces overshooting during controlling. 
 
Figure 2-5. Electric circuit design sketch of the temperature controlling system 
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For the controlling circuit, a reed relay is used to link the heating circuit and the 
controlling circuit, whose operational voltage is 5V. The probe tip of the 
thermocouple sticks inside the buffer to sense the local temperature. The Fuji PXR 
Temperature Controller provides a PID loop control, which is the center of the 
controlling mechanism. Tolerating lower and higher limits are preset on the Fuji PXR 
Temperature Controller. Based on the current and historical temperature data, it is 
able to give feedback and manipulate the “on” and “off” state of its inner passage. 
When the temperature inside the chamber is lower than the tolerating lower limit, the 
inner passage will be set as “on”, which ensures the connectivity of the controlling 
circuit. With currency flowing through the electromagnet inside the reed relay, it sets 
the magnetic switch as “on”, which ensures the connectivity of the heating circuit and 
heat-up of the conductive glass. After the temperature probed by the thermal couple is 
higher than the tolerating higher limit, the inner passage will be set as “off”, which cut 
off the controlling circuit. With no currency flowing through the electromagnet inside 
the reed relay, it set the magnetic switch as “off”, which cut off the heating circuit. 
The heating power stops working and the conductive glass and the whole chamber 
begin to cool down. 
With this temperature controlling system, the experimental temperature 
environment can be maintained relatively stable within 1℃. 
2.11 Statistical testing 
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All data are mean ± SEM. The statistical significance of the differences between 
two sets of data was determined by Student’s t test. For group analysis, two-way 
ANOVA was used. If significant differences were shown, the data were subjected to 
Tukey’s test for multiple comparisons, with p < 0.05 considered significant. 
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CHAPTER 3: CHARACTERIZATION AND REGUTAION 
OF INTEGRIN AFFINITY AND CONFORMATIONAL 
STATES 
3.1 Introduction 
Due to their flexible multi-domain structure, integrins can adopt multiple global 
conformational states, each of which corresponding to certain activity. Ectodomain 
extension, tailpiece separation (unclasping of the transmembrane and cytoplasmic 
domains) and hybrid domain swing-out are generally believed to be associated with 
integrin activation, in other words, a higher binding capacity97. This has been 
supported by the use of soluble integrin activators, like activating cations (e.g., Mn2+), 
certain activating antibodies, talin head domain and ligand-mimicking peptide binding 
40,43,47,60,97,98. The introduction of functional mutations also resulted in outnumbering 
of certain conformations as compared to wild-type (WT)99. For example, cells 
expressing β3 mutation D723R which causes the tail separation, showed significantly 
higher integrin activation and more pronounced outside-in signaling100,101. L138I, 
another β3 mutation that locks the integrin in the extended state, showed high affinity 
binding to ligands and higher efficiency in both outside-in and inside-out 
signaling101,102. In parallel, supported by a MD simulation work on αVβ3, a pulling 
force through ligand binding may also induce integrin conformational changes via 
mechanical effects103. Indeed, two recent works from our lab which characterized 
single integrin αLβ2 (LFA-1) binding kinetics and ectodomain bending/unbending 
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conformational changes, for the first time demonstrated a dual role of the mechanical 
force to concurrently up-regulate the integrin binding capacity and facilitate integrin 
extension29,63. These works broke the previous bottleneck in this field which only had 
access to static images but no dynamic process. Meanwhile, it raised more questions, 
like whether this could occur independent of cell surface environment, and how 
mutations and different ligands may regulate this. Surrounding these questions, I 
studied the affinity and conformational states of two integrins, αVβ3 and αMβ2. 
3.2 Results 
3.2.1 Integrin αVβ3 binding kinetics and bending/unbending 
conformational changes – a purified system study 
In this project, the conformational dynamics and binding activities of integrin 
αVβ3 was characterized by BFP in real-time, both in a cell-free system and on cell 
surface.  
3.2.1.1 αVβ3–fibronectin binding forms a catch-bond in Mn2+ which is suppressed in 
Ca2+/Mg2+ 
A biotinylated fragment of fibronectin, module III, domain 7-10 (FNIII7-10) was 
used as a substitute of the full-length protein, which contains both the integrin-binding 
RGD sequence in domain 10 and the synergy site in domain 9 (Fig. 1-3 C). The 
FNIII7-10 was immobilized on SA beads via SA-biotin interaction to make the probe 
beads (Fig. 3-1A,B). 
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Figure 3-1. BFP setup for studying recombinant αVβ3 (A,B), specificity test results (C), and 
lifetime vs. force results of αVβ3 binding to fibronectin (D) and antibodies LIBS-2 (E). Error 
bar: SEM. 
On the target beads, anti-pentahistidine antibody was immobilized following 
covalent linking protocol. A recombinant αVβ3 ectodomain construct clasped at the 
tail with a hexahistidine tag at the β3 C-terminus47 was then coated on via 
antibody-antigen interaction (Fig. 3-1 A,B). 
In the initial specificity testing, the beads coating densities were not titrated to be 
around 20%. In both 2mM Mn2+, a prevailingly used artificial integrin activation 
environment, and 1mM Ca2+/1mM Mg2+ conditions, robust level of adhesion 
exhibited between the two spheres. Addition of LM609, a αVβ3 blocking antibody, 
eliminated most of the binding, confirming that the adhesion was mainly contributed 
by αVβ3-FNIII7-10 interaction (Fig. 3-1 C). 
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Figure 3-2. BFP signatures of recombinant αVβ3 unbending (A,C,E) and bending (B,D,F) 
conformational changes in the clamping phase of a BFP signal. (A-D) Representative force vs. 
time data points showing a putative integrin unbending (A, C), and bending (B, D) event. A 
higher force resolution was obtained by smoothing the raw data using the Savitzky-Golay 
method (curves). Force changes (Δf), switching time (tsw), time-to-switch (t0) and post 
unbending/bending lifetime (t1) are indicated. (A,B) The overall signals of BFP cycles that 
contains an integrin unbending (A) or bending (B) event. (C,D) The zoom-in views of the BFP 
signal within the cyan-shaded time windows indicated in panel (A) or (B), which include the 
conformational changes of interest. The putative integrin global conformations were depicted 
by the cartoons before and after the said changes. (E,F) 100-point sliding variance of the 
displacement in (C) and (D) versus time. A decrease (E) or increase (F) in the thermal 
fluctuation (indicated by the values of σ2 and dashed lines) followed integrin unbending (I) or 
bending (J), indicating the stiffening or softening of the integrin molecule, respectively. 
Then the beads coating densities were titrated for lifetime measurements. The 
lifetime curve in Mn2+ manifested a clear catch-bond behavior in the force regime of 
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~5-~22 pN, with a gradual increase of lifetime along the increment of force. Over ~25 
pN, the curve transited to slip-bond, so that the lifetime dropped while force increased, 
and finally approached zero around 50 pN (Fig. 3-1 D). In Ca2+/Mg2+, the lifetime 
curve originated from similar amplitude to Mn2+ at force close to zero; however, the 
catch-bond behavior was well suppressed and instead the lifetime curve showed a 
“slip bond” signature. This caused a significant downward shift of the lifetime in most 
forces. Especially, at 22 pN where the Mn2+ curve peaks, the lifetime in Ca2+/Mg2+ is 
shortened by ~3-fold. The above data was consistent with the well-known role of 
Mn2+ as an integrin activator. Moreover, unlike integrin αLβ2 which consistently 
manifests a “catch-slip” signature in Ca2+/Mg2+, Mn2+ and Mg2+/EGTA29, αVβ3 
lifetime manifest different signatures in different cation conditions. 
Catch-bond behavior was discovered on multiple receptors, like T-cell receptor104, 
selectin105, cadherin106 and several integrins26,29,30. It is regarded as a mechanism to 
resist force-induced bond dissociation. Catch-bond formation in integrin family is 
often related to the allosteric effect of integrin conformations. Thus, the 
abovementioned lifetime difference between the two cation conditions may suggest 
their preference of a certain conformation. 
3.2.1.2 Observing αVβ3 bending and unbending conformational changes with BFP in 
a purified system 
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Figure 3-3. “Clamping force vs. displacement” scatter plots of recombinant αVβ3 unbending 
and bending events (A,C,E,G), and the distribution (B,D,F,H) and means ± SEM (I) of the 
displacements in Mn2+ or Ca2+/Mg2+. 
In distance/force clamp assay which holds the target bead at a fixed position, an 
integrin unbending event is signified by a concurrent decrease of force and thermal 
fluctuation level (Fig. 3-2 A,C,E), while bending by a concurrent increase of force 
and thermal fluctuation level (Fig. 3-2 B,D,F)63. The rationale of this judgment is as 
following:  
1) The distance between the probe micropipette tip and the target bead is fixed 
during the clamping phase, which is filled in by the serial linkage of RBC, probe bead 
and αVβ3-FNIII7-10 molecular complex. When the integrin extends, it claims more 
molecular length (Fig. 3-2 C insert), which causes the RBC to deform to engage less 
length, and that will be exhibited in the BFP signal as force decrease. Vice versa, 




Figure 3-4. Determining the molecular complex stiffness with a bent/extended integrin and 
the initial fractions of integrin populations in bent and extended conformations in Mn2+ and 
Ca2+/Mg2+. (A) Mean ± SEM of spring constants of the molecular complex (kmol) prior to 
unbending (filled bars) or bending (empty bars) of the indicated integrin. * = p < 0.05, 
assessed by unpaired, two-tailed Student’s t-test. (B) Data (points) and Gaussian fits (curves) 
of kmol distributions of measured from the ramping phase of BFP cycles with lifetime events 
during which integrin unbending (blue) or bending (orange) was observed in the clamping 
phase. The means of the two Gaussian distributions were indicated by dashed lines with the 
values annotated. Data from Mn2+ and Ca2+/Mg2+ were pooled together. (C,D) Histograms 
(bars) and dual Gaussian fits (blue and orange curves were fits to the two sub-populations; 
color-matched curves were fits to the whole populations) of kmol forαVβ3 pulled by FNIII7-10 in 
Mn2+ (C) and Ca2+/Mg2+ (D). The calculated fractions of bent and extended sub-populations 
returned from the dual Gaussian fitting were indicated in each panel. 
2) The integrin molecular stiffness is associated with the conformation. When the 
integrin is in the bent conformation, it is more flexible and softer, so that the thermal 
fluctuation will be less constrained, which results in a larger variation in the signal 
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(Fig. 3-2 E first half, 3-2 F second half). On the other hand, in the extended state the 
integrin becomes stiffer and thus the thermal fluctuation is better constrained (Fig. 3-2 
E second half, 3-2 F first half). This difference in the molecular stiffness will be 
testified and confirmed via experiment results and analysis below. 
In a bending/unbending signature, the force increase/drop divided by the RBC 
spring constant gives the integrin conformational change displacement. That is, how 
far the integrin headpiece is pulled away from proximity to the bead surface 
(unbending), or how far the headpiece pulls back (bending). Both unbending and 
bending occurred under all clamping forces where lifetimes are measurable, and the 
displacements all follow Gaussian distributions (Fig. 3-3 A-H). The average 
displacement (~13 nm) is indifferent to the clamping force or cation condition, and is 
comparable between unbending and bending events (Fig. 3-3 I). 
As controls, LIBS-2 were coated on the bead surface and interrogate the integrin. 
The epitope of LIBS-2 resides in the βTD domain, which is in close proximity to the 
membrane107 (Fig. 1-3), and thus should not be able to detect bending/unbending 
which only involve the headpiece movement. In agreement to that, LIBS-2 did not 
detect any bending or unbending events despite the long lifetimes (Table 3-1; Fig. 3-1 
E). 
3.2.1.3 Mn2+ cation condition favors the extended conformation of αVβ3 while 
Ca2+/Mg2+ favors the bent conformation 
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Occurrence probability is defined as the chance of an extended/bent integrin 
undergoing bending/unbending conformational changes during the time window of 
BFP force-clamping phase. It reflects how frequent/easy the conformational changes 
could happen, which is a gauge of the energy barrier that needs to be overcome. In 
order to derive that information, the fractions of integrin in bent and extended 
conformations before ligand binding need to be known. Previous works have utilized 
EM imaging technologies to visualize the static images of different integrin 
conformations46,60,108. In our system, the spring constant of the molecular complex 
was used to distinguish the conformations. As discussed in a previous publication, the 
αLβ2 integrin’s spring constant depends on whether it resides in the bent (softer) or 
extended (stiffer) conformation63. 
Based on Section 2.6.2.4, we are able to measure the spring constant of the 
molecular complex, which assuming single receptor-ligand interaction, is the serial 
linkage of an integrin, an immobilizing antibody, a covalent linker, a FNIII7-10 and a 
SA. Among these, the integrin is the only molecule in the complex that could 
contribute to changes in the spring constant. The spring constant of the molecular 
complex which later exhibited an unbending/bending conformational change event 
were measured. The rationale of distinguishing its conformational in the retraction 
phase is that, if it underwent unbending in the force-clamped phase, then in the 
retraction phase it has to adopt a bent conformation; while if it underwent bending in 
the force-clamped phase, then in the retraction phase it has to adopt an extended 
conformation. The bent and extended integrins induced a significant difference in the 
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overall spring constant of the molecular complex, which is softer with the integrin 
bent and stiffer with it extended (Fig. 3-4 A). Since the cation condition did not affect 
the spring constant (Fig. 3-4 A), we combined the spring constant data from both 
cation conditions and binned them to derive a column plot of “frequency vs. spring 
constant”. By assuming that the spring constant obeys a Gaussian distribution, we 
separately fit the data of bent and extended integrin group and then derived the mean 
spring constant to be 0.55 and 0.73 pN/nm respectively (Fig. 3-4 B). 
Table 3-1. Statistics of the recombinant αVβ3 binding to FNIII7-10 lifetime events and 
bending/unbending conformational change events under different conditions 
 
Following that, the spring constants of the molecular complex under Mn2+ 
condition were calculated and collected from no-conformational-change lifetime 
events (n = 200), and fit with a double-Gaussian distribution, with the two means 
pre-set as 0.55 and 0.73 pN/nm. Based on the fitting result, the fractions of bent and 
extended integrins under Mn2+ condition were respectively 71.19% and 28.81% (Fig. 
3-4 C). Similarly, the fractions under Ca2+/Mg2+ condition were calculated to be 89.29% 
and 10.71% (Fig. 3-4 D). 
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Under Mn2+ condition, a total of 1424 lifetime events (including those with 
bending/unbending conformational changes) were collected, which based on the 
fraction calculation, were from 1014 bent and 410 extended integrins (Table 3-1). In 
all lifetime events, 195 exhibited unbending conformational changes, which yielded 
an occurrence probability of 195 / 1014 = 19.23%. Similarly, the occurrence 
probability of bending was calculated to be 10.48%. Under Ca2+/Mg2+ condition, only 
9.14% of the bent integrins underwent unbending, while as many as 34.08% of the 
extended integrins underwent bending (Table 3-1). 
The fact that a higher fraction of the integrin population adopts an extended 
conformation in Mn2+ than Ca2+/Mg2+ in the solution, and that under force the integrin 
has a higher unbending occurrence probability but a lower bending occurrence 
probability in Mn2+, both indicated that Mn2+ favors the extended conformation of 
αVβ3. 
In a soluble form, the β3 antibody WOW-1 functionally blocks the active form of 
the integrin, while LIBS-2 facilitates the ectodomain extension107,109. The addition of 
soluble WOW-1 did not change the fraction of the bent/extended integrins available 
for FNIII7-10 binding (Table 3-1), but narrowed the force regime of the integrin 
lifetime curve to 0-30 pN and shortened the lifetime in the force regime of > 15 pN 
(Fig. 3-1). The probabilities of bending and unbending during interrogation were both 
lowered (Table 1), probably due to the shortened lifetime which constrained the time 
window for detection (Fig. 3-1). In comparison with WOW-1, soluble LIBS-2 brought 
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most of the integrins to an extended conformation and eliminated all bending events 
(Table 3-1). About 13.5% of the bent integrins underwent unbending during 
interrogation, the fraction of which slightly higher than in the absence of LIBS-2, 
probably due to the prolonged lifetime around 25 pN (Fig. 3-1D). 
 
Figure 3-5. Recombinant integrin bending and unbending switching time tsw± (A-C) and 
time-to-switch t0± (D-F) in Mn2+ (magenta) and Ca2+/Mg2+ (green). A and D averaged the 
data over all forces, while B, C, E, F plot the data against clamping force. Error bars: SEM. 
Two parameters from the BFP signatures characterize the conformational change 
dynamic processes: time-to-switch (t0±, defined in Fig. 3-2 A,B) and switching time 
(tsw±, defined in Fig. 3-2 C,D), which gauge the underlying energy to be overcome. In 
both cation conditions, bending requires a longer t0 and tsw than unbending (Fig. 3-5 
A,D). Compared to the physiological Ca2+/Mg2+ condition, Mn2+ shortened the 
unbending tsw+ and did not affect the t0+, but prolongs the t0- and tsw- of bending (Fig. 
3-5 A,D). Plotting them against different clamping forces revealed that the above 
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observations generalize under most forces (Fig. 3-5 B,C,E,F). Moreover, both t0+ and 
tsw+ of unbending monotonically decreased as the clamping force increased, which 
was reasonable considering that the direction of force aligns with the extension of the 
integrin, so that a higher force provides more energy to help overcome the energy 
well for unbending (Fig. 3-5 B,E). On the contrary, the clamping force works on the 
opposite direction than bending so that bending should adopt a slower kinetics under 
high forces. This was consistent with the bending data under lower forces, but show 
discrepancy under higher forces, probably due to the constraint of the binding lifetime 
length, which prevented the detection of extremely slow conformational changes (Fig. 
3-5 C,F). In support of this, the bending t0- and tsw- are comparable to the values of 
bond lifetimes (compare Fig. 3-5 C,F and Fig. 3-6 B,C). 
The fact that the bending requires a longer t0 and tsw than unbending was in 
agreement with that bending occurred less frequently that unbending in Mn2+ (Table 
3-1, 10.48% vs. 19.23%), but seems to disagree with the higher frequency of bending 
in Ca2+/Mg2+ (Table 3-1, 34.08% vs. 9.14%). This suggested that more complicated 
mechanisms may exist to affect the occurrence of integrin conformational changes. 
One reasonably hypothesized possibility is that, a subpopulation of the bent integrin is 
“locked” in the presence of Ca2+/Mg2+, so that they are unable to undergo unbending 
even under forces. The inertness of this subpopulation counteracted on the high 




Figure 3-6. Recombinant integrin post-bending and -unbending lifetime, averaged over all 
forces (A), and “lifetime vs. force” curves in comparison with the lifetime curves without 
bending/unbending in Mn2+ (B) and Ca2+/Mg2+ (C). 
3.2.1.4 Bending/unbending conformational change of αVβ3 shortens/prolongs its 
lifetime in Mn2+ but has no effect in Ca2+/Mg2+ 
How the integrin conformational changes regulate its binding capacity is an 
intriguing and important question to ask, which underlies the allosteric effects in 
integrin and acts in part as the mechanism of integrin outside-in and inside-out 
signaling on cells’ surface.  
Of each integrin-FNIII7-10 lifetime event in which a bending or unbending event 
was observed, the fraction of lifetime after bending/unbending was collected and 
respectively termed as post-bending and post-unbending lifetime. Results from cell 
surface LFA-1 have indicated that the bent/extended conformation of the integrin has 
a strong impact to the ligation bond kinetics63. In αVβ3 system under the Mn2+ cation 
condition, a somewhat similar behavior was observed. The post-unbending lifetime 
was much longer than post-bending under all forces; the lifetime collected from 
events without bending/unbending, which based on the spring constant analysis result 
was from a mixed population of bent and extended integrins (Fig. 3-4 C), manifested 
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a lifetime level in between of post-bending and post-unbending (Fig. 3-6 A,B). 
Interesting, all three curves showed a catch-slip-bond behavior. The forces under 
which the lifetime curve peaks were similar among all three (17-20 pN), whereas their 
peak values were drastically distinct, being 10.9, 5.7 and 3.6 secconds for the 
post-unbending, average, and post-bending lifetime respectively (Fig. 3-6 B). 
Different than in Mn2+, in Ca2+/Mg2+ the post-unbending and post-bending 
lifetimes were comparable and both curves overlapped well with the lifetime curve 
without bending/unbending, manifesting slip-bond behaviors (Fig. 3-6 A,C). This 
strongly suggested that in such a physiological cation condition, the integrin adopting 
a bent or unbending conformation does not affect its binding lifetime. This conclusion 
contradicts with the conventional view that the integrin ectodomain extension is a sign 
of integrin activation which is accompanied by an up-regulation of binding capacity. 
However, to be noted, the integrin extension under this circumstance was only in the 
presence of ligand engagement and force pulling through the ligand (outside-in 
signaling), which cannot represent the scenario where the integrin is regulated from 
the cytoplasmic terminus (inside-out signaling). 
3.2.2 Observing ligand binding and bending/unbending 
conformational changes of cell surface integrin αVβ3 regulated by 
mutations, force and ligands 
3.2.2.1 Force dependency of cell surface αVβ3 ligand binding and its regulation by 
functional mutations 
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To study the behaviors of αVβ3 on cell surface and compare with the purified 
system results, mouse lung endothelial cells (mLECs) were transfected with three 
types of human αVβ3 (WT, D723R, L138I) and tested in BFP experiments (Fig. 3-7 
A). Again, FNIII7-10-coated beads was used. Experiments were only performed in the 
physiological cation condition of 1mM Ca2+/Mg2+, and Mn2+ was not used 
considering its toxicity to cells. 
D723R is a point mutation in the cytoplasmic tail of β3 subunit (Fig. 3-7 B)82. It 
destabilizes the TMD (transmembrane domain)-tail interactions between α- and β- 
subunits and causes tail separation. By doing so, it shifts the equilibrium of integrin 
activity towards activation. L138I, on the other hand, resides in the βI-domain of β3 
subunit, and promotes ectodomain extension and activates the integrin (Fig. 3-7 B)101. 
All three cell lines expressing WT, D723R and L138I integrins resulted in high 
frequencies when binding to FNIII7-10 (Fig. 3-7 C). Non-transfected cells against 
FNIII7-10 and WT integrin transfected cells against SA both exhibited an adhesion 
frequency of ~5%, which confirmed the binding specificity of the integrin and the 
ligand respectively (Fig. 3-7 C). For all experiments following that, the binding 
frequencies of the three transfected cell lines were titrated by shortening the cell-bead 
contact time to ~20%, which ensured predominantly single-molecular interactions.  
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Figure 3-7. BFP setup and binding kinetics results of cell surface αVβ3 binding to FNIII7-10. 
(A)BFP setup for studying cell surface αVβ3. FNIII7-10 acts as the interrogating ligand, and a 
mLEC expressing human integrin αVβ3 acts as the target cell. (C) Sketch of a αVβ3 integrin 
with the residue D723 and L138 and the binding epitope of AP3 and LIBS-2 indicated. (D) 
specificity test results. (E) Lifetime vs. force curves of WT, D723R and L138I αVβ3 binding to 
FNIII7-10. (F) Lifetime vs. force curves of WT αVβ3 binding to AP3 and LIBS-2. Error bars: 
SEM. 
The “lifetime vs. force” curve of WT αVβ3 manifested a “slip-catch-slip” 
triphasic trend that resembled the “GPIbα-VWFA1” binding lifetime published before 
(Fig. 3-7 E)88. This suggested an activating role of force, which was more prominent 
when the force was larger so that the “slip” trend of the integrin was converted to 
“catch”, ensuring enduring binding. This trend change was not observed in the 
purified system under the same condition (Fig. 3-1 D), probably due to the structural 
difference of the recombinant integrin that constrained certain conformational 
changes like tail separation and in turn restricted the activation. In sharp contrast to 
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WT, the D723R and L138I αVβ3 resulted in highly similar “slip-bond” lifetime curves, 
which overlapped with WT at forces higher than 20 pN but split at lower forces, and 
reached as high as 10 s when the force approached zero (Fig. 3-7 E). As controls, WT 
integrin binding to two antibodies, AP3 and LIBS-2 both manifested slip-bonds (Fig. 
3-7 F).  
 
Figure 3-8. Characterization of the cell surface αVβ3 bending and unbending events. 
(A,C,E,G) Scatter plots of displacements (= Δf / kBFP where the Δf measurement was shown in 
Fig. 2, A and B and kBFP = 0.3 pN/nm is the preset spring constant of the RBC) vs. pre-switch 
force of unbending (A,E,G) and bending (C) events of WT (A,C), D723R (E) and L138I (G) 
αVβ3 pulled via an engaged FNIII7-10. Mean ± SD of displacements are shown as solid and 
dashed lines. (B,D,F,H) Histograms (bars) and Gaussian fits (curves) of the data from A, C, E, 
and G. (I,J) Displacement (I, means ± SEM) and frequency (J, error bar = SEM estimated by 
the binomial distribution of events whose numbers are indicated) of unbending (filled bar) 
and bending (empty bar) of indicated αVβ3 pulled by different ligands (FNIII7-10, 
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Fg)/antibodies (LIBS-2, AP3). ** = p < 0.01, assessed by unpaired, two-tailed Student’s t-test. 
N.A. = not applicable due to lack of data. 
3.2.2.2 Observation of integrin αVβ3 bending/unbending conformational change on 
cell surface and its regulation by functional mutations 
 
Figure 3-9. Determining the initial fractions of cell surface integrin subpopulations in bent 
and extended conformations. (A) Mean ± SEM of spring constants of the molecular complex 
(kmol) prior to unbending (filled bars) or bending (empty bars) of the indicated integrin. * = p 
< 0.05, assessed by unpaired, two-tailed Student’s t-test. (B) Data (points) and Gaussian fits 
(curves) of kmol distributions of measured from the ramping phase of BFP cycles with lifetime 
events during which integrin unbending (blue) or bending (orange) was observed in the 
clamping phase. The means of the two Gaussian distributions were indicated by dashed lines 
with the values annotated. Data from WT, D723R and L138I were pooled together, assuming 
that the two mutations had negligible effects in the integrin stiffness, as suggested by panel 
(A). (C-E) Histograms (bars) and dual Gaussian fits (blue and orange curves were fits to the 
two sub-populations; color-matched curves were fits to the whole populations) of kmol for WT 
(C), D723R (D) and L138I (E) αVβ3 pulled by FNIII7-10. The calculated fractions of bent and 
extended sub-populations returned from the dual Gaussian fitting were indicated in each 
panel. 
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Similar to purified system results, both bending and unbending events were 
observed from cell surface integrins for all three genotypes (Table 3-1).  
The displacements of WT αVβ3 bending events and WT, D723R and L138I 
unbending events were plotted against the clamping forces under which the 
conformational change occurred. To note, the bending of D723R and L138I αVβ3 
occurred extremely rarely (Table 3-1), and thus could not be plotted in this way. From 
the scatter plots it could be seen that integrin unbending evenly occurred under all 
clamping forces except for the low and high extremes, while bending favored lower 
clamping forces (Fig. 3-8 A,C,E,G). The displacements of these four analyzable 
conditions all followed Gaussian distributions, which agreed with the purified system 
results (Fig. 3-8 B,D,F,H). The average displacements of WT, D723R and L138I 
bending and unbending were all ~15 nm (Fig 3-8 I), which were indifferent to the 
integrin genotype or the direction of the conformational change, and ~2 nm longer 
than the purified system displacements (Fig. 3-3 I), probably because of the structural 
difference between the recombinant and cell-expressed integrin molecules. 
The frequency of observing unbending was much higher than bending in all three 
integrin genotypes, especially the two GOF MTs, where bending events were 
extremely rare (Fig. 3-8 J). 
Based on Section 2.6.2.4, the molecular complex stiffness before unbending and 
before bending was collected, which were indifferent to the genotype of the integrin 
(Fig. 3-9 A). Considering that, the stiffness of before unbending and before bending 
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subpopulations from all three genotypes were pooled together, each of which was 
well fitted by a Gaussian distribution (Fig. 3-9 B, blue curve and orange curve). The 
means of the two fits, 0.40 and 0.67 pN/nm, were the average spring constant of the 
molecular complex upon the integrin being bent and extended, respectively. 
Further fitting using these two average spring constants showed that the fractions 
of bent and extended populations of WT αVβ3 were 55.79% and 44.21% (Fig. 3-9 C), 
respectively, which by calculation resulted in probabilities of unbending and bending 
under force to be 22.50% and 11.09% (Table 3-1). The two GOF MTs had most of the 
integrins in the extended conformation before force pulling (Fig. 3-9 D,E). By 
calculation, the occurrence probabilities of unbending/bending events were 47.52/0.28% 
(D723R) and 21.94/0.31% (L138I) (Table 3-1). Compared to WT, these results 
indicated that both mutations strongly facilitate the extension of the integrin and 
impede bending. To note, because the lifetime length determines the time window of 
observing the conformational changes, the differences between WT, D723R and 
L138I lifetimes may also partially contribute to the abovementioned probability 
differences. 
When the bent and extended conformations of the integrin reach equilibrium in a 
dynamic fashion, the following equation should be valid: (Extended fraction) * 
(Unbending rate) = (Bent fraction) * (Bending rate). Thus: 
(Extended fraction)
(Bent fraction)
 =  (Bending rate) 
(Unbending rate)
                 (Equation 3-1) 
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In the scenario of force pulling through BFP manipulation, because the external 
force exerted onto the molecular complex was in the direction of integrin extension, it 
is reasonable to hypothesize that force facilitates unbending while inhibits bending, 
and thus shifts the conformation equilibrium towards extension. To test this 
hypothesis, the fractions of extended and bent integrin subpopulations under force 
were estimated. Because the lifetimes of bent and extended integrins are comparable 
(discussed in Section 3.2.2.4), (Probability of unbending) / (Probability of bending) = 
(Unbending rate) / (Bending rate). Thus, (Extended fraction) / (Bent fraction) = 
(Probability of unbending) / (Probability of bending). Based on this equation and the 
Probabilities of unbending/bending in Table 1, we are able to derive the equilibrium 
state of WT (33.03% bent, 66.97% extended), D723R (0.59% bent, 99.41% extended) 
and L138I (1.39% bent, 98.61% extended) under force. Comparing these numbers 
with those under zero-force (Table 1, Bent fraction and Extended fraction) revealed 
that the equilibrium was drastically shifted towards the extended state under force 
regulation. 
3.2.2.3 Kinetics of integrin conformational changes and their regulation by force and 
mutations 
The shifts of the bent and extended integrin population fractions following the 
introduction of the mutations D723R and L138I to the integrin, as well as the 
differences in the bending and unbending occurrence frequencies between the WT 
and MTs clearly indicated that the two mutations D723R and L138I realized a more 
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stable state for the extended conformation while disrupting the stability of the bent 
conformation as compared to WT. 
To derive more details in the underlying mechanisms of how the two mutations 
shift the equilibrium between the bent and extended conformations, the time-to-switch 
(t0) and switching time (tSW) of the bending and unbending events were collected. 
Similar to results from the purified system, WT bending t0 and tSW were both much 
longer than unbending, which held true under all clamping forces (Fig. 3-10 A-D). 
This is probably due to the force pulling on the integrin, which facilitates unbending 
and inhibits bending. The mutants D723R and L138I both caused a drastic decrease of 
the unbending tsw, so that their averages were much smaller than the WT, and both 
curves were rotated counterclockwise around ~32 pN where all three curves 
converged at ~0 s. However, only D723R shortened the t0+, while L138I had 
negligible effects (Fig. 3-10 B,D). This indicated that both D723R and L138I 
substantially accelerated integrin unbending, but only D723R destabilized the bent 
conformation. This discovery should partially account for the shifted equilibrium 
between the bent and unbending integrin populations that existed in the scenario of 
both mutations. 
Because the force imposed onto the integrin through ligand binding was towards 
the direction of integrin extension, it provides a positive/negative work to the integrin 
during unbending/bending. This means that the force should affect the kinetics of 
integrin bending/unbending, in the way that a higher force accelerates and stabilizes 
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the unbending but decelerates and destabilizes bending. Agreeing with that, the 
unbending tsw+ and t0+ of all three genotypes monotonically decreases along with 
force increase, which is consistent with the previously reported cell surface integrin 
αLβ2 conformational changes. Interestingly, the WT bending tsw- and t0- first 
increased and then decreased along with force instead of monotonically increasing 
(Fig. 3-10 C,D). This is probably due to the constraint of the integrin-ligand bond 
lifetime: the bending or unbending events being observable in the BFP system require 
them to occur prior to the dissociation of the bond. Thus, those bending events that 
occurred slowly may not be recorded. This constraining effect becomes more 
influential when the kinetics of the conformational changes were comparable or 
slower than the binding kinetics. Indeed, the αVβ3-FNIII7-10 lifetime (Fig. 3-10 E) was 
at the same scale as tsw- and t0- under all forces. More importantly, the average 
lifetime vs. force curve also manifested a catch-slip bond behavior, with the “catch” 
regime to be 0 - ~20 pN, consistent with the tsw- and t0- vs. force curves. 
In the previous section, tensile force was shown to shift the conformation 
equilibrium towards extension. However, whether this was sensitive to the level of 
force was not clear. Because Unbending/Bending t0 is the reciprocal of 
Unbending/Bending rate, Equation 3-1 can be converted to: 
(Extended fraction)
(Bent fraction)
 =  (Unbending t0) 
(Bending t0)
                  Equation 3-2 
showing that the ratio of time-to-extend to time-to-bend can directly reflect the 
equilibrium between extended and bent conformation. Thus, the ratio of WT αVβ3 
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time-to-extend to time-to-bend vs. clamping force was calculated, which exhibited an 
obvious force-dependency (Fig. 3-10 F, filled circles). The zero-force ratio was 
calculated by the ratio of the extended to bent integrin sub-populations estimated from 
Fig. 3-9 E according to Equation 3-2, which exhibited a smooth extrapolation from 
the points under force (Fig. 3-10 F, open circle). Under all forces, the ratio of 
time-to-extend to time-to-bend monotonically decreased with force increase, 
indicating that the conformation equilibrium was gradually shifted towards extension 
(Fig. 3-10F). 
3.2.2.4 Lack of effect of αVβ3 bent/extended conformation or bending/unbending on 
its ligand dissociation rate under force 
In the purified system, in Ca2+/Mg2+ the WT integrin lifetime was not affected by 
the bending or unbending conformational change (Fig. 3-6 C). Consistent with that, in 
the cell-surface system, the WT post-bending and post-unbending lifetimes appeared 
to be comparable (Fig. 3-11 A). By segregating the lifetime events into different force 
regimes, the post-bending and post-unbending lifetimes were shown to nearly overlap 
under all forces, which also aligned well with the average lifetime curve derived from 
measurements not containing bending/unbending events (Fig. 3-11 B). Similarly, the 
post-unbending lifetime curve of the two MTs, D723R and L138I, also overlapped 
with their respective average lifetime curve (Fig. 3-11 C,D). 
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Figure 3-10. Analyzing the dynamics of the cell surface integrin conformational changes. 
(A,B) Mean ± SEM of the switching time (tsw±, A) or time-to-switch (t0±, B) averaged over all 
clamping forces. (C,D) Bending (open symbols) and unbending (filled symbols) tsw± (C) or t0± 
(D) vs. pre-switch force curves for indicated integrins (Mean ± SEM). In A-D, bending of 
D723R and L138I αVβ3 occurred too infrequently to obtain sufficient data for statistically 
stable characterization thus were not summarized. (E) WT αVβ3-FNIII7-10 lifetime vs. force 
data from measurements not containing bending and unbending events, to show the potential 
constraints of the receptor–ligand bond lifetime to the observable tsw± (C) and t0± (D). (F) 
Ratio of WT αVβ3 time-to-unbend t0+ to time-to-bend t0- vs. clamping force, showing the 
force-dependent bent/extended state equilibrium. The solid circles were calculated from data 
in panel D. The value of the open circle was the ratio of the extended to bent integrin 
sub-populations estimated from Fig. 4E. N.S. = not significant; * = p < 0.05; ** = p < 0.01; 
*** = p < 0.001 **** = p < 0.0001, assessed by unpaired, two-tailed Student’s t-test. 
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Figure 3-11. Lack of effect of cell surface αVβ3 bending/unbending on its ligand dissociation 
rate under force. (A) Mean ± SEM of the post-unbending/bending lifetime averaged over all 
clamping forces. (B-D) Average, post-bending and post-unbending bond lifetime (mean ± 
SEM) vs. force curves of WT (B), D723R (C) and L138I (D) αVβ3 integrin. The average 
lifetime was from measurements not containing bending/unbending events. The lower force 
regime (< 35 pN) fragment of the WT average lifetime curve (B, red filled circle) is identical 
to Fig. 5 F. Bending of D723R and L138I αVβ3 occurred too rarely to obtain sufficient data 
for statistically stable characterization. (E) Scatter plots of WT (magenta circle), D723R 
(green rectangle) and L138I (brown triangle) αVβ3–FNIII7-10 bond lifetime vs. molecular 
complex spring constant under 20 pN clamping force. The molecular complex spring constant 
was measured during the ramping phase as described in Fig. 4 A and B. (F) Average lifetimes 
of two subgroups of integrins with different molecular complex spring constants, kmol > and < 
0.535 pN/nm (dashed line in panel (E)). The number of events is indicated in each bar. N.S. = 
not significant, assessed by unpaired, two-tailed Student’s t-test. 
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To further confirm that the initial integrin conformation does not affect its bond 
dissociation, the lifetimes under 20 pN clamping force of all three genotypes were 
plotted against the molecular complex stiffness kmol, given that the stiffness is an 
indicator of the integrin conformation, which showed no correlation at all (Fig. 3-11 
E). Segregating the lifetime events according to kmol < or > 0.535 pN/nm (the average 
of kbent and kextended), which acted as a rough method to separate bent and extended 
integrins, also showed no difference in the average lifetime (Fig. 3-11 F), suggesting 
that the lifetime is not dependent on kmol. 
This suggested that in the physiological cation condition Ca2+/Mg2+, the binding 
strength of integrin αVβ3 was not dependent on the extended/bent conformation or 
bending/unbending conformational changes, but rather probably some other 
conformational changes, like tail separation or hybrid-domain swing-out. However, to 
be noted, the bond lifetime is only a reflection of the off-rate, thus no prediction 
should be made on the on-rate or affinity of the binding. 
3.2.2.5 Observation of fibrinogen-bound integrin αVβ3 bending/unbending 
conformational change 
The fact that the probabilities of WT αVβ3 bending/unbending conformational 
changes reported by AP3 were much lower than by FNIII7-10, despite much higher 
lifetimes in most of the forces (compare Fig. 3-7 F, dark green curve with Fig. 3-11 B, 
red curve), raised the possibility that these conformational changes are 
ligand-discriminating. To test this hypothesis, fibrinogen, another ligand for αVβ3, 
71 
was used to interrogate the WT αVβ3. Both bending and unbending conformational 
change events were observed, the displacements of which distributed as single-peak 
Gaussians respectively (Fig. 3-12 A-D). The average bending and unbending 
displacements were both ~15 nm, which were identical to those of FNIII7-10-bound 
αVβ3 (Fig. 3-8 I). However, the frequency and probability of both bending and 
unbending of fibrinogen-bound WT αVβ3 were slightly lower as compared to 
FNIII7-10-bound (Fig. 3-8 J and Table 3-1), suggesting that fibrinogen may be 
unfavorable to the bending/unbending conformational changes. 
The unbending tsw+ of fibrinogen-bound αVβ3 was comparable to FNIII7-10-bound 
(compared Fig. 3-10 C and Fig. 3-12 E, both curves with magenta solid squares), but 
t0+ appeared to be slightly longer under all forces (compared Fig. 3-10 D and Fig. 
3-12 F, both curves with magenta solid squares), which may at least partially explain 
the lower probability of unbending. On the other hand, the bending tsw- of 
fibrinogen-bound αVβ3 was longer than FNIII7-10-bound (compared Fig. 3-10 C and 
Fig. 3-12 E, both curves with magenta open circles), while the t0- comparable at 
lower forces and shorter at higher forces (compared Fig. 3-10 D and Fig. 3-12 F, both 
curves with magenta open circles). To note, however, because the fibrinogen-αVβ3 
lifetime is a slip bond (Fig. 3-12 G, solid red circles) while the FNIII7-10-αVβ3 lifetime 
is a catch-slip bond (Fig. 3-10 E), the lifetime of αVβ3 binding to fibrinogen was 
longer than FNIII7-10 at low forces but became shorter when force is larger than 15 pN, 
which potentially brought more constraints to the observable t0± at higher forces. 
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Figure 3-12. Observing bending/unbending conformational changes of fibrinogen-bound WT 
αVβ3 on cell surface. (A,C) Scatter plots of displacements vs. pre-switch forces of the 
unbending (A) and bending (C) events. Mean ± SD of displacements are shown as solid and 
dashed lines. (B,D) Histograms (bars) and Gaussian fits (curves) of the data from A and C. 
(E,F) Bending and unbending switching tsw (E) or t0 (F) vs. pre-switch force curves (Mean ± 
SEM). (G) Average, post-bending and post-unbending bond lifetime vs. force curves (Mean ± 
SEM). The average lifetime was from measurements not containing bending/unbending events. 
(G) Mean ± SEM, αVβ3–fibrinogen average lifetime vs. molecular complex spring constant 
under 15 pN clamping force. 
The post-bending, post-unbending and average lifetime curves of 
fibrinogen-bound αVβ3 all well overlapped under all forces (Fig. 3-12 G). Moreover, 
the average lifetime under 15 pN clamping force showed no correlation with the 
molecular complex spring constant (Fig. 3-12 H). These results indicated that, similar 
to FNIII7-10 being the ligand, the bent/extended conformation or the 
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bending/unbending conformational change has negligible effects in the 
αVβ3-fibrinogen dissociation rate under force. 
3.2.3 Observation of integrin αVβ3 bending/unbending 
conformational change by High-Speed Atomic Force Microscopy 
(HS-AFM) 
 The dynamic process of integrin conformational changes has never been directly 
visualized. High-Speed Atomic Force Microscopy (HS-AFM) is an upgraded version 
of the conventional AFM setup, which was invented by Dr. Toshio Ando. It has a 
strong advantage in imaging high speed conformational and structural changes of 
macro-molecules110,111. In collaboration with Dr. Peter Hinterdorfer lab at Johannes 
Kepler University (JKU) Linz, Austria, we employed a HS-AFM to directly image 
and characterize the real-time bending and unbending conformational changes of the 
recombinant integrin αVβ3. All the HS-AFM experimental results under this section 
were collected by Dr. Johannes Preiner, JKU, with my on-site help. 
 A mica surface pre-treated with 30 mM NiCl2 was immersed by a working 
solution that contained physiological concentrations of Ca2+ and Mg2+. Recombinant 
αVβ3 integrins were then seeded on to the surface. A high-speed super-resolution 
cantilever tip scanned over the surface of the mica with a spacial resolution of 1 nm 
and temporal resolution of 50 ms in a 20*20 nm2 area (Fig. 3-13 A). The topography 
of the scanned surface was reflected by the brightness in the image, with higher places 
indicated with a brighter color (Fig. 3-13 A). Both bent and extended integrins could 
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be visualized, with the positions of the headpiece and tailpiece easily recognizable 
based on the globular size and height (Fig. 3-13 B,C). 
 
Figure 3-13. Imaging recombinant αVβ3 in bent and extended conformations using a HS-AFM 
(contributed by Dr. Johannes Preiner, JKU). (A) Sketch of the HS-AFM setup. Recmonbinant 
αVβ3 was seeded onto a mica surface in a Ni2+-contain solution. A high-speed cantilever 
quickly scans the mica surface in the search of integrins and concurrently reflects the surface 
topography. (B) A HS-AFM image of a bent integrin. (C) A HS-AFM image of the same 
integrin in an extended conformation. (B,C) The positions of the headpiece and tailpiece were 
recognized by the size and shape, which were indicated on the panels.  
By tracking a single integrin over time, we successfully captured the process of 
integrin bending/unbending conformational changes. Each integrin was undergoing 
highly dynamic conformational changes back-and-forth almost all the time, which 
agrees with the previous speculation of dynamic equilibrium (Fig. 3-14 A,B). 
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Interestingly, different than BFP observations, it appeared that in the absence of force, 
the integrin could reverse the direction of the conformational change in anywhere 
half-way, or temporarily oscillate within a small angle range. 
 
Figure 3-14. Imaging recombinant αVβ3 bending/unbending conformational changes using a 
HS-AFM (contributed by Dr. Johannes Preiner, JKU). (A) Images of a recmonbinant αVβ3 
selected from a HS-AFM video, with a time interval of 3 seconds between two adjacent 
images. (B) A sketch of the postulated orientation of a bent (upper panel) and extended 
(upper panel) integrin. (C) Distribution and dual Gaussian fitting of the integrin end to end 
distance dEE. The proportions and fitted means of dEE of bent and extended integrins were 
indicated on the graph next to the corresponding conformation plot. (D,E) Scatter plots of 
time-to-extend (D) and time-to-bend (E). The averages (mean ± SEM) were indicated at the 
right up corners. 
The end to end distance dEE of the integrin, measured as the linear distance from 
the ligand binding site of the head-piece to the C-terminus of the tail, of the bent and 
extended integrins distributed as a dual Gaussian, with the two means being 10.55 and 
16.36 nm, which were presumably the dEE of the integrin in bent and extended 
conformations. The difference, 5.79 nm, was much shorter than the average 
bending/unbending displacements measured on BFP (~13 nm in the purified system 
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and ~15 nm in the cell-surface system). We suspect this was due to that in BFP 
experiments the probe bead interrogated the integrin via ligand (FNIII7-10 or fibrinogen) 
binding to the headpiece of the integrin, which increased the overall length of the 
rotating radius, and thus added up to the conformational change displacement.  
 The time-to-switch was then collected for both unbending and bending, which 
had the average of 1.046 s and 2.353 s, respectively (Fig. 3-14 D,E). The average 
time-to-extend was in agreement with the zero-force extrapolation of BFP results 
under the same condition, assuming that the time-to-extend exponentially decays with 
force (Fig. 3-5 B). 
3.3 Discussion 
The idea that integrins are undergoing reversible bending and unbending 
conformational changes in dynamic equilibrium has been speculated long time ago, 
but was confirmed only recently on a αI domain containing integrin, αLβ263. Based on 
the same technical approach, my study under this aim recapitulated this observation 
on a αI-absent integrin,αVβ3, both in a purified system and on cell surface. Moreover, 
we for the first time ever visualized these conformational changes with a HS-AFM. 
Integrins can adopt multiple binding states against ligands. In the inactive state, 
integrins have a low affinity when binding to ligands, which will be drastically 
up-regulated upon activation (e.g., Mn2+ or talin head domain association). So far, this 
multi-binding-state property have been exhibited in integrin α5β1, αLβ2, αIIbβ3 and 
αMβ2 in single molecular level 26,27,29,57, manifested by the change of dissociation rate 
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under different forces that does not follow Bell’s model 96. Similarly, the lifetime of 
purified integrin αVβ3-FNIII7-10 in Mn2+ showed a catch-bond while in Ca2+/Mg2+ 
manifesting a slip-bond (Fig. 3-6 C), suggesting the existence of multiple binding 
states. Compared with α5β1 and αLβ2 whose catch-slip behavior was persistent in all 
tested cation conditions, αVβ3 possesses both catch- and slip-bond behaviors. In 
discrepancy with cell-free system, the lifetime of cell-surface WT αVβ3-FNIII7-10 
binding was in the form of “slip-catch-slip” in Ca2+/Mg2+, which allows the bond to 
withstand a considerable level of force (Fig. 3-11 B). Nonetheless, all the lifetime 
curves of WT αVβ3-FNIII7-10 regardless of in the cell-free or cell-surface system, 
diminished at force > ~40pN, which agreed with the previous quantification of the 
maximal force the cell could exert on a single αVβ3-fibrinotin bond112. Interestingly, 
the lifetime curves of D723R and L138I αVβ3 well overlapped, both manifesting a 
slip-bond which prolonged the lifetime under low forces but became identical to WT 
at force > 20 pN (Fig. 3-11 C,D). 
Both bending and unbending can be observed on cell surface αVβ3 when 
interrogated by a RGD-containing fibronectin fragment FNIII7-10, fibrinogen or even 
antibody AP3 which targets on an epitope distal of the ligand bind site. Nonetheless, 
their occurring frequencies did show substantial differences, with FNIII7-10 and 
fibrinogen higher than AP3 in both unbending and bending (Fig.3J). These data 
suggested that the dynamic bending/unbending switch is an interior attribute of the 
integrin, which is not relying on, but rather dependent on ligand association. This 
ligand dependency further extends to the kinetics characterizations of conformational 
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changes, exhibiting discrepancy between FNIII7-10- and fibrinogen-bound integrins in 
the tsw and t0 vs. force (Fig. 5C,D; Fig. 7E,F). We suspect that this ligand 
discrimination in bending and unbending is realized by the distinctive docking of the 
binding motifs of FNIII7-10 (RGD) and fibrinogen (AGDV), which results in varied 
allosteric effects that propagate from the N-terminal ligand binding epitope to the 
overall structure of the integrin. 
The criteria of distinguishing bending/unbending events from BFP lifetime 
signals is based on the stiffness difference in bent and extended conformations of the 
integrin. To confirm that, we measured the receptor-ligand molecular complex spring 
constants before bending and unbending events, which reflect the relative stiffness of 
the integrin in two conformations. Agreeing with the criteria and previous results on 
αLβ263, the integrin αVβ3 was measured to be softer in the bent conformation, and 
stiffer when extended (Fig. 3-4 B; Fig. 3-9 C). Taking advantage of these results, we 
employed Gaussian and dual Gaussian fittings and determined the initial fractions of 
bent and extended integrin sub-populations in the absence of force regulation (Fig. 
3-4 C,D; Fig. 3-9 E-G). 
Functional mutations have been utilized in the studies of integrin activity and 
signaling101,113. The GOF mutation L138I results in a larger proportion of extended 
integrin than WT, which is in consistency with its reported function (Fig. 3-9 F)101. 
Interestingly, D723R, which causes tailpiece separation, also favored more extension, 
suggesting a allosteric relay between different categories of conformational changes 
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(Fig. 3-9 G)101. Moreover, as compared to WT, D723R significantly shortened the tsw 
and t0 of integrin unbending conformational change under force while L138I only 
shortened tsw (Fig. 3-10 A-D), which should at least partially explain both MTs’ sharp 
shift of the bent/extended fraction equilibrium towards extension. 
Mechanical force regulates the conformational changes by providing a positive or 
negative work to the molecule when the headpiece travels along or against the 
direction of force pulling. Intuitively, one should assume that the tensile force exerted 
via ligand engagement should impede bending and favor unbending. Indeed, as 
reflected by tsw and t0 vs. force characterizations, force accelerates unbending and 
stabilizes the extended state, while decelerating bending and destabilizing the bent 
state (Fig. 3-5 B,C,E,F; Fig. 3-10 C,D). Calculation results also confirmed that force 
drastically tilted the equilibrium between bent and extended states towards unbending. 
αVβ3 was reported to initiate cell mechanotransduction via ligand engagement 112,114. 
However, the details of this process as well as how integrin conformational changes 
are aligned with transmembrane signaling still lack insights. The force-stimulated 
integrin extension could potentially serve as a manner of signaling initiation, 
considering that it may trigger certain deformations or rearrangements in the 
juxtamembrane domains 19. 
The relationship between integrin conformational states and binding capacity 
states has been implicated and confirmed in many different works, most of which 
provided only strong correlative but not causal evidences, so that in the inactive state, 
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integrins adopt a bent conformation and weak binding capacity, which undergo 
binding strength enhancement and ectodomain unbending upon activation 40,46,47. 
Agreeing with that, in this work, the correlation was also implicated by the two 
mutations that are associated with stronger binding and an obvious favor of unbending 
over bending. Chen et al used BFP to provide the first direct evidence that the 
bent/extended conformation by itself can have impact on the integrin binding, so that 
extended αLβ2 dissociated slower than bent63. However, surprisingly, in αVβ3 this did 
not apply in the physiological Ca2+/Mg2+ cation condition: 1) bending and unbending 
had negligible effects on the post-switch lifetime (Fig. 3.6 C; Fig. 3-11 B-D; Fig. 3-12 
G); 2) integrins in bent/extended conformations had comparable average lifetime (Fig. 
3-11 E,F; Fig. 3-12 H). These evidences indicated that the bent/extended 
conformational states of integrin αVβ3 do not have direct correlation with the binding 
dissociation rate. In Mn2+, however, the dependency showed up (Fig. 3.6 B). 
Nonetheless, considering that during unbending the upward movement and the 
re-orientation of the headpiece which should become more favorable for ligand 
binding, one may speculate that unbending increases the on-rate or affinity of integrin 
binding under all conditions, which obviously requires further investigations. For 
example, it was reported that ligand binding led to headpiece opening of αIIbβ3, which 
up-regulated its binding affinity for >200 folds, suggesting that ligand 
binding-induced integrin conformational changes can affect their binding115. 
The fact that the dynamic switch of bending/unbending conformational changes 
can occur independent of cells, both under force (BFP) or without force (HS-AFM) 
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suggests that this reversible movement of integrins does not require external energy 
source, but may be fulfilled with the help of non-specific interactions like 
atom/molecule collision. However, considering that the bending could be observed in 
the presence of a considerable pulling force, e.g., 30 pN with a traveling distance 
(displacement) of ~15 nm, which applied a work of ~450 pN/nm, or 109.32 kBT, in 
which kB is the Boltzmann constant and T = 298.15 K is the room temperature. It 
becomes intriguing and puzzling that how a single molecule could provide such a 
huge amount of energy. 
 
Figure 3-15. Integrin bistability model. (A) The integrin undergoes bending and unbending as 
an intact molecule. However, as postulated, when apart, the α and β subunits adopt extended 
and bent conformations respectively, where they can adopt a minimal energy. The two 
subunits act as two springs, so that when they are associated together, their elastic potential 
energies counteract with each other. The angle changes, φα and φβ, were indicated in the 
graph. (B) A rough sketch demonstrating the energy vs. angle of the α and β subunits and the 
combined intact integrin. The energy of “combined” is the simple addition of “α” and “β”. 
 Inspired by the bistable behavior of certain mechanical structures realized by the 
counteraction of pre-stress inside the structure116, I proposed here a integrin bistability 
model (Fig. 3-15 A). In this model, the two subunits of the integrin, α and β, adopt an 
extended conformation and a bent conformation respectively when apart (for the ease 
of demonstration, assume that the α subunit is extended and β bent), where they reach 
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the minimum of their energy wells. As long as they are away from the default 
conformation (quantified by the angle change, φα and φβ), work needs to be done to 
account for the energy increase, and presumably this energy keeps increasing with a 
larger deformation (Fig. 3-15 B). When the two subunits are forced to associate, in the 
bent conformation, the potential energy is small in α but large in β; while in the 
extended conformation, the potential energy is small in β but large in α. Their elastic 
forces counteract with each other, which creates a energy pan-out with two energy 
wells surrounding the bent and extended conformations (Fig. 3-15 B). This realizes 
two stable conformational states of the integrin, bent and extended, and it will switch 
between them dynamics stimulated presumably by molecular vibration and collision. 
The validation of this model will definitely need further investigations. 
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CHAPTER 4: CHARACTERIZING 
GPIB-ΑLPHA-INITIATED PLATELET 
MECHANOSENSING IN SINGLE MOLECULAR LEVEL 
(This chapter of work was equally contributed by Dr. Lining Ju. No 
conflict of interest is claimed.) 
4.1 Introduction 
Platelets rapidly respond to changes in hydrodynamic forces and substrate 
stiffness2,117,118, and  its signaling pathways are substantially simplified due to the 
enucleated structure makes the investigations relatively easier. Previous studies have 
demonstrated the role of GPIbα as a mechanoreceptor for the process of platelet 
mechanosensing10,11,119. As stated in Section 1.2.7, this mechanical-biochemical 
process can be broken down into four steps including mechanopresentation (ligand, 
VWF-A1), mechanoreception (GPIbα headpiece), mechanotransmission (GPIbα stalk 
region) and mechanotransduction (molecules currently unknown). A few biological or 
biomechanical evidences have been collected in the context of platelet GPIbα 
functionality and signaling: 1) GPIbα-mediated Ca2+ signaling is coupled to binding 
events, and the signaling intensity had a reverse relationship with platelet rolling 
velocity in the flow chamber system10,11; 2) pulling force induces LRRD unfolding, 
which prolongs A1-GPIb bond lifetime89; 3) force also unfolds the MSD, which has 
been implicated in platelet mechanosensing16; 4) GPIbα cytoplasmic domain is in 
direct association with a cytoplasmic protein 14-3-3ζ, which is essential for its 
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signaling120. However, how the inter-connected mechanosensing steps are 
orchestrated and associated with the conformational change of the molecule to enable 
the information encoded by force to be translated into biochemical signals is still 
poorly understood. 
4.2 Results 
4.2.1 Fluorescence BFP setup for studying GPIbα-mediated Ca2+ 
signaling 
The BFP system is a suitable approach to study VWF–GPIbα interaction because 
its cycle-wise operation mimics the sequential formation, force loading, and 
dissociation of VWF–GPIbα bonds during the translocation of a platelet on the 
sub-endothelium. In this BFP setup, the probe bead was functionalized with VWF-A1 
or an anti-GPIb monoclonal antibody (mAb), serving as a surrogate sub-endothelial 
surface (Fig. 4-1A,B). A platelet was aspired by the target pipette to move in 
repetitive force-ramp or force-clamp cycles (Fig. 4-1 C,D) (Materials and Methods). 
Adhesion frequencies from these cycles were kept low (<20%) by adjusting the ligand 
or antibody density. Control experiments using beads lacking ligand showed no 
binding, and blocking with mAb AK2 (epitope mapped to LRR1-2 overlapping with 
the A1 binding site) eliminated GPIbα binding to A1 but not mAb WM23 (epitope 
mapped to the MP below LRRD121) (Fig. 1D). This confirmed binding specificity and 
that the binding site of A1 is within LRRD but that of WM23 is outside16. 
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We then used the single-platelet calcium imaging by a fluorescence BFP 
(fBFP)91,104 (see Materials and Methods) to study how platelet signaling was triggered 
by GPIbα mechanoreception. Each platelet was interrogated by a sequence of 
intermittent single GPIbα bonding events in a 200-s observation time, and the resulted 
Ca2+ signal was collected. 
 
Figure 4-1. BFP analysis of ligand binding kinetics. (A) BFP micrograph. A 
micropipette-aspirated RBC with a probe bead attached to the apex (left) was aligned against 
a platelet held by an opposing micropipette (right). (B) BFP functionalization. The probe 
bead was coated with streptavidin (SA, for attachment to the biotinylated RBC) and VWF-A1 
or mAb (left) for interaction with platelet GPIbα (right). (C,D) Representative force vs. time 
signals of repetitive force-clamp (C) and fore-ramp (D) cycles over a 200-s period. Cycles 
produced different results are color-coded (black: no bond; blue: bond-rupture; red: 
bond-lifetime). (E) Mean ± s.e.m. of adhesion frequencies (n ≥ 3) of platelets binding to beads 
functionalized with indicated proteins in the absence (open) or presence (closed) of 50 µg/ml 
AK2. *** = p < 0.001 by t-test.  
4.2.2 Identification of GPIbα-mediated Ca2+ signaling types 
The Ca2+ signals over a 200-s observation time were classified into three types 
(Fig. 4-2 A): i) null-type, featured by a basal trace with a maximum Ca2+ intensity 
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increase (normalized by its initial value) ΔImax<0.05 (Fig. 4-2 B); ii) α-type, featured 
by an initial latent phase followed by a spike (mostly ΔImax>0.5) with a quick decay 
(Fig. 4-2 C); iii) β-type, featured by fluctuating signals around the baseline or 
gradually increasing signals to an intermediate level (mostly ΔImax<0.5) followed by a 
gradual decay to baseline (Fig. 4-2 D). The null type reflects background noise, while 
the α- and β-types match the previous characterization of Ca2+ signals triggered by 
VWF–GPIbα bonds measured in flow chamber-based population assays10,11. For each 
platelet, the calcium trace was overlaid with the sequential binding events, bond 
lifetimes (if any), and their accumulation over the interrogation time was recorded 
(Figure 4-2C). 
 
Figure 4-2. Concurrent analysis of single-platelet Ca2+ flux and GPIb-mediated single-bond 
binding at 25 pN clamped force. (A) Representative epi-fluorescence pseudo-colored images 
of intraplatelet Ca2+ of null (top row), α- (middle row), and β- (bottom row) types at indicated 
times. (B-D) Representative time courses of normalized Ca2+ intensity of the null (B), α (C) 
and β (D) types. In (C), the concurrent measurement of bond lifetime events (symbol) and the 
cumulative lifetime (curve) is overlaid. The pre-Ca2+ longest lifetime (tmax) and the maximum 
intensity increase of the α-type Ca2+ (ΔImax) are indicated. 
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4.2.3 The necessity of durable bonds in GPIbα-mediated 
mechanotransduction 
We asked the question whether the mechanoreceptor GPIbα is capable of sensing 
differences in the force waveform and in the ligand through which force is applied. 
We first performed force-ramp experiment using three ramping rates to generate a 
wide range of rupture forces: 100, 1,000 and 10,000 pN/s. However, only low levels 
of β-type and background level of null-type Ca2+ were resulted, which showed no 
correlation with the mean rupture force prior to calcium onset (Figure 4-3 B,D, right 
ordinate), regardless of whether platelets were tested by A1WT (Fig. 4-3A,B) or 
A1R1450E (Fig. 4-3C,D). In sharp contrast, pulled by a 25pN clamp force which 
realizes the highest average lifetime23, A1WT–GPIbα bonds triggered much higher 
ΔImax, showing 28, 42, and 30% of null-, α- and β-types, respectively (Fig. 4-3 E,F). 
A1R1450E which yielded much shorter lifetimes when binding to GPIbα under 25 pN, 
on the other hand, resulted in much lower ΔImax and only 5% of α-type (Fig. 4-3 E,F). 
Moreover, we took advantage of the force-dependence of the binding kinetics23, and 
manipulated the GPIbα lifetime via changing the clamp forces (10, 25, 40, 60 pN). 
The ΔImax and the α-type Ca2+ ratio both elicited a strong correlation with the average 
lifetime for both A1WT and A1R1450E (This part of data has been thoroughly 
illustrated in the Ph.D. dissertation of my colleague and collaborator, Dr. Lining Ju122, 
and will not be reiterated here). All these results reflected the essential role of durable 
bonding to successfully trigger Ca2+ signaling. 
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As controls, merely holding aspirated platelets or contacting them using beads not 
coated with ligands showed null-type Ca2+ only (Fig. 4-3E,F). GPIbα pulled by an 
antibody AN51 resulted in robust Ca2+ signaling following durable binding events, 
with the ratio of null-, α- and β-types similar to A1WT (Fig. 4-3E,F). However, an 
antibody against GPIbβ (LS-B3174) only induced low level Ca2+ although under the 
same clamp force and with similar average lifetime (Fig. 4-3E,F), despite that GPIbβ 
is tightly connected with GPIbα and has been postulated to play a role in signaling 
through GPIb123. These data demonstrated the necessity of GPIbα engagement to 
trigger intraplatelet Ca2+, which agree with the previous report that α-type Ca2+ peaks 
occur when platelets are transiently arrested in the whole blood flow10.  
 
Figure 4-3. Robust platelet Ca2+ signal requires sustained bonding on GPIbα. (A-D) 
Individual ΔImax values and their mean ± s.e.m. (A,C, points), Ca2+ types (B,D, stacked bars, 
left ordinate), and mean ± s.e.m. of pre-Ca2+ average rupture force (B,D, black square, right 
ordinate) are plotted vs. force ramping rate for A1WT (A,B) or A1R1450E (C,D). (E,F) 
Individual ΔImax values and their mean ± s.e.m. (points, left ordinate) and mean ± s.e.m. tmax 
(gray bar, right ordinate) (E) and fractions (F) of Ca2+ types triggered by different 
stimulations. Each point in (E) represents results from one platelet and the numbers of 
platelets in each column are indicated in the corresponding bar in (F), with matched colors 
indicating Ca2+ types. 
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4.2.4 A single durable bond mediating mechanism of GPIbα 
mechanotransduction 
The concurrently measurements of VWF–GPIbα binding kinetics and 
intraplatelet Ca2+ allowed us to determine the pre-Ca2+ bond lifetimes (Fig. 4-2C), 
enabling single platelet correlative analysis of binding and signaling. Using the 
normalized maximum calcium intensity ΔImax to represent the Ca2+ level, we 
compared its correlations with three statistics of A1WT–GPIbα bond lifetime that 
occurred prior to Ca2+ onset. We found that ΔImax correlates best with the pre-Ca2+ 
longest bond lifetime tmax (Fig. 4-4 A), similarly well with the pre-Ca2+ cumulative 
lifetime Σti (Fig. 4-4 B), but poorly with the pre-Ca2+ average lifetime <t> (Fig. 
4-4C). Careful examination of many overlaid calcium and bond lifetime traces like 
that exemplified in Fig. 4-2C revealed that the Σti values are generally dominated by 
the tmax values, which are usually much longer than the rests of the pre-Ca2+ bond 
lifetimes and are immediately followed by the calcium onset before observing 
additional shorter bond lifetimes. In other words, for each platelet usually Σti could be 
approximated by tmax but <t> is of a smaller and variable value. This observation 
explains why calcium correlates equally well with tmax and Σti but not with <t>. 
Importantly, this data also suggests that a single long-lived VWF–GPIbα bond is 
sufficient to trigger Ca2+ in a platelet. This assertion has been further supported by the 
parallel analysis of the data for A1R1450E. Although for R1450E tmax was 
significantly shorter and α-type Ca2+ population was greatly reduced, the ΔImax still 
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showed similar correlation with tmax (Fig. 4-4D). Thus the pre-Ca2+ longest bond 
lifetime correlates the Ca2+ strength. 
4.2.5 Cooperative unfolding of lucine-rich repeat domain (LRRD) 
and mechano-sensitive domain (MSD) 
 
Figure 4-4. Quantitative correlation of GPIbα lifetime and platelet Ca2+ signaling. (A,D) 
Scatter graphs of ΔImax vs. tmax for A1WT (A) and A1R1450E (D). The solid lines are linear 
fits to respective data with corresponding Pearson coefficients indicated. The yellow and red 
colors of the dots indicate the observed Ca2+ signal type of corresponding platelets. (B,C) 
Scatter graphs of ΔImax vs. ∑t i (B) or <t> (C) for A1WT. The dashed lines are linear fits to 
respective data with corresponding Pearson coefficients indicated. 
Using an optical trap, Zhang et al. observed force-induced MSD unfolding in 
purified recombinant full-length GPIb-IX and a GPIbα stalk region construct16. Using 
a BFP, we observed LRRD unfolding in glycocalicin (GC)89, the extracellular 
segment of GPIbα lacking the MSD (Liang et al., 2013) (Fig. 1-2B). The average 
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unfolding distance of MSD and LRRD was respectively determined to be 20 and 36 
nm. Here we pulled GPIbα on platelets with ramped and clamped force waveforms 
and identified two corresponding unfolding signatures: a) ramped unfolding, featured 
by a sudden force kink at 5-20pN occurring in the ramping phase (Fig. 4-5A insert); b) 
clamped unfolding, featured by an abrupt force drop occurring in the clamping phase 
(Fig. 4-5 A,B). Unfolding lengths derived from both signatures were measured from 
the probe bead position vs. time data (Figure 4-5A insert and B), based on which, 
three subpopulations were segregated by Gaussians fit that respectively peaked at 20, 
36 and 65 nm. Further experimental evidences showed that, the first two 
subpopulations were from single MSD and LRRD unfolding, while the last one were 
a combination of two domains unfolding concurrently (data not shown). 
Interestingly, the two force waveforms induced unfolding of different GPIbα 
domains. Clamped forces unfolded only MSD as the unfolding lengths obtained by 
pulling platelet GPIbα via A1 or AN51 distribute as a single peak at 20nm. LRRD 
unfolding was observed in the ramping phase only. These results indicate that MSD 
can be unfolded by increasing forces as well as constant forces, while LRRD 
unfolding requires a force gradient. Some pulling cycles generated two consecutive 
unfolding events, one in the ramping and the other in the clamping phase, with 
respective unfolding lengths of 34-55nm and 13-25nm that total 47-80nm, agreeing 
with those of the LRRD, MSD, and MSD+LRRD subpopulations. Together, these 
results provide criteria to determine whether and which GPIbα domain(s) unfolded 
(Table 4-1). 
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To characterize responses of GPIbα to mechanical cues it receives, we measured 
the frequency of LRRD and MSD unfolding induced by a range of clamped forces 
exerted on platelet GPIbα via an engaged A1WT or a type 2B VWD mutant 
A1R1450E. The frequency of LRRD unfolding, which occurred in the ramping phase 
only, was undetectable at ≤10pN but increased with the preset force at higher levels 
(Fig. 4-5 C). Interestingly, LRRD unfolded more frequently when pulled by A1WT 
than A1R1450E (Fig. 4-5 C).  
 
Figure 4-5. Force regulated and ligand-dependent cooperative unfolding of GPIbα LRRD 
and MSD. (A) Force vs. time trace of a representative BFP cycle showing unfolding 
signatures in both ramping and clamping phases. The inset zooms in the ramped unfolding 
signature and indicates the unfolding distance. (B) Zoom-in view of the clamped unfolding 
signature in (A). Higher displacement resolutions were obtained after smoothing the raw data 
(points) by the Savitzky-Golay method (curves). Time to unfolding (tu) is indicated. (C-E) 
Frequency of LRRD unfolding (C), MSD ramped unfolding (D) or MSD clamped unfolding (E) 
events by pulling via A1WT (blue) or A1R1450E (red) to the indicated clamped forces. (F) 
The degree of cooperativity, defined as ∆P/P = P(MSD,LRRD)/[P(MSD)P(LRRD)] -1, is 
plotted vs. clamped force. P(LRRD), P(MSD) and P(LRRD,MSD) are the observed 
occurrence frequencies of unfolding events of LRRD alone, MSD alone and both LRRD and 
MSD, respectively. (G,H) Cooperativity assessment by (negative log10 of) p-value of the χ2 
test of the null hypothesis H0: MSD unfolding and LRRD unfolding are independent. The χ2 
test was not performed at 10pN since under this force LRRD unfolding did not occur and 
hence no unfolding cooperativity. 
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By comparison, MSD ramped unfolding occurrence was indifferent to the ligand 
(Figure 4-5 D). Surprisingly, distinctive force-dependent trends of MSD clamped 
unfolding were observed when force was applied to platelet GPIbα via different 
ligands. When pulled by A1WT, the unfolding occurrence first increased with the 
clamped force, reached a maximum at 25pN, and decreased thereafter (Fig. 4-5 E, 
blue). When pulled by A1R1450E, by comparison, the MSD unfolding occurrence 
decreased monotonically with the clamped force (Fig. 4-5 E, red). These data provide 
evidence that the mechanoreceptor GPIbα may be able to interpret mechanical cues 
and discriminate ligands by responding to different force waveforms applied via 
different ligands with distinct LRRD and MSD unfolding frequencies. 
The spatial separation of LRRD and MSD by the >30nm long MP region and the 
distinctive dependences of their unfolding on the force waveform would seem to favor 
these two GPIbα domains to unfold independently. This hypothesis predicts that the 
probability for LRRD and MSD to unfold concurrently should be equal to the product 
of the respective probabilities for LRRD and MSD to unfold separately. To test this 
hypothesis, we estimated these probabilities from the observed unfolding occurrence 
frequencies. At 25pN, the 34.5% of BFP force-clamp cycles with unfolding events 
consist of 7.6, 17.2, 6.9, and 2.8% of unfolding of LRRD alone, MSD alone, LRRD 
and MSD sequentially, and concurrently (Table 4-1). Significantly, the frequency of 
observing both LRRD and MSD unfolding in the same binding cycle, calculated by 
pooling together both cases of two domains unfolding sequentially and concurrently, 
P(MSD,LRRD) = 9.7%, is much higher than the product of their respective 
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occurrence frequencies, P(MSD)×P(LRRD) = 4.65%, which is the joint probability 
for both to unfold assuming that they were independent (Table 4-2). Similar results 
were observed under higher forces as well for A1WT, but not A1R1450E (Table 4-2). 
These evidences suggest that the two domains may unfold cooperatively, i.e., one 
domain unfolding may increase the likelihood for the other to unfold. To quantify the 
degree of such cooperativity, we defined a relative probability difference, ∆P/P = 
[P(MSD,LRRD) - P(MSD)P(LRRD)]/[P(MSD)P(LRRD)]. ∆P/P > 0 indicates 
positive cooperativity between LRRD and MSD unfolding. No cooperativity was 
observed at 10pN, which is expected because this force is insufficient to induce 
appreciable LRRD unfolding. Pulled with A1WT by a 25pN clamped force generated 
high cooperativity, and further increase in force decreased cooperativity (Fig. 4-5 F). 
Remarkably, unfolding cooperativity was completely abolished at all forces when 
applied via the VWD mutant A1R1450E (Fig. 4-5 F). Furthermore, χ2 test was used 
by our collaborator, Prof. Lingzhou Xue (The Pennsylvania State University) to determine 
if the hypothesis that MSD and LRRD unfolded independently should be rejected. 
Significant (p < 0.05) unfolding cooperativity was observed only for A1WT at 25 and 
40pN. These data show that the cooperativity between LRRD and MSD unfolding is 
force-regulated and ligand-dependent. 
4.2.6 Model for cooperativity between LRRD and MSD unfolding 
To elucidate the mechanism underlying the force- and ligand-dependent 
unfolding cooperativity, we note that when the MSD unfolding events were separately 
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analyzed according to their occurrence in the ramping or clamping phase, MSD 
clamped, but not ramped, unfolding, was significantly (p=8.79×10-3 vs. 0.076 at 25pN) 
enhanced by LRRD unfolding (Fig. 4-5 G), which occurred in the ramping phase only. 
This dominance of cooperativity by sequential rather than concurrent unfolding 
suggests a model for LRRD unfolding to impact MSD unfolding, which includes 
three ideas. The first idea has to do with the MSD time-to-unfold, tu (cf. Fig. 4-5 B). 
Our force-clamp measurement revealed similar slip-bond trends for A1WT and 
A1R1450E (Fig. 4-6 C). The only exception is at 10pN where A1WT resulted in a 
shorter tu than A1R1450E. This can be explained by their differential bond lifetimes 
with GPIbα (Fig. 4-6 A,B). Compared to A1R1450E, the much shorter GPIbα bond 
lifetime of A1WT at 10pN may result in underestimation of MSD clamped unfolding 
because early dissociation would have prevented the observation of slow MSD 
unfolding events. This reasoning provides the second idea for our model: MSD 
clamped unfolding should occur before VWF–GPIbα bond dissociation. The third 
idea comes from our previous observation89 that LRRD unfolding significantly 
prolonged GPIbα bond lifetime with A1WT (Fig. 4-6 A) but not A1R1450E (Fig. 4-6 
B). Combining these three ideas, our model proposes that the VWF–GPIbα bond 
lifetime, regulated by force and prolonged by LRRD unfolding in respective 
ligand-specific manners, determines the occurrence of MSD clamped unfolding, 
which, despite its ligand-independent unfolding kinetics, results in a cooperativity 
pattern that maximizes at the optimal force of 25pN for A1WT but shows no 
cooperativity for A1R1450E. 
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Table 4-1. Decision rules for and statistical summary of GPIbα domain unfolding in 
force-clamp experiment mode. Criteria for deciding whether or not (+ or -) and which (LRRD, 
MSD, or both) GPIbα domain(s) was (were) unfolded are based on BFP profile signatures 
and the unfolding length. YES = observed, NO = not observed. NA = not applicable. 
 
To formulate the model mathematically, we multiplied the respective probability 
densities of the exponentially distributed MSD time-to-unfold (tu) (Fig. 4-6 D) and 
 
  Clamped Force (pN) 






phase LRRD MSD 
WT A1 vs. 
Platelet 
10 
NO NO - - 115 93.50% 
<25nm NO - + 1 0.81% 
NO <25nm - + 7 5.69% 
25 
NO NO - - 95 65.52% 
25-56 nm NO + - 11 7.59% 
<25nm NO - + 5 3.45% 
NO <25nm - + 20 13.79% 
<56nm <25nm + + 10 6.90% 
>56nm NO + + 4 2.76% 
40 
NO NO - - 60 61.86% 
25-56 nm NO + - 10 10.31% 
<25nm NO - + 8 8.25% 
NO <25nm - + 10 10.31% 
<56nm <25nm + + 6 6.19% 
>56nm NO + + 3 3.09% 
60 
NO NO - - 45 60.81% 
25-56 nm NO + - 10 13.51% 
<25nm NO - + 7 9.46% 
NO <25nm - + 6 8.11% 
<56nm <25nm + + 3 4.05% 




NO NO - - 80 85.11% 
25-56 nm NO + - 0 0.00% 
<25nm NO - + 1 1.06% 
NO <25nm - + 13 13.83% 
<56nm <25nm + + 0 0.00% 
>56nm NO + + 0 0.00% 
25 
NO NO - - 93 74.40% 
25-56 nm NO + - 10 8.00% 
<25nm NO - + 8 6.40% 
NO <25nm - + 12 9.60% 
<56nm <25nm + + 0 0.00% 
>56nm NO + + 2 1.60% 
40 
NO NO - - 81 69.83% 
25-56 nm NO + - 13 11.21% 
<25nm NO - + 12 10.34% 
NO <25nm - + 7 6.03% 
<56nm <25nm + + 0 0.00% 
>56nm NO + + 3 2.59% 
60 
NO NO - - 45 68.18% 
25-56 nm NO + - 8 12.12% 
<25nm NO - + 8 12.12% 
NO <25nm - + 3 4.55% 
<56nm <25nm + + 0 0.00% 
>56nm NO + + 2 3.03% 
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the dual-exponentially distributed lifetime (tb) of GPIbα bonds with A1WT or 
A1R1450E (Tale 4-3)88 to construct a joint probability density surface over the tu-tb 
plane (Fig. 4-6 E,F): 
Step 1: Derive the parameters of lifetime and unfolding kinetics 
The measured MSD time-to-unfold tu distributed as a single exponential decay: 
𝑒𝑒u(𝑡𝑡u) = 𝑘𝑘u𝑒𝑒−𝑘𝑘u𝑡𝑡u, where pu is the probability density and ku is the unfolding rate of 
MSD under a clamping force. By fitting the semi-log plotted experimental distribution 
with a straight line, the unfolding rate at 25pN was evaluated from the negative slope 
or the reciprocal average time-to-unfold, ku = 1/<tu> = 0.870 s-1 (Figure 4-6 D). 
Modeling the force-dependent MSD unfolding kinetics by the Bell equation96, we 
found the zero-force unfolding rate and the width of the energy barrier to be 0.26s-1 
and 0.242nm for A1WT. For A1R1450E, the respective values are 0.31s-1 and 
0.261nm. 
We previously reported that the A1–GPIbα bond lifetime tb distributed as a dual 
exponential decay with a fast- and a slow-dissociating off-rate88. We also recently 
showed that unfolding of LRRD prolongs A1–GPIbα bond lifetime89. These results 
were also observed in this work, which comprise individual measurements that gave 
rise to the averaged results in Fig. 4-6 A. 
For LRRD-: 𝑒𝑒1(𝑡𝑡b) = 𝑤𝑤11𝑘𝑘11𝑒𝑒−𝑘𝑘11𝑡𝑡b + 𝑤𝑤12𝑘𝑘12𝑒𝑒−𝑘𝑘12𝑡𝑡b    (Equation 4-1) 
For LRRD+: 𝑒𝑒2(𝑡𝑡b) = 𝑤𝑤21𝑘𝑘21𝑒𝑒−𝑘𝑘21𝑡𝑡b + 𝑤𝑤22𝑘𝑘22𝑒𝑒−𝑘𝑘22𝑡𝑡b           (Equation 4-2) 
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Table 4-2. Evaluation of LRRD and MSD unfolding cooperativity. All probabilities were 
calculated from occurrence data in Supplementary Table 1. Observed joint probabilities were 
compared to their predicted counterparts based on the assumption that LRRD and MSD 
unfolded independently. For example, in “WT A1 vs. Platelet” under 25 pN: The probability 
of LRRD unfolding is P(LRRD) = 3.4% + 6.9% + 2.76% =13.06%. The probability of MSD 
unfolding is P(MSD) = 7.6% + 13.8% + 6.9% + 2.76% =31.06%. The probability of MSD 
ramped unfolding is P(MSD, ramp) = 7.6% + 2.76% =10.36%. The probability of MSD clamped 
unfolding is P(MSD, clamp) = 13.8% + 6.9% =20.7%. 
 
where kij and wij (wi1 + wi2 = 1) denote, respectively, off-rates and associated 
fractions of bonds under a clamped force, with the first subscript indicating without 
 
  Clamped Force (pN) Unfolding 
Observed 









LRRD +,  
MSD + 0.00% P(MSD) * P(LRRD) 0.00% 0 
LRRD +,  
MSD ramped + 0.00% 
P(MSD, ramp) * 
P(LRRD) 
0.00% 0 
LRRD +,  
MSD clamped + 0.00% 




LRRD +,  
MSD + 9.66% P(MSD) * P(LRRD) 4.65% 1.1 
LRRD +,  
MSD ramped + 2.76% 
P(MSD, ramp) * 
P(LRRD) 
1.07% 1.6 
LRRD +,  
MSD clamped + 6.90% 




LRRD +,  
MSD + 9.28% P(MSD) * P(LRRD) 5.45% 0.70  
LRRD +,  
MSD ramped + 4.12% 
P(MSD, ramp) * 
P(LRRD) 
2.42% 0.70  
LRRD +,  
MSD clamped + 5.16% 
P(MSD, clamp) * 
P(LRRD) 
3.03% 0.70  
60 
LRRD +,  
MSD + 8.11% P(MSD) * P(LRRD) 5.56% 0.46  
LRRD +,  
MSD ramped + 5.41% 
P(MSD, ramp) * 
P(LRRD) 
3.21% 0.68  
LRRD +,  
MSD clamped + 2.70% 
P(MSD, clamp) * 
P(LRRD) 





LRRD +,  
MSD + 0.00% P(MSD) * P(LRRD) 0.00% 0 
LRRD +,  
MSD ramped + 0.00% 
P(MSD, ramp) * 
P(LRRD) 
0.00% 0 
LRRD +,  
MSD clamped + 0.00% 




LRRD +,  
MSD + 1.60% P(MSD) * P(LRRD) 1.69% -0.05  
LRRD +,  
MSD ramped + 1.60% 
P(MSD, ramp) * 
P(LRRD) 
0.77% 1.08  
LRRD +,  
MSD clamped + 0% 
P(MSD, clamp) * 
P(LRRD) 
0.92% -1.00  
40 
LRRD +,  
MSD + 2.59% P(MSD) * P(LRRD) 2.62% -0.01  
LRRD +,  
MSD ramped + 2.59% 
P(MSD, ramp) * 
P(LRRD) 
1.78% 0.45  
LRRD +,  
MSD clamped + 0.00% 
P(MSD, clamp) * 
P(LRRD) 
0.83% -1.00  
60 
LRRD +,  
MSD + 3.03% P(MSD) * P(LRRD) 2.98% 0.02  
LRRD +,  
MSD ramped + 3.03% 
P(MSD, ramp) * 
P(LRRD) 
2.30% 0.32  
LRRD +,  
MSD clamped + 0.00% 
P(MSD, clamp) * 
P(LRRD) 
0.69% -1.00  
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(Eq. 4-1) or with (Eq. 4-2) a prior LRRD unfolding and the second subscript 
indicating the fast (Eq. 4-1) or slow (Eq. 4-2) dissociation pathway. By fitting the 
above model to data89, the parameters were calculated (Table 4-3). 
Step 2: calculate the unfolding probability using the model 
Assuming that MSD unfolding and A1–GPIbα unbinding are independent events, 
the joint probability density for MSD unfolding at time tu and A1–GPIbα unbinding at 
time tb is p(tu, tb) = pu(tu)pi(tb) where i = 1, 2 depending on whether LRRD unfolding 
occurs. This joint probability is depicted as a surface in Fig. 4-6 E,F using respective 
A1WT and A1R1450E data measured at 25pN clamped force. The condition for 
observing MSD clamped unfolding is that the A1–GPIbα bond lifetime tb lasts longer 
than the time-to-unfold tu. Thus, the probability of observing MSD unfolding in the 
clamping phase Pui is the volume under the probability density surface over the region 
0<tu<tb<∞, which is marked by the vertical red planes in Fig. 4-6 E,F. For instance, in 
the absence of LRRD unfolding, the probability of observing MSD unfolding in the 
clamping phase of 25pN is: 









= 21.5%  (Equation 4-3) 






= 46.2%               (Equation 4-4) 
The model was applied to predict the MSD clamped unfolding probability under 
different clamped forces pulled by A1R1450E as well. In these conditions, the  
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Figure 4-6. LRRD unfolding prolongs VWF–GPIbα bond lifetime and facilitates MSD 
clamped unfolding. (A-C) Mean ± s.e.m. GPIbα bond lifetimes (tb, A,B) and MSD 
time-to-unfold (tu, A) with A1WT (blue) or A1R1450E (red) were measured in the clamping 
phase at different forces in the absence (-) or presence (+) of LRRD unfolding in the same 
BFP cycle. No LRRD unfolding occurred at 10pN; hence no bond lifetime was measured 
under this condition. (D) Time-to-unfold (tu) distributions of MSD clamped unfolding with 
(red) and without (black) a preceding LRRD unfolding at 25pN clamped force. The unfolding 
rate ku were calculated from the slope of ln(survival frequency) vs. time-to-unfold overlaid 
plot and the error were estimated from the 95% confident interval. (E,F) 3D plot of the 
surface of joint probability density (z-axis) of A1WT (E) or A1R1450E (F) to dissociate from 
GPIbα at tb (x-axis) and MSD to unfold at tu (y-axis). (G, H) Measured (solid bar) and 
predicted (open bar) frequency of MSD unfolding events occurred in the clamping phase 
induced by A1WT (G) and A1R1450E (H) at indicated forces in the presence (+) or absence 
(-) of LRRD unfolding in the same BFP cycle. N.D. = not detected. Error bar = s.e.m. 
estimated by the multinomial distribution of events. 
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ensemble MSD clamped unfolding events were no longer segregated into LRRD- and 
LRRD+ groups, because few MSD clamped unfolding events occurred following 
LRRD unfolding due to the reduced bond lifetime. 
Table 4-3. MSD unfolding rates (ku) and the fraction (w1) and off-rates (k1, k2) of GPIbα 
binding to A1WT or A1R1450E under different forces. w1 represents the fraction of binding 
events that dissociate with the off-rate k1. The fraction of events that dissociate with the 
off-rate of k2 is simply calculated as w2 = 1- w1. NA = not applicable. 
 
When the model was tested against experiment, not only did the calculated 
force-dependent MSD unfolding frequency match the biphasic pattern for A1WT (Fig. 
4-6 G) and the monophasic pattern for A1R1450E (Fig. 4-6 H), but it also compared 
well with the observed occurrence frequencies numerically at all forces. Remarkably, 
the model predicts both the quantitative enhancement of MSD unfolding by LRRD 
unfolding for A1WT and the lack of enhancement for A1R1450E. The excellent 
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agreement between theory and experiment has provided strong support to our model 
and explained the data in Fig. 4-6 G,H. 
4.2.7 LRRD unfolding strengthens signaling by prolonging the 
lifetime while MSD unfolding is key to determining Ca2+ type 
The findings that durable force is important to both MSD unfolding and Ca2+ 
triggering prompted us to investigate the relation between GPIbα domain unfolding 
and platelet signal initiation. We segregated the Ca2+ data generated by a 25pN 
clamped force on A1WT bonds according to whether and which domain(s) was (were) 
unfolded prior to calcium onset. Platelets whose tests contained without unfolding 
events showed short tmax and low calcium of β- and null-types (Fig. 4-7A). Platelets 
whose tests contained at least one pre-Ca2+ MSD unfolding event but no LRRD 
unfolding showed slightly longer tmax and higher calcium of mostly α-type. By 
comparison, only β-type Ca2+ was observed in the rare (2.6%) cases where LRRD but 
not MSD unfolded despite the much longer tmax, excluding tmax as the direct 
determining parameter for the Ca2+ type. Remarkably, the group with both a LRRD 
and a MSD unfolding event exhibited long tmax and high post-unfolding calcium of 
mostly α-type. Consistent results were obtained using WM23 to pull GPIbα to bypass 
LRRD unfolding, showing significantly longer tmax and higher calcium for platelets 
with than without a MSD unfolding event and a clear α- vs. β-type signal distinction 
between them (Fig. 4-7B). The data in Figure 4-7 A,B indicate that at least one MSD 
unfolding event is required for triggering α-type Ca2+. Interestingly, regardless of 
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strong pulling represented by bond rupture forces (Fig. 4-7C,D, right ordinate), the 
force-ramp experiments that triggered only null/β-type but not α-type Ca2+ (Fig. 4-3 
B,D and 4-7 C,D, left ordinate) generated very infrequent MSD unfolding events for 
both A1WT and WM23 cases (Fig. 4-7 C,D). This indicates that both force-induced 
MSD unfolding and bond lifetime are necessary for triggering α-type Ca2+. In 83% of 
the cases only a single MSD unfolding event was observed. Of these, 43% showed 
only one bond with lifetime prior to Ca2+ onset. Thus, platelet signaling can be 
induced by a single A1–GPIbα bond.  
 
Figure 4-7. Correlation between GPIbα domain unfolding and Ca2+ triggering at 25pN 
clamped force. Individual ΔImax values and their mean ± s.e.m. (points, left ordinate) in 
platelets triggered by A1 (A,C) or WM23 (B, D) binding were plotted, which were from events 
with (+) or without (-) unfolding of LRRD and/or MSD. Each point represents measurement 
from a platelet. The frequency of each unfolding combination to occur was indicated. (A,B) 
Data obtained from 25pN force-clamp experiments. Corresponding tmax (gray bars, right 
ordinate) were overlaid with ΔImax. (C,D) Data obtained from 1,000pN/s force-ramp 
experiments. Corresponding pre-Ca2+ largest rupture force fmax (gray bars, right ordinate) 
were overlaid with ΔImax. 
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Furthermore, using a sensitivity-specificity analysis that slides a putative 
threshold through the tmax vs. Ca2+ type data, Prof. Xue found tmax>2s to be the best 
predictor for A1WT to trigger α-type Ca2+ (Fig. 4-4 A, dashed line). Thus, a 
longer-lived bond favors MSD unfolding, thereby triggering α-type Ca2+; otherwise, it 
tends to trigger β-type Ca2+. Together, our data suggest separate roles of LRRD and 
MSD unfolding in GPIbα signaling, with the former intensifying the Ca2+ level and the 
latter determining the Ca2+ type digitally. 
4.2.8 Perturbing cytoplasmic association of GPIbα with 14-3-3ζ 
inhibits mechanoreception 
 
Figure 4-8. The effect of 14-3-3ζ blockade to platelet Ca2+ signaling and a proposed model. 
(A) Percentage of total events of three Ca2+ types in platelets in the same experiments as in 
Fig. 4-7 (A) and (B) (left bars) as well as additional experiments performed in the presence of 
MPαC (middle bars) or MαCsc (right bars). Error bar = s.e.m. estimated from the 
multinomial distribution of events. (C) A postulated model of GPIbα-mediated 
mechanosensing. Force applied via VWF-A1 induces GPIbα LRRD and MSD unfolding. 
GPIbβ head domain binds to the unfolded MSD and causes the dissociation of its cytoplasmic 
tail from GPIbα-associated 14-3-3ζ, which transduces signals across the platelet membrane 
and further downstream, finally leading to α-type Ca2+. Component names of the 
mechanotransduction system are indicated. 
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To understand GPIbα-mediated mechanotransduction requires analysis of not 
only ligand binding and domain unfolding in the extracellular segment of GPIbα but 
also events in its cytoplasmic region. 14-3-3ζ is a cytoplasmic protein that has direct 
association with both GPIbα and GPIbβ at C-terminus14 and regulates their 
signaling124. To investigate the role of 14-3-3ζ in GPIbα-mediated Ca2+ signaling, we 
perturbed the system with a myristoylated peptide (MPαC) that blocks the association 
of GPIb cytoplasmic terminus to 14-3-3ζ. MPαC mimics the 14-3-3ζ binding 
sequence of GPIbα; a scramble peptide (MαCsc) was used as control. Consistent with 
the previously reported signaling inhibition effect124,125, MPαC reduced the fraction of 
α-type Ca2+ from 34 to 3% without affecting β-type Ca2+, whereas MαCsc had no 
effect (Fig. 4-8A). Similar results were obtained by pulling GPIbα via WM23 (Fig. 
4-8B). Thus, GPIb–14-3-3ζ association, a biochemical event, is crucial for the 
transduction of MSD unfolding, a mechanical event, into intracellular signals. These 
observations indicate that GPIb–14-3-3ζ serves, at least in part, as a mechanosensor. 
Incorporating previous discoveries, I proposed that this mechanosensor works in the 
following way: a durable binding of the headpiece of GPIbα induces LRRD unfolding, 
which prolongs the lifetime and cooperatively favors MSD unfolding. The unfolding 
of MSD exposes a domain for the headpiece of GPIbβ to bind, which causes the 
motion and rotation of the whole GPIbβ and the dissociation of its cytoplasmic tail 
from GPIbα-associated 14-3-3ζ. This dissociation exposes certain domains in the 
GPIbβ or 14-3-3ζ that may act as a catalytic domain to facilitate further chemical 
reactions and finally leads to acute and robust intraplatelet granule Ca2+ release 
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(α-type) (Fig. 4-8C, 4-9 C). If the bond is not lasting, no time is given to allow MSD 
unfolding, which fails to trigger the above Ca2+ signaling. However, the transient 
engagement of GPIbα via ligand binding under force should still lead to certain 
intraplatelet reactions which adopt an alternative signaling pathway, resulting in 
β-type Ca2+ (Fig. 4-9 B). To note, β-type Ca2+ was regarded in previous publications 
as a more trivial signal because of its low intensity. If no bond is form at all, then only 
null-type Ca2+ should be observed as a result of no signal transduction at all (Fig. 4-9 
C).  
4.3 Discussion 
The mechanoreception of GPIbα has been supported by direct observations of 
transient intracellular Ca2+ spike (termed type α/β peak) upon platelet translocation on 
VWF under shear, with Ca2+ intensity reversely proportional to the platelet 
translocation velocity10,11. Our observation of similar α/β type Ca2+ signals that 
increased with the A1WT–GPIbα bond lifetime suggests that, despite their isolated, 
aglycosylated and monomeric nature, recombinant A1 domains may be used as a 
valid model for studying force-dependent dissociation of GPIbα bonds and unfolding 
of GPIbα domains. However, many questions remain unresolved. Using fBFP 
real-time single-molecule, single-platelet analysis of ligand binding kinetics, receptor 
mechanical unfolding and intraplatelet calcium imaging, we have: 1) identified, 
characterized and mathematically modeled the force regulated and ligand-dependent 
cooperativity between LRRD and MSD unfolding; 2) defined an optimal magnitude 
and a threshold duration of clamped force for platelet signal initiation via a single 
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A1WT–GPIbα bond; 3) uncovered mechanopresentation defects in a type 2B VWD 
mutant A1R1450E; 4) delineated the interplay among ligand engagement, GPIbα 
domain unfolding and signal induction; and 5) revealed inhibition of GPIbα 
mechanoreception by perturbing its cytoplasmic association with 14-3-3ζ.  
 
Figure 4-9. Model of GPIb-mediated platelet mechanotransduction. For a circulating platelet 
above an injured site without physical contact, its GPIbα signaling will not be triggered (A). 
Upon interacting with VWF, platelets tether and translocate on the sub-endothelial surface 
via sequential intermittent A1–GPIbα bonds that provide adhesive forces. Having relatively 
short lifetimes, these forces unlikely induce MSD unfolding on GPIbα, hence only trigger 
β-type Ca2+ (B). LRRD unfolding under a ramped force prolongs bond lifetime to result in 
temporary platelet attachment, providing a higher chance for MSD unfolding, which triggers 
α-type Ca2+ (C). 
It is an interesting yet challenging problem to define the minimum mechanical 
stimulation for inducing mechanotransduction. We demonstrated that pulling a single 
GPIbα by a 25pN force of >2s to unfold MSD once is necessary and sufficient to 
induce α-type Ca2+ signals. By comparison, to trigger calcium in a naïve CD8+ T 
lymphocyte requires a sequence of intermittent bonds with a total of >10s lifetimes 
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under 10pN accumulated in the first 60s of contacts between T cell receptors and 
agonist peptide-major histocompatibility complex molecules104. In both cases durable 
forces are required, as ramped forces without a clamp phase are unable to trigger 
appreciable levels of α-type Ca2+ regardless of its magnitude (Fig. 4-3 A-D).  
The binding defects of VWF-A1 with type 2B VWD mutations have long been 
recognized126. A recent study has shown one such mutation, V1316M, also causes 
signaling defects127. We showed that another mutation, A1R1450E, also has signaling 
defect. Interestingly, the defect to induce calcium has the same root as the binding 
defect, namely, the conversion of the wild-type catch-slip bond to the mutant slip-only 
bond23. Consequently, force exerted on GPIbα by A1R1450E is less able to unfold 
LRRD (Fig. 4-5 C), lasts shorter at 25pN to unfold MSD less frequently (Fig. 4-5 E), 
does not generate unbinding cooperativity between the LRRD and MSD (Fig. 4-6 G,H, 
Table 4-2), and induces lower level and frequency of α-type Ca2+ at 25 pN (Fig. 4-3 
E,F, 4-4 D). Thus, the mechanical requirements for signal induction result in 
force-dependent patterns of VWF–GPIbα bond lifetimes, MSD unfolding frequencies, 
unfolding cooperativities, and Ca2+ levels/types that are similar for the same A1 
construct but distinct between A1WT and A1R1450E. These findings show that the 
GPIbα mechanoreceptor can discriminate ligands and shed light to the biophysical 
mechanisms of type 2B VWD. 
Our new data on the interplay among VWF binding, GPIbα unfolding, and Ca2+ 
signaling have provided new insights into the inner workings of the A1–GPIb–
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14-3-3ζ molecular assembly (Fig. 4-8). By residing in the juxtamembrane stalk region, 
the MSD has been suggested to play a role in mechanosensing, hence termed 
mechanosensitive domain16. In the present work, we found that MSD unfolding is 
required to trigger α-type Ca2+ (Fig. 4-7 A,B), showing that this extracellular 
mechanical event is transduced into intracellular biochemical signals via the 14-3-3ζ 
connection. By overlapping with the ligand-binding site, the LRRD can feel the 
structural change in the A1 and respond with an altered unfolding frequency and 
changed bond lifetime with and without unfolding its tertiary structure. Further, 
LRRD unfolding increased the frequency of α-type Ca2+ and its level (Fig. 4-7 A). 
Our findings have broad implications since LRRD is a common structure shared by 
many adhesion and signaling receptors, e.g., toll-like receptors. Thus, our study has 
elucidated part of a mechanosensor that includes three components: 1) a MSD in the 
juxamembrane region whose conformational change leads to a binary decision of Ca2+ 
type, 2) a LRRD in the ligand-binding region whose conformational change leads to 
continuous alterations in ligand-binding, signal level and fractions of different signal 
types, and 3) a MP region that transmits force over a distance and provides coupling 
between the two domains. Such a delicate mechanosensing system may be important 
for the platelet to balance its functions between the hemostasis and thrombosis. Future 




CHAPTER 5: GPIB-ΑLPHA 
MECHANOTRANSDUCTION PRIMES PLATELETS 
INTO AN INTERMEDIATE ACTIVATION STATE 
5.1 Introduction 
Platelet functioning requires activation by soluble agonists (e.g., ADP and 
thrombin) or via surface receptor mechanotransduction (e.g., through GPIbα and 
GPVI), which leads to granule release, P-selectin expression, phosphatidylserine 
exposure, and the up-regulation of integrin αIIbβ344,74,128-131.  
Previous works demonstrated that platelet αIIbβ3 could be activated by 1) 
inside-out signaling, which involves binding of talin and kindlin to the β3 cytoplasmic 
domain and the integrin tail separation 36,40-44,132,133; and 2) outside-in signaling, which 
requires ligand association at its headpiece and the downward signal transmission in a 
structurally allosteric fashion 134. Inhibition of αIIbβ3 activation by talin blockage and 
mutation caused bleeding disorders in vivo 10,11,81,135,136.  
P-selectin expression is a key step in platelet activation, because it is originally 
stored in the α-granule and will only be available on the cytoplasmic membrane 
surface upon granule release. P-selectin expression was found on platelets 
downstream of in vivo intracoronary stenosis, suggesting a correlation between 
stenosis and platelet activation69,117,137. PS exposure allows coagulant activity of 
platelets, which mainly contributes to the later stages of hemostasis. PS exposure was 
originally regarded as a sign of platelet apoptosis. But recently it was discovered that 
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platelet activation could result in PS exposure in a non-apoptotic manner71,138. 
Interestingly, shear force played a critical role in both above observations. 
However, important questions remain unanswered. Exactly how is the platelet 
integrin activity regulated on the single-molecular and populational scales? Can 
platelets discriminate different stimulating signals with regard to integrin activation? 
Is there a receptor that mediates P-selectin expression and PS exposure under shear 
force, if so, which one? Is platelet activation reversible in the physiological context? 
To answer these questions, we invented the switch BFP approach and measured 
integrin binding kinetics on the single-cell level, the results of which was 
complemented by a populational flow-chamber assay (not included in this thesis). Our 
results provide a conceptual advance to the current model which regards the αIIbβ3 
activation as a binary result, and demonstrated four related and hierarchical 
adhesiveness states following different stimulations (inactive; intermediate, following 
GPIbα mechanotransduction; active, following ADP or thrombin activation, or 
realized by a cooperation of GPIbα and αIIbβ3 mechano-signaling; and hyperactive, 
following ADP and αIIbβ3 cooperative signaling); each state is associated with distinct 
signaling pathways and integrin conformations. On the other hand, I for the first 
demonstrated that GPIbα—A1 interaction can trigger low level P-selectin expression 
and PS exposure. 
My work for the first time provides mechanistic insights of integrin activity 
regulation on live cell surface. Moreover, the low-level up-regulation of integrin 
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αIIbβ3, together with moderate level of P-selectin expression and PS exposure, defines 
an intermediate activation state of platelets following GPIbα mechanotrasnduction. 
5.2 Results 
5.2.1 Bidirectional signals drive multi-state transition of integrin 
αIIbβ3 on platelets 
In this project, we are curious about how inside-out and outside-in signaling 
regulate integrin αIIbβ3 activity on live platelets. The conformational dynamics and 
binding activities of integrin αIIbβ3 on platelets were characterized by BFP. 
5.2.1.1 Single durable adhesion through GPIbα triggers platelet integrin up-regulation 
Platelet integrin αIIbβ3 can be activated through GPIbα-mediated 
mechano-signaling9-11. To study this process in the single-cell level, a freshly isolated 
human platelet was gently aspirated by a micropipette and served as the target. Plasma 
VWF, which interacts with both GPIbα and integrins αIIbβ3139, was coated onto a 
streptavidin (SA)-coupled glass bead that served as the probe. Adhesion frequency 
experiments were performed, and adhesion events were was enumerated over 50 and 
100 cycles of touch (see Materials and Methods) to yield adhesion frequencies. The 
reason to trace the adhesion frequency for two different numbers of cycles is 
considering that the integrin up-regulation might be a gradual process. Surprisingly, 
the adhesion frequencies were comparable to control which blocked β3 integrins 
binding by integrilin140, indicating negligible integrin activity (Fig. 5-1A left). In 
113 
sharp contrast, force-clamp experiments which allowed durable binding (see Materials 
and Methods) drastically up-regulated the adhesion frequency to ~2-fold (Fig. 5-1A 
right).  
To rule out the possibility that the binding strengthening was due to 
conformational changes of the VWF by force stretching, two separate platelet ligands, 
mA1 and FNIII7-10 were instead used as a dual ligand setup to repeat the experiments. 
The Arg-Gly-Asp (RGD) sequence FNIII7-10 contains in domain 10 is shared by 
VWF15,141-143. To note, the synergy site contained in fibronectin domain 9 is important 
in α5β1 binding144, but secondary for αIIbβ3 and trivial for αVβ3145. After blocking one 
of the dual receptor-ligand interactions with 6G1 (mA1 blocking Ab) 146 or integrilin 
(αIIbβ3 antagonist), the adhesion frequency exhibited no difference over touches and 
between the lifetime-absent/-present conditions, confirming the stability of sole 
GPIbα-mA1 and αIIbβ3-FNIII7-10 interactions (Fig. 5-1B). Overlaying the sole 
GPIbα-mA1 and αIIbβ3-FNIII7-10 interactions yielded an adhesion frequency (Fig. 
5-1B, dashed line) that was comparable to the lifetime-absent dual-receptor 
interaction, suggesting no receptor inter-talk in the absence of durable binding. In 
comparison, allowing durable binding substantially elevated the adhesion frequency 
to >1.5-fold, which (50%) was much higher than the overlay of the two sole 
interactions (26% + 4%) (Fig. 5-1B). As controls, adenosine diphosphate 
(ADP)-activated platelets yielded a high adhesion frequency even after 6G1 blockade 
that reflected a strong integrin activity, which was nearly eliminated by integrilin and 
soluble RGDS135 (Fig. 5-1C). 
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Figure 5-1. Identification of β3 integrin up-regulation following GPIbα mechanotransduction. 
(A-C) Adhesion frequencies of platelets vs. plasma VWF (A) or dually-coated A1+ FNIII7-10 
(B,C). Each platelet–bead pair was tested repeatedly for 50 and 100 cycles to estimate two 
separate adhesion frequencies. Four pairs were tested to obtain mean ± SEM. 10 μg/ml 
integrilin and 2μM 6G1 were used to respectively block β3 integrins and GPIbα binding. The 
permission of lifetime events was decided by pre-setting the experimental mode to force-ramp 
(lifetime -) or force-clamp (lifetime +). The average number of lifetime events, if permitted, 
was indicated under each bar. (B) Horizontal dashed line: overlay of the averaged sole 
GPIbα-mA1 (P1) and αIIbβ3-FNIII7-10 (P2) adhesion frequencies by P1+2 = 1- (1- P1)* (1- P2). 
(C) Platelets were treated with ADP for activation. (D) Scatter plot of platelet-A1 lifetime vs. 
platelet-FNIII7-10 adhesion frequency. Each point represented one platelet under interrogation. 
The two dashed red lines were linear fittings of the data in lifetime regimes of [0~5 s] and 
[5~80 s]. Each platelet–bead pair was tested repeatedly for 30 cycles with a 1 s contact time 
to estimate the adhesion frequency. (E) Post-switch platelet-FNIII7-10 adhesion frequency vs. 
switch time, showing instability of integrin up-regulation. The switch time was defined as the 
interval between the end of the platelet touching Probe I and the beginning of it touching 
Probe II. Magenta and gray stripes marked the time range that each adhesion frequency data 
point was summarized from (30 cycles = 75 seconds). N.S. = not statically significant; * = p 
< 0.05; ** = p < 0.01; *** = p < 0.001; assessed by unpaired, two-tailed Student’s t-test. 
To look into more details of GPIbα mechanotransduction and the dual-receptor 
inter-talk process, we upgraded our BFP system to perform a switch BFP assay, in 
which two probes were assembled to sequentially interrogate a single platelet (see 
Materials and Methods). The beads of Probe I and II were respectively functionalized 
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with mA1 and FNIII7-10 (or Fg in following experiments). A platelet was first aligned 
and repeatedly touched with Probe I in force-clamp mode allowing durable binding 
under ~25 pico-Newton (pN), the force that realized peak lifetime in GPIbα-mA1 
catch-bond (Fig. 2-4A) 23,89,105,146. Once a lifetime event was observed, the 
platelet-holding micropipette would be quickly maneuvered to move upward and 
align with Probe II and began repeated touches to test integrin activity (Fig. 2-4B). 
Using this newly built dual BFP system, we investigated the temporal 
requirements for integrin activation by GPIbα-induced inside-out signaling. In the 
first experiment, once a bond lifetime event with the A1-bearing Probe I was observed, 
the platelet was switched to the FNIII7-10-bearing Probe II to test integrin binding. It 
took ~30 s to switch the platelet from Probe I to II. The integrin–FNIII7-10 binding 
frequency, estimated from 30 repetitive touches that took ~75 s to complete, was 
plotted vs. the GPIbα–A1 bond lifetime both measured using the same platelet (Fig. 
5-1D). The reason to use 30 instead of 50 or 100 touches here was to avoid the 
contamination of the data by further integrin up-regulation via its outside-in signaling. 
Platelet adhesion to FNIII7-10 increased with GPIbα–A1 bond lifetime initially but 
reached a steady-state of ~30% at 2 s (Fig. 5-1D, red dashed line). These data 
demonstrate the necessity of a durable force for GPIbα mechanotransduction and the 
sufficiency of a single GPIbα bond for upregulation of platelet integrins. The 2-s 
threshold also agreed well with the lifetime threshold defined in Chapter 4 that 
triggers mostly α-type Ca2+ (Fig. 4-4A), further confirming the central role of α-type 
Ca2+ in platelet activation. 
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In the second experiment, we prolonged the time to switch from Probe I to II to 
examine the sustainability of integrin activation. The result was plotted on Fig. 5-1E, 
showing that, once triggered by a >2-s GPIbα–A1 bond lifetime event, platelet 
integrins remained activated for ~130 s, but were downregulated gradually with 
further increase in switch time, and eventually returned to the low activity state. This 
reversal of integrin activation coincided with the cease of active shape changes in 
platelets, which were often observed in our BFP experiments when they were 
repeatedly touched by GPIbα-bearing beads. The return to their discoid shape 
suggested that platelet and integrin activation triggered by GPIbα 
mechanotransduction is reversible11. 
5.2.1.2 GPIbα mechanotransduction primed platelet αIIbβ3 into an intermediate state 
Platelet αIIbβ3 can be chemically activated by soluble agonists like ADP and 
thrombin, which is in parallel with mechanotransduction by adhesions37,44,135. We 
wondered whether the mechano-activation and chemo-activation of platelets lead to 
distinct integrin up-regulations. To test that, we conducted adhesion frequency 
experiments between platelets and FNIII7-10 beads. Non-treated platelets exhibited 
very weak binding of ~5% adhesion frequency (Fig. 5-2A, green non-patterned bar). 
Agreeing with their activating roles, pre-treatment of ADP and thrombin drastically 
promoted the adhesion frequency over all contact times (Fig. 5-2A, red and brown 
bars). The adhesion frequency data were fitted to a Poisson distribution to evaluate the 
equilibrated average number of receptor-ligand bonds that form between the two 
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surfaces at contact (see Materials and Methods for details), which was then 
normalized by the FNIII7-10 site density to derive <n>total/ml92,95, which revealed a 
>10-fold difference between non-treated and ADP-/thrombin-activated groups (Fig. 
5-2C). To note, because a low adhesion frequency may compromise the accuracy of 
fitting, beads with a higher site density (60 / μm2 vs. 28 / μm2) were used to repeat the 
experiments for the non-treated group, the results of which were normalized based on 
the site density to derive the average number of bonds (Fig. 5-2A).  
 
Figure 5-2. Characterization of platelet binding kinetics against FNIII7-10 and fibrinogen. (A,B) 
Adhesion frequency of platelets binding to FNIII7-10 (A) and fibrinogen (B) at 5-s contact time. 
The platelets were without pre-treatment (green curves), triggered by durable mA1 binding 
(blue curves) or incubated with 100 μM ADP (red curves) or 0.1 U/ml thrombin (brown curve 
in panel A). The experiments were performed both in Ca2+/Mg2+ and Mg2+/EGTA. Each 
platelet–bead pair was tested repeatedly for 30 cycles to estimate the adhesion frequency; 
four pairs were tested under each contact time to obtain mean ± SEM. (C,D) Mean ± SEM of 
average number of bonds normalized by ligand site density (<n>total/m l) of platelet binding to 
FNIII7-10 (C) or fibrinogen (D), with and without αIIbβ3-blocking antibody 10E5 and 
αVβ3-blocking antibody LM609. (E) αIIbβ3-FNIII7-10 and αIIbβ3-Fg average effective affinity. 
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N.S. = not statically significant; ** = p < 0.01; assessed by unpaired, two-tailed Student’s 
t-test. 
Remarkably, mA1 triggering realized an intermediate level of adhesion frequency 
which resided between the non-treated and ADP-/thrombin-activated groups (Fig. 
5-2A). The <n>total/ml was 5-fold more than the non-treated group but 2.5-fold less 
than ADP-/thrombin-activated groups (Fig. 5-2C). Substituting mA1 with dimeric 
VWF A1 to allow cis-crosslinking of GPIbα molecules did not make any difference to 
the adhesion frequency (Fig. 5-3, dark blue bar). Priming ADP-activated platelets 
with mA1 does not further elevate the adhesion level, suggesting that the effects of 
ADP and mA1 are not cooperative (Fig. 5-3, black bar). 
Despite the predominant abundance of αIIbβ3 on platelet surface, the contribution 
of other two integrins, αVβ3 and α5β1, to the binding may still need to be reckoned 
with. The addition of integrilin eliminated all binding of both mA1-triggered and 
ADP-activated platelets to FNIII7-10, ruling out the involvement of α5β1 (Fig. 5-3). On 
the other hand, 10E5, an Ab that specifically blocks αIIbβ3 but not αVβ3147, eliminated 
almost all binding of mA1-triggered platelets, whereas ADP-activated platelets still 
maintained a considerable level of binding (Fig. 5-2C). Consistent with that, LM609, 
a αVβ3-specific blocking Ab148, caused negligible effects to mA1-triggered platelets, 
but slightly weakened the binding of ADP-activated platelets (Fig. 5-2C). Fitting the 
two ADP-activated adhesion frequency data suggested that the average number of 
bonds formed by αIIbβ3 was ~8-fold of αVβ3. As a control, pre-incubating the platelets 
with a T-cell receptor antibody which is non-specific to this system yielded no effect 
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at all (Fig. 5-3). All these results indicated that ADP-activated strong adhesiveness 
was co-contributed by αIIbβ3 and αVβ3 activation in which αIIbβ3 played the dominant 
role, while the mA1-triggered intermediate adhesiveness was solely from αIIbβ3. 
 
Figure 5-3. Platelet–FN (left) and –Fg (right) adhesion frequency after different treatments 
(indicated in the figure). Each platelet–bead pair was tested repeatedly for 30 cycles to 
estimate the adhesion frequency; four pairs were tested under each contact time to obtain 
mean ± SEM. 
The <n>total/ml with LM609 blockade was then divided by mr to derive three 
distinctive average effective affinities of αIIbβ3 – binding capacity averaged over all 
αIIbβ3 population – following no treatment, mA1 triggering and ADP activation (Fig. 
5-2E). These results defined three populational states of platelet surface αIIbβ3 – 
inactive, intermediate and active. 
Remarkably, platelets also exhibited three distinct states against another major β3 
ligand, fibrinogen, following no treatment, mA1 triggering and ADP activation (Fig. 
5-2B). Blockade by integrilin, LM609 and 10E5 further confirmed that these three 
adhesivenesses were again predominantly realized by αIIbβ3 (Fig. 5-2, 5-3). αVβ3 had 
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no activity on inactive and A1-triggered platelets, but was up-regulated on 
ADP-activated platelets. To note, much stronger binding was observed from 
non-treated platelet αIIbβ3 against fibrinogen than FNIII7-10, consistent with the fact 
that non-activated platelets could attach onto surfaces with immobilized fibrinogen 
(Fig. 5-2E, compare two green bars)149. Chelating the extracellular Ca2+ by EGTA 
slightly strengthened the binding with no statistical significance under all conditions, 
indicating that extracellular Ca2+ was unessential in these activation pathways (Fig. 
5-2 A,B). Remember that Mg2+ is a weak integrin activator and moderately activates 
cell surface integrins29,150,151, it becomes puzzling that Mg2+/EGTA failed to make any 
difference in this context. We postulate that this was owing to the strong platelet 
regulation on the integrins, which overrode the cation interference. 
5.2.1.3 Progression and recession of the intermediate state 
Integrins could transduce signals bi-directionally, namely, inside-out and 
outside-in signaling135,152. Binding of αIIbβ3 to immobilized VWF was shown to 
induce robust Ca2+ influx (γ-type signaling) following GPIbα-triggered transient Ca2+ 
(α/β-type signaling)10,11. To investigate how this outside-in signaling changes the 
activity of αIIbβ3, repeated touches of FNIII7-10 were applied to the post-switch 
platelets over 200 cycles, considering that the signal transduction should consume 
time. After ~50 cycles’ of relatively stable activity, the slide frequency (adhesion 
frequency within a 30-cycle sliding window) started to gradually increase, which 
eventually stabilized at a much higher level after ~80 cycles, indicating a 
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second-stage up-regulation of the integrins (Fig. 5-4 A,C, magenta). In sharp contrast, 
chelating extracellular Ca2+ by EGTA deprived the integrins’ capability to be primed, 
and instead caused a gradual recession that reached minimum after ~100 cycles (Fig. 
5-4 A,C, cyan). As controls, non-treated platelets exhibited a low level of binding 
throughout the 200 cycles in both Ca2+/Mg2+ and Mg2+/EGTA (Fig. 5-4B). 
Substituting FNIII7-10 with PAC-1, a ligand-mimicking Ab specifically targeting the 
active binding epitope, also yielded similar results of binding progression in 
Ca2+/Mg2+ (Fig. 5-4F). However, the anticipated recession in Mg2+/EGTA was not 
observed (Fig. 5-4G).  
 
Figure 5-4. Progression and recession of intermediate state. LM609 was added in all 
experiments to block αVβ3. (A,B) Representative platelet-FNIII7-10 binding slide frequency 
(window size: 30) vs. #test cycles after mA1 triggering (A) or without pre-treatment (B). The 
experiments were performed in Ca2+/Mg2+ (magenta curves) or Mg2+/EGTA (cyan curves). (C) 
Adhesion frequency vs. contact time of mA1-triggered platelets binding to FNIII7-10 after 100 
cycles in Ca2+/Mg2+ (magenta curve) or Mg2+/EGTA (cyan curve). (D) Mean ± SEM of 
average effective 2-D affinity (<AcKa>) calculated from fitting Equation 1 in Materials and 
Methods to the adhesion frequency data in (C) followed by applying Equation 9. (E) Adhesion 
frequency vs. switch time of mA1-triggered platelets binding to FNIII7-10 after 100 cycles in 
Ca2+/Mg2+. (F,G) Adhesion frequency vs. contact time of mA1-triggered platelets binding to 
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FNIII7-10 in Ca2+/Mg2+ (F) or Mg2+/EGTA (G) (blue curves: first 30 cycles; magenta (F) or 
cyan (G) curves: 101~130th cycles). In panels C, E, F and G, each platelet–bead pair was 
tested repeatedly for 30 cycles to estimate the adhesion frequency; four pairs were tested 
under each contact time to obtain mean ± SEM. N.S. = not statically significant; * = p < 0.05; 
*** = p < 0.001; assessed by unpaired, two-tailed Student’s t-test. 
The αIIbβ3-FNIII7-10 adhesion frequency vs. contact time curves (Fig. 5-4C) were 
fitted to the 2D kinetics model to evaluate <AcKa> after 100 cycles of touch. 
Intriguingly, the affinity of platelets under Ca2+/Mg2+ condition was comparable to 
ADP-activated platelets, while that under Mg2+/EGTA condition similar to 
non-treated (compare Fig. 5-4D and 5-2F).  
All the above evidences, together with the aforementioned “post-switch adhesion 
frequency vs. switch time” results (Fig. 5-1E), implicated that the intermediate but not 
inactive state will progress into the active state upon αIIbβ3 outside-in signaling, 
which requires both ligand priming and extracellular Ca2+. Or else, it will fast recess 
back to the weak adhesiveness state. 
5.2.1.4 Identification of three bond dissociating states 
Integrins may adopt more than one conformational state and affinity state, which 
reach different equilibriums on the populational level under different environmental, 
cellular and mechanical conditions27,29,47,153. We hypothesized that the observed 
distinct adhesiveness states of αIIbβ3 were a collective effect of the state equilibrium 
shifts of individual integrins. To test this hypothesis, bond lifetimes were measured 
using BFP force-clamp assay to collect bond kinetics information on the 
single-molecular level. Plotting average lifetime versus clamping force revealed that 
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the non-treated platelet αIIbβ3 binding to FNIII7-10 manifested a “slip-bond” 
behavior105, with the lifetime monotonically decreasing with force increase and 
eventually diminishing at 30 pN (Fig. 5-5A, green). ADP-activated platelets realized a 
robust catch-bond that ranged from 0 to 30 pN, reaching a peak of 18 s 105; afterwards, 
it started to decrease and eventually approached zero at 85 pN (Fig. 5-5A, red). 
Interestingly, the lifetime of the mA1-triggered group again resided in between of 
these two groups (Fig. 5-5A, blue). The curve exhibited a subtle “catch” behavior 
below 6 pN, and the force range was 0-37 pN, broader that non-treated but narrower 
than ADP-treated platelets (Fig. 5-5A, blue). The distinction among the three curves 
suggested that at least three bond states were involved. To confirm this postulation 
and gain more insights into the force regulation on the binding kinetics, we fit the 
lifetime data with a multi-state model, assuming a mixture of several subpopulations 
of bonds, each of which follows first-order dissociation kinetics that governs an 
exponential distribution of lifetimes under any constant force (see Materials and 
Methods). The semi-log survival frequency vs. lifetime curves (Fig. 5-6) were 
well-fitted by a three-state model (Table 5-1, setting R2 > 0.90 as the criteria of good 
fitting), which yielded the off-rates and subpopulation fractions of each state – fast-, 
intermediate- and slow-dissociating states – under forces (Fig. 5-5 B-E). Remarkably, 
when the off-rates of the three states were superimposed onto the same semi-log plot 
against force, they beautifully aligned with three linear fittings, indicating that the 
off-rates of the three states decreased exponentially with increasing force (Fig. 5-5B), 
in agreement with the Bell’s model 96 (see Materials and Methods). The three fitting 
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lines thus defined the off-rates of the three bond states under all forces (Table 5-2). 
The subpopulation composition of non-treated group was simple: all integrins adopted 
the fast-dissociating state (Fig. 5-5C). A mixture of fast- and intermediate-dissociating 
bonds formed in the mA1-triggered group, with the respective fractions of 
subpopulation monotonically deceasing and increasing along force increase, 
suggesting a force-activating mechanism (Fig. 5-5C). ADP-activated group, on the 
other hand, formed bonds from all three dissociating states. The fractions of fast- and 
slow-dissociating bonds monotonically increased along force increase, while that of 
intermediate-dissociating bonds appeared to be oscillatory (Fig. 5-5D). To note, under 
the maximal force of non-treated, mA1-triggered and ADP-activated groups, the bond 
composition was respectively dominated by the fast-, intermediate- and 
slow-dissociating state. 
Different than FNIII7-10, all three αIIbβ3-Fg lifetime curves exhibited evident 
“catch-slip” signatures, but with step-wise developmentally broadened catch-bond 
regime, higher peak lifetime amplitude and wider force range (Fig. 5-5F). To note, the 
non-treated lifetime curve showing a catch-bond was in discrepancy with the previous 
results collected in a purified system58, which we speculated was owing to the cellular 
regulation of the platelet. Further analysis revealed that the Fg binding also followed a 
three-state model, each of the states again benignly following the Bell’s model (Fig. 
5-5G, Table 5-1, 5-2). However, the composition of bond states became more 
complicated: besides fast-dissociating bonds, non-treated platelets also formed 
intermediate-dissociating bonds under force priming, whereas mA1-triggered and 
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ADP-activated platelets realized all three bond states under certain forces (Fig. 5-5 
H-J). These results indicated a ligand-discriminative mechanism in the 
force-regulation of αIIbβ3 binding. Nonetheless, in consistency with FNIII7-10 binding, 
increase of force again monotonically increased the fraction of slower-dissociating 
states, and decreased the fraction of faster-dissociating states in all Fg binding (Fig. 
5-5 H-J). All these results identified three bond states of αIIbβ3 binding to both 
FNIII7-10 and Fg, which reach different equilibriums under different conditions; both 
force and platelet activation shifted the equilibrium towards more stronger and less 
weaker bonds. 
 
Figure 5-5. Characterization and three-state model of αIIbβ3-ligand bond dissociation under 
forces. LM609 was added in all experiments to block αVβ3. (A,F) Mean ± SEM of lifetime vs. 
force of non-treated (green curves), mA1-triggered (blue curves) and ADP-activated (red 
curves) platelets binding to FNIII7-10 (A) or fibrinogen (F) in Ca2+/Mg2+. (B,G) Plots of 
off-rates (koff) of the fast- (open symbols), intermediate- (half-filled symbols), and 
slow-dissociating states evaluated from fitting a three-state model to the αIIbβ3-FNIII7-10 or 
αIIbβ3-fibrinogen lifetime survival frequency (Supplemental Fig. 4; Materials and Methods, 
Equation 10). (C-E,H-J) Fraction of αIIbβ3-FNIII7-10 (C-E) or αIIbβ3-fibrinogen (H-J) bonds in 
fast- (open symbols), intermediate- (half-filled symbols), and slow-dissociating states. (B,G) 
The points in fast-, intermediate- and slow-dissociating states were fitted by the Bell’s model 
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respectively (dashed lines; Materials and Methods, Equation 11). The platelets were 
non-treated (C,H), mA1-triggered (D,I), or ADP-activated (E,J). Error bars: SEM. 
 
Figure 5-6. Semi-log survival frequency vs. lifetime of platelet αIIbβ3 binding to FNIII7-10 (A-D) 
and fibrinogen (E-H) under different forces. The platelets were non-treated (A,E), 
mA1-triggered (B,F), or ADP-activated (C,D,G,H). A linear distribution indicates one bond 
dissociating state, while a kink in the curve indicates a mixture of multiple states. 
When force approached zero, non-treated platelets only formed fast-dissociating 
bonds, whereas mA1 and ADP promoted a fraction of the bonds to the 
intermediate-dissociating state (Fig. 5-5 C-E, H-J). This information, together with the 
enhanced adhesiveness of mA1-triggered and ADP-activated platelets observed from 
adhesion frequency enhancement, suggested that activations primed a proportion of 
the integrins into a higher affinity state with an intermediate off-rate. However, one 
should not assume that the affinity states of individual integrins have one-to-one 
correspondence to the bond states. For example, the 6-fold increase in the FNIII7-10 
binding <AcKa> following mA1 triggering meant that the average number of bonds 
formed by these platelets were 6-fold more than non-treated (Fig. 5-2F), suggesting 
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that the up-regulated integrins contributed most of the bonds; however, based on 
lifetime fitting results, the intermediate-dissociating state only contributed ~1/5 of the 
total bond number (Fig. 5-5D), exhibiting a huge discrepancy. Remember that affinity 
is the ratio of on-rate and off-rate, it is likely that a considerable fraction of the 
integrin population had their affinity substantially elevated, but still remained in the 
fast-dissociating bond state, realizing an intermediate-affinity state with high on-rate 
and high off-rate. 
Table 5-1. Goodness-of-fit of one-, two- or three-state model fitting to the survival frequency 
vs. lifetime of platelet αIIbβ3 binding to FNIII7-10 and fibrinogen under different forces (Fig. 
5-6). 
 
5.2.1.5 Signaling pathway and integrin conformation of the intermediate and active 
states 
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Physiological activation of integrins involves talin binding to the β-subunit 
cytoplasmic tail, which disrupts the clasping and causes separation of the two subunits 
in the tailpiece, and subsequently enhances integrin binding activity via allosteric 
effects40,44,46,132,154. Two recent works further demonstrated that soluble platelets 
agonists triggers two opposite yet sequential waves of talin and Gα13 binding to αIIbβ3, 
which are respectively involved in inside-out and outside-in signaling135,155. To 
investigate the relation of these signaling events with the adhesiveness states defined 
above, platelets were treated with two β3 cytoplasmic sequence mimicking peptides 
mP13 (blocking both talin and Gα13) and mP6 (blocking Gα13)135. mP13 drastically 
weakened the binding of both mA1-triggered and ADP-/thrombin-activated platelets 
to the level indistinguishable from the non-treated group (Fig. 5-7A), reflecting an 
indispensable role of talin binding to realizing both the intermediate and active states. 
On the other hand, mP6 had no effect on the mA1-triggered platelets, but lowered the 
binding of ADP-/thrombin-activated platelets to the same level as mA1-triggered, 
indicating that Gα13 binding is respectively necessary and superfluous for the 
intermediate and active states. As controls, two scrambled control peptides exhibited 
no effect to ADP and thrombin activation at all (Fig. 5-7 A,B) 135, and DMSO alone 
also showed no difference to all states (Fig. 5-3E). 
Integrins could adopt multiple global conformations, including a bent or extended 
ectodomain, a joined or separated tailpiece and a close or opened β subunit hybrid 
domain; integrin signaling and activation are accompanied by conformational changes 
47,108,152,153,156,157. To identify the conformations of αIIbβ3 under the different 
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adhesiveness states, we coated several conformation-sensitive Abs onto probe beads, 
and measured their binding to platelets. PAC-1 manifested minimal binding to both 
non-treated and mA1-triggered platelets, but strongly bound to ADP-activated 
platelets, indicating that the active ligand binding epitope was not exposed by GPIbα 
mechanotreanduction (Fig. 5-7C, magenta). This also explained the lacked recession 
of platelet intermediate state under the interrogation of PAC-1 (Fig. 5-4G), because 
the intermediate state is specific to ligands but not PAC-1. Similarly, AP5, an Ab that 
reports β3 hybrid domain swing-out158, only bound to platelets after ADP activation 
but not mA1 stimulation. On the other hand, LIBS-2 (ab62), which reports 
ectodomain extension, exhibited similarly high binding to mA1-triggered and 
ADP-activated platelets.  
Table 5-2, parameters of fast-, intermediate- and slow-dissociating states of platelet αIIbβ3 
binding to FNIII7-10 or Fg, fitted by Bell’s model (Governing Equation). 
 
Integrins act as a spring under a tensile force, with the stiffness dependent on the 
conformation. Previous studies reported that integrins αLβ263 and α4β1159 were softer 
and stiffer when the ectodomain was respectively bent and extended. The molecular 
stiffness thus provides an alternative approach to inspect the integrin conformation.  
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Figure 5-7. αIIbβ3 inside-out signaling pathway and conformational changes following 
up-regulation. (A,B) Mean ± SEM, adhesion frequency vs. contact time of non-treated (green), 
mA1-triggered (blue), and ADP- (red) and thrombin- (brown) activated platelets binding to 
FNIII7-10 after treatment of mP13 (A) and mP6 (B). Scrambled peptides (A: mP13Scr or B: 
mP6Scr) treated platelets were activated by ADP (dark red) or thrombin (black) as control. 
(C) Mean ± SEM of adhesion frequency of non-treated, mA1-triggered, and ADP-activated 
platelets binding to HIP8- (gray), PAC-1- (magenta), AP5- (orange), and LIBS-2- (cyan) 
coated beads. N.S. = not statically significant; *** = p < 0.001; assessed by unpaired, 
two-tailed Student’s t-test. (D-F) Histograms (bars) and single (D), dual (E), or triple (F) 
Gaussian fits (purple, orange and cyan curves were respectively fits to the first, second and 
third sub-population; color-matched curves were fits to the whole populations) of kmol for 
non-treated (D, k1,null), mA1-triggered (E, k1,mA1 and k2,mA1) and ADP-activated (F, k1,ADP, 
k2,ADP and k3,ADP) platelets pulled by FNIII7-10. The calculated fractions of each sub-population 
were indicated. (G) Hypothetical model of αIIbβ3 sequential association with talin and Gα13 
and the concomitant conformational changes. The accessibility of LIBS-2, PAC-1 and AP5 to 
the integrin was indicated. (H-K) kmol vs. lifetime of mA1-triggered (H,I; clamping force: 17, 
32 pN) and ADP-activated (J,K; clamping force: 31, 60 pN) platelets binding to FNIII7-10. 
Horizontal dashed lines: lifetime threshold for different bond dissociating states. Open, 
half-filled, and filled symbols indicate lifetimes categorized in fast-, intermediate- and 
slow-dissociating states respectively. Vertical dashed lines: means of Gaussian fits on the 
spring constant distribution from panel E (H and I) or F (J and K), with the colors matched. 
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By using a stretch method (see Materials and Methods) to analyze the lifetime 
events data mentioned above which ensured predominant single-molecular binding, 
we measured the stiffness of single αIIbβ3-FNIII7-10 molecular complex, kmol from all 
three conditions. The stiffness distribution from non-treated platelets obeyed a single 
Gaussian fitting with the mean at k1,null = 0.48 pN/nm (Goodness-of-fit: R2 = 0.99), 
confirming the existence of only one bent conformation (Fig. 5-7D). The distribution 
from mA1-triggered platelets, however, was better fitted by a dual Gaussian with two 
means at k1,mA1 = 0.47 and k2,mA1 =0.80 pN/nm (R2 = 0.98; single-Gaussian: R2 = 
0.89), indicating the appearance of a higher stiffness subpopulation corresponding to 
the extended integrins, agreeing with αLβ263 and α4β1159. Interestingly, fitting of the 
data from ADP-activated platelets required three Gaussians, with means at k1,ADP = 
0.42, k2,ADP = 0.75 and k3,ADP = 1.04 pN/nm (R2 = 0.997; single Gaussian: R2 = 0.73; 
dual Gaussian: R2 = 0.83). The first two agreed with the respective stiffness of bent 
and extended integrins, while the stiffest subpopulation could be explained by hybrid 
domain swing-out. Fraction calculations revealed that mA1 and ADP stimulated the 
extension of more than 70% integrins, while ADP also resulted in 49% hybrid domain 
swing-out. 
The above results indicated that, the intermediate state triggered by GPIbα 
mechanotreanduction is associated with a conformation of αIIbβ3 that adopts an 
extended ectodomain, a closed hybrid domain and a ligand-binding epitope 
unrecognizable by PAC-1; while the active state, triggered by ADP activation, is 
associated with a conformation with an extended ectodomain, an open hybrid domain 
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and a PAC-1 recognizable ligand-binding epitope. This, together with the correlation 
of talin and Gα13 with the adhesiveness states, suggested a two-step inside-out 
signaling model: the first wave of binding by talin caused the unclasping of the 
cytoplasmic tails, which allosterically triggered integrin ectodomain extension, and 
primed the integrins into the intermediate state; the second wave of binding by Gα13 
which substituted talin association, furthermore realized hybrid domain swing-out and 
activated the integrins into the active state (Fig. 5-7G). GPIbα mechanotransduction 
could only trigger the recruitment of talin and thus realized the intermediate state; 
whereas ADP (and presumably thrombin as well, considering its stronger stimulating 
function) induced both talin and Gα13 association, and thus was capable to realize the 
active state. 
To test the relation between integrin activation and conformational change, we 
measured the kmol from lifetime events of mA1-triggered and ADP-activated groups. 
Lifetimes were roughly segregated into different dissociating states using the kink in 
the semi-log survival frequency vs. lifetime plots (Fig. 5-6) as a threshold. 
Remarkably, in the mA1-triggered group, kmol corresponding to fast- and 
intermediate-dissociating lifetimes was respectively distributed like the bent and 
extended conformations (Fig. 5-7 H,I). Similarly, kmol corresponding to intermediate- 
and slow-dissociating lifetimes in the ADP-activated group was respectively 
distributed like the [ectodomain extended, hybrid domain swung-in] and [ectodomain 
extended, hybrid domain swung-out] conformations (Fig. 5-7 J,K). This evidence 
133 
linked the three integrin conformations characterized in this work with the three bond 
states. 
5.2.1.6 Synergy of chemical inside-out and mechanical outside-in signaling realize a 
fourth, hyperactive state 
 
Figure 5-8. αIIbβ3 outside-in mechanical signaling following ADP activation. (A) 
Adhesion frequency vs. time of ADP-activated platelets binding to FNIII7-10 over repeated 
contacts in Ca2+/Mg2+ (dark red) and Mg2+/EGTA (gray). The adhesion frequency was 
calculated every 30 cycles. Four pairs were tested under each contact time to obtain mean ± 
SEM. (B) Mean ± SEM, lifetime vs. force curves of ADP-activated platelets after 210 cycles of 
contact with FNIII7-10 in Ca2+/Mg2+ (dark red) and Mg2+/EGTA (gray). Insert: fitted fractions 
of bonds of the intermediate- (half-filled symbols) and slow-dissociation (filled symbols) 
states of ADP+FNIII7-10-activated platelets in Ca2+/Mg2+. (C,D) Histograms (bars) and dual 
(C) or triple (D) Gaussian fits (purple, orange and cyan curves were respectively fits to the 
first, second and third sub-population; color-matched curves were fits to the whole 
populations) of kmol for ADP-activated platelets after 210 cycles of contact with FNIII7-10 in 
Ca2+/Mg2+ (C) and Mg2+/EGTA (D). The calculated fractions of each sub-population were 
indicated. Ab LM609 was added in all experiments to block αVβ3. 
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The fact that GPIbα mechanotransduction and ADP stimulation could only 
activate a portion of the integrins into the intermediate-dissociating bond state in the 
absence of force suggests a huge potential of further improvement. Remember from 
above that integrin outside-in signaling realized the progression of mA1-triggered 
intermediate state, we asked whether an ensuing outside-in signaling could also 
realize the progression of ADP-triggered active state. 
To test this hypothesis, ADP-activated platelets were interrogated by a low site 
density FNIII7-10 bead (3/μm2). The adhesion frequency was first at a relatively low 
level (20%), but promptly increased after ~50 contacts and finally reached a plateau 
with slight oscillation (Fig. 5-8A, dark red). Fitting the adhesion frequency vs. contact 
time data prior to and after this progression revealed a 13.5-fold increase in the 
average effective affinity (Fig. 5-8A). On the other hand, post-progression bond 
lifetime measurement by the switch assay using a 0.1X FNIII7-10 bead and an even 
more sparsely coated FNIII7-10 bead yielded a distinct lifetime vs. force curve as well: 
the catch-bond regime substantially shrank leftwards to 0-14 pN; average lifetimes 
over the lower force regime (<35 pN) were all elongated while the higher force 
regime (>35 pN) remained similar to ADP-activated platelets (Fig. 5-8B). Multi-state 
analysis reflected that the lifetime events in this context was composed of bonds in 
intermediate- and slow-, but not fast-dissociating state (Fig. 5-8B, insert). Again, the 
increase of force monotonically enhanced and declined the fraction of slow- and 
intermediate-dissociating states, respectively. Spring constant analysis revealed that 
only two stiffer subpopulations remained while the softest disappeared, indicating that 
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the mechanical outside-in signaling following ADP activation primed all integrins to 
extend (Fig. 5-8C). All the above results indicated the existence of a fourth, 
hyperactive state, which was overwhelmingly more powerful than, and was reached 
by the progression of, the ADP-induced active state. This progression was again 
realized by the state equilibrium shift of the integrin subpopulations. 
In comparison, chelating Ca2+ by EGTA eliminated this progression: the adhesion 
frequency only elicited a temporary and moderate elevation during the repeated 
touches, but eventually dropped to even lower than the initial value (Fig. 5-8, gray). 
Agreeing with the affinity decrease, the lifetime in Mg2+/EGTA was also shorter than 
the ADP activated group, especially at ~35 pN where the peak of the catch-bond was 
reached; but at low and high forces, the difference became less distinguishable. Spring 
constant analysis revealed that, FNIII7-10 priming ADP activated platelets in 
Mg2+/EGTA caused a slight decrease of the fractions of extended subpopulations and 
an increase of that of bent (Fig. 5-8D). These data suggested that extracellular Ca2+ is 
necessary to the mechanical outside-in signaling of αIIbβ3 following ADP activation. 
5.2.2 GPIbα-triggered signal primes low-level P-selectin expression 
on platelet surface 
 I used two probe proteins to detect the P-selectin expression of platelets, AK4, a 
monoclonal Ab against P-selectin160, and 2GSP6, a binding epitope bearing fragment 
of the P-selectin ligand PSGL-1161. Unstimulated platelets exhibited very low level of 
adhesion frequency against both AK4 and 2GSP6, confirming that they do not express 
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P-selectin (Fig. 5-9A). ADP-activated platelets manifest a dose-dependent behavior, 
so that a higher concentration of ADP would induce a higher level of P-selectin 
expression; while a low dosage (0.1 U/ml) of thrombin was already sufficient to 
trigger 100% adhesion frequency against AK4 and 70% against 2GSP6, even higher 
than the 1000 μM ADP group (Fig. 5-9A). Compared with above, mA1-triggered 
platelets bound to AK4 and 2GSP6 beads with an adhesion frequency of ~65% and 
~40%, respectively, comparable to the 1000 μM ADP group (Fig. 5-9A). These 
results indicated that GPIbα-triggered signal primes low-level P-selectin expression, 
which is comparable to extremely high dosage ADP treatment, but weaker than 
thrombin. 
 
Figure 5-9. Platelet P-selectin expression after different treatments. (A) Detection of platelet 
P-selectin expression after no treatment, mA1 stimulation and ADP or thrombin activation, as 
probed by AK4 and 2GSP6 coated beads. * = p < 0.05; ** = p < 0.01; assessed by unpaired, 
two-tailed Student’s t-test. (B) Slide frequency (window size: 20 contacts) of A1-triggered 
platelets binding to AK4 coated beads over repeated contacts, averaged over four 
platelet—bead pairs. 
 We then looked into the time dependency of the AK4 binding frequency after 
mA1 triggering. Surprisingly, the slide frequency decreased from ~65% to <40% over 
100 contacts, with a considerable oscillation in the middle (Fig. 5-9B). Considering 
that P-selectin is a membrane surface expressed receptor, it becomes puzzling why the 
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AK4 binding would weaken over time. A possible explanation is the functional 
suppression by the platelet due to a lack of further hemostatic stimulation; 
alternatively, it could be also due to the internalization of P-selectin. 
5.2.3 GPIbα-triggered signal primes PS exposure in platelet outer 
membrane layer 
 Annexin V was used to detect the PS exposure of platelets138. Unstimulated 
platelets exhibited very low level of adhesion frequency against Annexin V, 
confirming that they barely have PS exposed to the exterior surface (Fig. 5-10A). 
ADP-activated platelets manifest a dose-dependent behavior similar to what was 
observed in P-selectin expression (Fig. 5-9A); however, even with an extremely high 
ADP concentration the detected PS exposure was still low, manifested by a 20% 
adhesion frequency (Fig. 5-10A). A low dosage (0.1 U/ml) of thrombin only triggered 
a moderate level of PS exposure, but increasing the dosage to 1 U/ml remarkably 
enhanced the adhesion frequency to a much higher level (Fig. 5-10A). These agreed 
with previously published observation that soluble agonists did not have strong effects 
in stimulating PS exposure138. Compared with above, mA1-triggered platelets bound 
to Annexin V beads with an adhesion frequency of ~45%, even higher than the 1000 
μM ADP group but slightly lower than the 1 U/ml thrombin group (Fig. 5-10A). 
These results indicated that GPIbα-triggered signal primes low-level PS exposure. 
 Different to the decay of P-selectin detection over time (Fig. 5-9B), the slide 
frequency of Annexin V binding to mA1-triggered platelets was relatively stable over 
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a total of 150 contacts, equaling to ~6 min (Fig. 5-10B). This suggested that the PS 
exposure stimulated by GPIbα mechanotransduction is persistent, even without 
further stimulation from GPIbα. 
 
Figure 5-10. Platelet PS exposure after different treatments. (A) Detection of platelet PS 
exposure after no treatment, mA1 stimulation and ADP or thrombin activation, as probed by 
Annexin V coated beads. N.S. = not statically significant; * = p < 0.05; ** = p < 0.01; 
assessed by unpaired, two-tailed Student’s t-test. (B) Slide frequency (window size: 20 
contacts) of A1-triggered platelets binding to Annexin V coated beads over repeated contacts, 
averaged over four platelet—bead pairs. 
5.3 Discussion 
αIIbβ3, as the first defined member of the integrin superfamily, has been studied 
for decades162. Integrins mediate cell adhesion and transduce signals bidirectionally, 
allowing the cells to communicate with the extracellular environment. Especially, 
integrin αIIbβ3 which is primarily expressed on platelet surface, plays a critical role in 
platelet activation, adhesion and mechanosensing11,117,135,149,163. A good amount of 
works have substantially characterized αIIbβ3 in three aspects: 1) structure and 
conformation43,46,47,147,158,164; 2) adhesion activity28,57,58,165,166; and 3) signaling 
pathways10,11,81,135,149,167. However, the study of platelet surface αIIbβ3 activity 
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regulation still remains in its infancy. For example, the detection of integrin activation, 
by either ligand or PAC-1 binding, was still limited to a binary resolution82. 
GPIbα triggers mechano-signaling through ligand binding and in turn 
up-regulates αIIbβ3 by inside-out signaling9,10. Due to technical difficulties, the 
mechanism of this mechano-signaling process has never been thoroughly figured out. 
Our results indicated a lifetime-dependence of GPIbα mechanotransduction, and a 
lifetime threshold mechanism for β3 integrin up-regulation (Fig. 5-1 D), which as 
confirmed by further investigation was realized by αIIbβ3 alone (Fig. 5-2 D-F). 
Comparing this with another way of inside-out signaling, namely, via stimulation of 
soluble agonists, revealed a remarkable weakness in the binding kinetics, defining two 
distinct adhesiveness states of αIIbβ3 – intermediate and active – on top of the inactive 
state seen on unstimulated platelets (Fig. 5-2). This intermediate state associated with 
GPIbα mechanotransduction appeared not to be a middle-stage product in the 
proceeding of αIIbβ3 to the active state, because even extremely long-duration 
GPIbα-ligand associations and crosslinking of GPIbα receptors by dimeric A1 cannot 
further enhance the binding (Fig. 5-1E, 5-3B). To note, ADP but not mA1 triggering 
can up-regulate integrin αVβ3 to realize feeble binding, which suggests its auxiliary 
role in the later but not earlier stages of arterial hemostasis (Fig. 5-2D). The 
intermediate state is highly transient, so that when repeatedly primed by ligands or a 
ligand-mimicking Abs in the presence of extracellular Ca2+, the integrins will progress 
to the active state within minutes, indicating integrin up-regulation by outside-in 
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signaling. On the contrary, without sufficient stimulations, it would recess to the weak 
adhesiveness state (Fig. 5-4).  
The developmental inhibitory effects of mP6 and mP13 suggested a two-stage 
integrin up-regulation procedure which sequentially requires talin-integrin and 
Gα13-integrin associations (Fig. 5-7 A,B). To note, the inhibitory effect of mP6 on 
integrin activation was not observable in the original work that invented this peptide, 
which reported positive fluorescence staining of both Fg and PAC-1135. We suspect 
this was due to the co-incubation of platelets with thrombin and Fg/PAC-1 over time, 
which allowed a cooperative inside-out and outside-in signaling that overcome the 
inhibition. The conformations of integrins, as detected by two mutually 
complementary approaches, revealed a [ectodomain bent, hybrid domain swung-in] -> 
[ectodomain extended, hybrid domain swung-in] -> [ectodomain extended, hybrid 
domain swung-out] shift following the two-wave talin and Gα13 association, the 
proceeding of adhesiveness states (Fig. 5-7 C-F) and also the bond dissociating states 
(Fig. 5-7 H-K). This is in consistency with previous works demonstrating that both 
ectodomain extension and hybrid domain swing-out are associated with integrin 
activation 45,47,98,168,169. Models of talin binding leading to integrin tailpiece separation 
and ectodomain extension have been proposed in previous studies 46,170; the point that 
Gα13 binding triggers hybrid domain swing-out, as suggested by this work, requires 
further confirmation. 
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The fact that PAC-1 cannot distinguish the intermediate state suggested that it is 
not sensitive enough to detect low-level integrin activations. Remember that previous 
studies prevailingly relied on PAC-1 staining as a canonical marker of integrin 
activation, this result implicates that the conclusion of integrin activation based on 
PAC-1 staining should be drawn with more caution. 
Inspired by the progression of the intermediate state, we wondered whether the 
ADP –activated integrins still possess the potential to be further up-regulated. Indeed, 
repeated ligand priming triggered outside-in signaling to boost the progression of the 
active state to a hyperactive state, which defined the fourth state (Fig. 5-8A). 
The discovery of the distinct and relative independent active states on the 
populational scale gave rise to two alternative hypotheses: 1) agreeing with the 
conventional binary model, the individual αIIbβ3 molecules could only adopt either an 
inactive state with low affinity or an active state with high affinity, and the 
equilibrium shift of the two subpopulations realized all different adhesiveness states; 
and 2) individual αIIbβ3 molecules could adopt multiple affinity states, which add up 
to a more complicated equilibrium model. By measuring bond dissociation rates, we 
gained in-depth insights of the integrin activity on single-molecular level, which 
reflected the existence of three dissociating states. The transitions between 
adhesiveness states closely correlated with a shift of the equilibrium between the 
dissociating states towards larger slower-dissociating subpopulations and smaller 
faster-dissociating subpopulations, while an increase in the pulling force also induced 
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a similar effect (Fig. 5-5, 5-8B). Further analysis argues that the number of αIIbβ3 
affinity states should be at least 4, with the fast-dissociating bond state associated with 
two, and the intermediate- and slow-dissociating bond states each associated with one, 
which we artificially name as low-, intermediate-, high- and hyper-affinity states. We 
suspect that the evolvement of intermediate-affinity state from low-affinity state was 
realized by the ectodomain extension, which realizes a more accessible orientation of 
the ligand binding site in the integrin headpiece, but does not guarantee an 
intermediate-dissociating bond state, that is more related to the local conformation of 
the ligand binding epitope. To note, the lifetime results and multi-state analysis 
reflected a remarkable discrimination over the two ligands despite their overlapping 
binding epitope (Fig. 5-5, compare A-E with F-J). We suspect that this is caused by 
the distinctive docking of the binding motifs of FNIII7-10 and Fg171, which produces 
different allosteric effects that propagate from the N-terminal ligand binding epitope 
to the overall integrin structure. 
Integrins adopting multiple bond states has been known for long26,150, but 
conventionally it is believed that a three-state bond dissociating model can only be 
realized by αI-domain bearing integrins, taking advantage of the cooperation between 
the αI and βI-domains. Agreeing with that, αLβ2 was found to bear three bond states 
when binding to its ligand ICAM-129, while purified αIIbβ3-Fg only contained two57,58. 
However, our work for the first time demonstrated the three-state model in the platelet 
surface αIIbβ3, disputing the necessity of αI-βI cooperation. The discrepancy in 
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αIIbβ3-Fg association between the purified system and platelet surface system is also 
intriguing and informative.  
 
Fig. 5-11. Shifts between multiple states of individual αIIbβ3 realized four populational states: 
inactive, intermediate, active and hyperactive. The average effective affinity (<AcKa>) of 
each state was annotated. The conformational states and bond states the integrins switch 
among under each state were indicated, which in combination define the four affinity states 
(left). Three colors of the headpiece represented three bond states: fast- (green), 
intermediate- (orange) and slow- (red) dissociating (left). The required 
conditions/stimulations to transit between states were indicated besides the corresponding 
arrowheads. Inside-out and outside-in signaling pathways were marked by cyan and brown 
respectively. The coupled reversely directional red arrowheads indicated dynamic 
equilibrium between different integrin states, with the relative thickness indicating the 
dominant state. The car transmission gear positions as a metaphor of αIIbβ3 activity were 
annotated by the representing letters (P, park; R, reverse; N, neutral; D1, drive1; D2, drive2). 
To better illustrate the discoveries in this work, I summarized them as a model of 
platelet αIIbβ3 regulation by bidirectional signaling events. On inactive platelets, 
αIIbβ3 integrins reside in the low-affinity state, and thus realize a weak adhesiveness 
state of the platelet (Fig. 5-11, Weak). Upon GPIbα mechanotranduction, most of the 
integrins extend and adopt the intermediate-affinity state, a portion of which further 
adopts the intermediate-dissociating bond state and evolves into the high-affinity state. 
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The mixture of these three affinity states defines the intermediate state (Fig. 5-11, 
Intermediate), and also the ADP/thrombin-stimulated active state with fractional 
differences (Fig. 5-11, Active). Under the active state, a portion of integrins undergoes 
hybrid domain swing-out conformational change, which probably does not affect their 
affinity but enables them to enter the slow-dissociating bond state under force (Fig. 
5-11, Active). The hyperactive state is realized by only the high- and hyper-affinity 
states (Fig. 5-11, Hyperactive). Integrins under all adhesiveness states are capable of 
reacting to force which promotes their bond states to manifest a catch-bond behavior 
(Fig. 5-11, lower row). This enables the platelets to resist the high shear under arterial 
environments. To note, part of this model, e.g., the reversibility of the intermediate 
state and the correspondence between single integrin affinity states and populational 
adhesiveness states, specifically applies to the interaction with RGD-bearing ligands 
VWF and fibronectin. The regulation of platelet-fibrinogen interaction is more 
complicated, and requires further investigations. 
The four adhesiveness states of platelet αIIbβ3 indicate a multi-step mechanism of 
platelet activation instead of the one-step “suicidal attack” model, which we believe 
reflects the realistic situation. It was probably because in physiological condition, all 
of the stimulations to platelets appear within such a very short period of time, that it 
becomes difficult to beware of each step of platelet activation. We figured that this 
highly mimics the operation of a transmission that controls the movement of a car, 
considering that integrin activation to some extent “drives” the proceeding of 
hemostasis. The weak adhesiveness state “locks” the integrins to remain inert, which 
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is similar to the gear “P” (Park). The intermediate state prepares the integrins for 
adhesion and pregression, similar to the gear “N” (Neutral). The active and 
hyperactive states realize different levels of strong adhesion, which are similar to 
different gears of Drive, “D1” and “D2”. Importantly, recession of the intermediate 
state in the absence of further stimulation provides the system with an opportunity to 
dissipate the activation, which is similar to reversing a car using the gear “R” 
(Reverse). This discovery for the first time suggests a reversibility of the platelet 
activation through a physiological pathway instead of inhibitor/drug interference, 
which should be important in maintaining the balance between hemostasis and 
thrombosis. In conclusion, this transmission-mimicking mechanism ensures 




Fig. 5-12. Multi-dimensional model of platelet activation. The three axis’s represent the 
extent of integrin αIIbβ3 activation, P-selectin expression and PS exposure, respectively. Red 
arrowheads indicate the direction of the platelet activation under this coordinate triggered 
respectively by GPIbα mechanotransduction, ADP and thrombin. 
 
In addition to up-regulating αIIbβ3, GPIbα mechanotranduction also stimulates 
moderate levels of P-selectin expression, a marker of platelet granule release, and PS 
exposure, a sign of platelets gaining procoagulant activities (Figs. 6-9, 6-10). 
Remember from a recent publication that shear force is critical to trigger platelet PS 
exposure in cooperation with soluble agonists’ treatment138, my results further 
illustrated that mechanical force alone suffices independent of soluble agonists, and 
specifically, the mecano-receptor involved is GPIbα.  
Conventionally, GPIbα’s role in initiating platelet activation signaling was 
believed to be secondary, while more focus was put on soluble agonists and also 
GPVI (more important in low-shear vascular environment). However, my studies 
provide an enormous amount of evidences to dispute and argue that, GPIbα 
mechanotranduction plays an important and indispensable role in platelet activation 
and activity: 1) GPIbα up-regulates the integrin αIIbβ3 into an intermediate state, 
which gains a considerable binding activity and prepares it ready to be further 
activated; and 2) GPIbα mechanotranduction has similar effects to ADP and thrombin 
activation with regard to inducing P-selectin expression and PS exposure indicate. To 
note, the mismatch of GPIbα, ADP and thrombin in triggering αIIbβ3 activation 
(GPIbα < ADP ≈ thrombin), P-selectin expression (ADP ≤ GPIbα < thrombin) and PS 
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exposure (ADP < GPIbα ≤ thrombin) is suggestive that, platelet activation by 
different stimulus may not only differ in the extent of activation, but can rather lead to 
distinctive directions on a multi-dimensional coordinate of activation. With that said, 
one single gauge of “platelet activation” will never exist anymore. 
CHAPTER 6: CONCLUSIONS 
6.1 Summary 
 Mechanosensing is a complicated yet intriguing problem for biologists and 
biophysicists, which acts as a symbolic example of mechanical regulation in biology. 
Mechanosensing is of extreme importance in the functionality of platelets, because 
changes in the vascular hydraulic environment is a critical result of vascular injuries, 
which has to be perceived by platelet surface receptors to initiate hemostasis. On the 
other hand, in thrombosis the pathological environment — like stenosis and high 
blood pressure, also causes certain changes to the mechanical properties of the blood, 
which is likely associated with the reported platelet hyperreactivity. This is related to 
severe diseases including obesity, diabetes, high blood pressure and coronary and 
peripheral arterial disease. In this context, an important, yet incompletely understood, 
question in hemostasis and thrombosis is: how platelet adhesion leads to signaling and 
activation? 
 Cell signal transduction is accomplished by the cooperation of a number of 
molecules in a sequential fashion. However, before studying the cooperation, it is 
important to understand these molecules by themselves first, especially the 
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mechano-receptors. My previous colleague and collaborator, Dr. Lining Ju, focused 
his Ph.D. research on the molecule GPIbα. I, on the other hand, selected integrins. 
Integrins have a highly flexible structure, so that they can adopt multiple 
conformational and affinity states, which regulate and are regulated by cellular and 
environmental mechano-signals. In Chapter 3, I characterized the integrin αVβ3 
bending and unbending conformational changes. I found: 
1) The bending and unbending conformational changes can occur both on 
purified integrin molecules and on those expressed on cell surface, both with 
and without ligand, indicating that they are spontaneous molecular dynamic 
processes that do not require cellular support and ligand engagement. 
2) Mechanical force favors unbending and suppresses bending, presumably by 
providing and consuming mechanical energy, suggesting an activating role of 
mechanical force in β3 integrin regulation. 
3) The dynamics of bending and unbending are also regulated by the cation 
condition, mutation and the engaged ligand. 
4) Bending and unbending conformational changes do not affect the lifetime of 
the integrin binding to its ligands in Ca2+/Mg2+, but in Mn2+ unbending 
facilitates the lifetime prolongation while bending shortens the lifetime. 
Furthermore, in Chapter 4 I started to collaborate with Dr. Ju and investigated the 
platelet GPIbα mechanosensing. Similar to integrins, GPIbα can also undergo 
conformational changes, specifically, LRRD and MSD unfolding. But unlike integrin 
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bending unbending, these two domains’ unfolding appears to be irreversible under 
constant force pulling. Further study revealed that: 
1) A single durable GPIbα bonding is necessary and also sufficient to trigger 
platelet intracellular calcium signaling, manifested as an acute pulse of 
calcium flux. The signal intensity is linearly correlated with the bond lifetime 
duration. 
2) The LRRD and MSD unfolding is cooperative, so that LRRD unfolding 
should facilitate MSD unfolding. 
3) LRRD unfolding increases the calcium signal intensity by prolonging the 
bond lifetime, while the MSD unfolding digitally determines the α/β type of 
the signal. 
4) A type 2B VWD mutant R1450E has mechanotransduction defect because of 
the lifetime shortening under higher forces. 
5) Inhibition of GPIbα mechanoreception by perturbing its association with 
14-3-3ζ. 
This work developed novel biophysical methods and analyses (fBFP) to visualize 
in real-time a chain of coordinated single-molecular events on a living cell, enabling 
us to elucidate the inner workings of a mechanoreceptor important to platelet biology. 
Our findings have defined the minimum mechanical stimulation for inducing 
mechanotransduction, which should be of broad interests to scientists working in cell 
and molecular biology, single-molecule biophysics, and hematology. Because LRRD 
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and MSD are common structures shared by many receptors, the mechanosensory 
system we described may represent a general mechanism in mechanobiology. The 
design principles elucidated herein may serve as guidelines for synthetic biology 
approaches to a generic mechanosensing machine. 
 
Figure 6-1. Hypothesized model of normal and defected hemostasis from humans that have 
WT (A-D) and R1450E VWD MT (E-H) plasma VWF. Robust calcium of platelet via binding 
to WT VWF (B) triggers integrin activation (C) and in turn the platelet aggregate formation 
which stops bleeding (D). R1450E does not trigger robust calcium (F) and thus fails to induce 
integrin activation (G) and the bleeding becomes excessive (H). 
 VWD was conventional regarded as an adhesion deficiency disease. Until 
recently it was discovered that a type 2B VWD mutant, V1316M, inhibits activation 
of integrin αIIbβ3 and facilitates thrombocytopathy127, which for the first time 
demonstrated a signal deficiency caused by VWD. Agreeing with that, we found that 
another type 2B VWD mutant, R1450E, also failed to trigger robust calcium signal 
under high forces. Based on this, I postulate that unlike WT VWF that triggers platelet 
calcium signaling under high shear rates in arterial environments and lead to integrin 
activation (Fig. 6-1A-D), R1450E cannot initiate calcium signal and integrin 
activation and thus compromises the platelet firm adhesion and aggregation, resulting 
in excessive bleeding (Fig. 6-1E-H). 
 Continuing from above, in Chapter 5 I followed the signaling pathway to 
downstream and investigated the integrins activation, P-selectin expression and PS 
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exposure induced by GPIbα mechanotransduction, as well as the 
mechanotransduction of activated integrin αIIbβ3. It is found that: 
1) GPIbα mechanotransduction up-regulates αIIbβ3 into a transient intermediate 
activity state, which is in between of the inactive state and ADP or thrombin 
triggered active state. 
2) In both the intermediate and active states but not the inactive state, αIIbβ3 can 
initiate outside-in mechanical signaling by repeatedly binding to its ligand so 
as to further promote its binding capacity. This process does not require 
durable binding as GPIbα but requires extracellular calcium. 
3) The different states of αIIbβ3 adopt distinctive compositions of subpopulations 
with different binding affinities, bond strengths, as well as molecular 
conformations. 
4) The intermediate state requires talin binding to β3 tail, whereas the active 
state requires the binding of both talin and Gα13. 
5) GPIbα mechanotransduction triggers low-level P-selectin expression and PS 
exposure. 
This work developed a novel approach to study cis-crosstalk of heterogeneous 
receptors on the same living cell, realizing a step forward in the field of biomechanics 
and platelet mechano-biology. Our scientific findings refine the understanding of 
αIIbβ3 regulation and platelet activation, revealing that both involve multiple serial 
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steps and can be finely controlled. Our work should also be of broad interests to 
mechano-biologists, since integrins form a big family of adhesion molecules and are 
expressed on almost all cells as mechano-receptors. 
A bioengineer needs to think about scientific questions in two completely 
different mindsets: “bio” and “engineer”. Being a biologist, one has to investigate 
unknown and unclear biological phenomena and invent new approaches to fight 
against inabilities and diseases, which serves to improve the physical health of human. 
On the other hand, a qualified engineer not only has to develop tools and techniques 
to accommodate new projects, but also need the ability to solve scientific problems 
that are associated with engineering, like mechanics, electronics and more. In my 
Ph.D. career, with honor, I accomplished a series of projects that were contributed by 
both the biologist and engineer inside me. In Chapter 2, I helped in the assembly of 
the fluorescence function of BFP, and solely improved the BFP system with a 
temperature controlling system, which were both used in the study in Chapter 4, 
where we investigated the mechanisms of GPIbα mechanosensing. I also built the 
dual-probe system which is used in the “switch BFP” assay, a new approach that can 
investigate the receptors’ cis-cross-talk. This assay became the core technique of 
Chapter 5, where we studied the mechanical signal transduction between GPIbα and 
integrin αIIbβ3. Moreover, my training in mechanical engineering also helped me 
tremendously in addressing the scientific questions. For example, the lifetime 
multi-state analysis originated from biomechanics. Also, when characterizing integrin 
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bending and unbending conformational changes, I calculated the energy generation 
and consumption. 
To summarize, I used and invented several single-cell biomechanical techniques 
and certain engineering skills, and studied the molecular dynamics of β3 integrins and 
GPIbα and the mechanosensing mechanisms of platelets. I investigated how the 
conformational changes of β3 integrins and GPIbα are regulated mechanically, 
chemically and biologically, and related them to their roles of adhesion and 
mechanotransdution. I deciphered how platelets interpret mechanical signals and 
convert them to chemical signals accordingly through those mechano-receptors, and 
gained insights into the related signaling pathways. 
6.2 Future works 
 Like two sides of a coin, the subsequent adhesion and signal transduction of 
platelets lead to platelet activation/aggregation and normal hemostasis; however, an 
exaggerated platelet activation response can result in acute thrombotic events, leading 
to arterial thrombotic events such as ischemic stroke and myocardial infarction, which 
claim 2,200 American lives every day172. Platelets in patients with thrombotic 
diseases could transiently or persistently become hyperreactive, achieving robust 
activation with the stimulation of sub-threshold concentrations of agonists173-175, 
which is often associated with pathological conditions including obesity, diabetes, 
hypertension and peripheral artery disease (PAD)176-178. Insulin resistance, 
hyperglycemia and inflammation were reported to be the major contributors to 
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platelet hyperreactivity in both type I and II diabetes. Unfortunately, our knowledge 
on platelet hyperreactivity is still superficial, which is reflected from the fact that, all 
the current commercialized anti-coagulant agents have a severe side-effect of causing 
excessive bleeding, making even small traumas fatal for patients who take them. 
Especially, due to the limitations in instrumentation and methodology, the relation of 
diabetes -associated platelet hyperreactivity with platelet adhesion and 
mechano-activation remains unclear.  
Continuing from Chapter 3-5, which majorly target on the platelet physiology, in 
this section I will describe my tentative works on the study of platelet pathology, 
specifically, platelet mechanical hyperreactivity in diabetes. This work has not been 
finished yet, and will be one of the future research directions for the younger fellows. 
6.2.1 Type I Diabetes – a preliminary study in platelet biomechanical 
thrombosis 
 In collaboration with Dr. Eric Felner from Emory University, we had stable 
access to blood samples of diabetic and healthy adolescents. 
Remember from Chapter 5 that, inactive platelet αIIbβ3 from healthy donors have 
low binding ability to its ligands fibronectin and fibrinogen, which was re-confirmed 
here on healthy adolescents, 5% against FNIII7-10 and 10% against Fg (Fig. 6-2A,B, 
green). In contrast, however, platelets purified from diabetic patients’ blood had much 
stronger binding, which reached 20% against both FNIII7-10 and Fg (Fig. 6-2A,B, 
green), which mimics the intermediate state of healthy platelet αIIbβ3. Moreover, in 
155 
Chapter 5 I demonstrated that healthy platelet αIIbβ3 cannot trigger outside-in 
mechanical signaling to up-regulate itself from the inactive state by binding to 
FNIII7-10, which is also reflected here by data from healthy adolescents (Fig. 6-2C, 
green). But in the diabetic group this signaling pathway appeared to be open, so that 
over repeated touches the binding frequency was elevated from 20% to ~80% (Fig. 
6-2C, blue). These results suggested that, on the inactive diabetic platelets, the αIIbβ3 
integrins already adopt an intermediate or similar activity state, which broke the 
self-suppressive mechanism observed in healthy platelets. 
 
Figure 6-2. Adhesion and signaling abnormality of Type I diabetic GPIbα and αIIbβ3. (A,B) 
adhesion frequency of healthy and patient (with and without ADP activation) platelets 
binding to FNIII7-10 (A) and Fg (B) coated beads. (C) Slide frequency of healthy and patient 
platelets binding to FNIII7-10 over repeated contacts. (D) Mean ± SEM, lifetime vs. force of 
healthy and patient GPIbα binding to VWF A1. ** = p < 0.01; *** = p < 0.001; **** = p < 
0.0001; assessed by unpaired, two-tailed Student’s t-test. 
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 On the other hand, the lifetime of diabetic platelet GPIbα was much longer than 
healthy group under all forces. Especially, the catch-slip-catch signature became 
much more sound, so that at ~25 pN where both lifetime curves peaked, the maximal 
lifetime was prolonged from <1 s to 4 s (Fig. 6-2D). 
6.2.2 Type II Diabetes – a preliminary study in platelet 
biomechanical thrombosis 
 I investigated the Type II Diabetic GPIbα adhesion and signaling and compared it 
with healthy control. The lifetime of patient group GPIbα was significantly elevated 
(Fig. 6-3A). The linear correlation between pre-Ca2+ longest lifetime and Ca2+ signal 
intensity still stands for the diabetic group; however, compared with the healthy group, 
its linear fitting was upward shifted in parallel, indicating a higher trigger efficiency 
(Fig. 6-3B). As an additive result of these two effects, the overall Ca2+ triggered in 
diabetic platelet was much higher than healthy (Fig. 6-3C). 
 
Figure 6-3. Adhesion and signaling abnormality of Type II diabetic GPIbα. (A) Mean ± SEM, 
lifetime of healthy and patient GPIbα binding to VWF A1 under 25 pN. (B) Scatter graphs of 
ΔImax vs. tmax for Healthy (black) and Patient (green) groups derived from platelet—A1 
clamped binding under 25 pN. The dashed lines are linear fits to respective data with 
corresponding Pearson coefficients indicated. (C) Mean ± SEM, average Ca2+ increase 
triggered by healthy and patient GPIbα mechanotransduction. 
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6.2.3 Summary 
 These tentative works indicated that, platelets from diabetes patients are 
mechanically hyperreactive, so that both adhesion and mechano-signaling of their 
GPIbα and αIIbβ3 are pathologically exaggerated. As a result, diabetic platelets are 
more adhesive, and also more responsive to adhesion initiated mechano-signaling to 
realize activation, which we postulate will ease the process of platelets adhering to 
unwounded blood vessels and attracting more cells and proteins to massively 
aggregate, leading to thrombosis. 
 To make this work more clinically relevant, the next step will be to study the 
molecular mechanism of these abnormalities. It is speculated that they were due to the 
disturbance of the internal activation-suppressing signaling pathways of platelets by 
the diabetic pathological environments, which 1) activates the two receptors GPIbα 
and αIIbβ3 to become more adhesive; and 2) reinforces the functioning of certain 
signaling proteins like PI3 kinase. 
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CHAPTER 7: MISCELLANEOUS PROJECTS 
Regulation of Mac-1 (integrin αMβ2) affinity and conformational 
states by a lupus-associated mutation 
This work was part of a collaboration project with Dr. Tanya Mayadas lab from 
Harvard Medical School. It has been published in 2015 as a research report27. 
Systemic lupus erythematosus (SLE) is an auto-immune disease that lacks cure. 
~5 million people are suffering from SLE worldwide. In healthy humans, leukocytes 
are only immuno-active to pathogens. However, leukocytes in SLE patients can be 
activated by and attack autologous cells, causing multi-organ damages like heart 
inflammation and kidney failure. Genetic studies identified a SLE-associated variant 
of the ITGAM gene, which poses a R77H mutation in the α-subunit of integrin αMβ2, 
a critical adhesion receptor on leukocytes’ surface179. αMβ2 is involved in the 
activation of leukocytes, and mediates their crawling on and infiltration through the 
vascular wall. However, how R77H affects the function of αMβ2, and why it is 
correlated to high susceptibility of SLE is unclear. 
 To address the above questions, Mayadas lab used a flow chamber technique and 
found that R77H αMβ2 has a weakened adhesion capability under flow, but has 
similar binding behavior to WT in a static environment, suggesting that the impact of 
R77H is force-related. 
 Following that, I used BFP to measure the adhesion of cell surface αMβ2 and the 
impact of R77H on the single cell and single molecular level. It was discovered that: 1) 
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R77H reduces both the binding affinity and binding strength of αMβ2, compromising 
the catch-bond behavior of WT integrin under high forces; 2) The defects in binding 
resulted by R77H could be rescued by an activating antibody (CBR LFA-1/2) and 
certain artificial mutations (ΔGFFKR, V124A). This work characterized the αMβ2 
binding kinetics in single-molecular level, and shed more light on the SLE-associated 
mutation R77H. Interestingly, this was the first work that described that a mutation in 
a binding epitope distal domain, the α-subunit β-propeller domain, could have 
substantial impacts on the binding of an integrin, which provides valuable information 
to the future studies of integrin structure. 
Based on these results and results from previous works, we hypothesized that 
R77H, by weakening the binding of αMβ2, suppresses its mechano-signaling function, 
and in turn facilitates leukocyte over-activation and SLE development. Obviously, 
this requires further investigations, which are still undergoing. The activating 
antibody CBR LFA-1/2 and mutations ΔGFFKR and V124A which were 
demonstrated to have rescuing effects to the R77H mutation may inspire new 
biomedical approaches in the future to fight against SLE.  
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B.S., Theoretical and Applied Mechanics, Peking University, China. GPA: 3.68/4.0 
B.S., Major in Economics (Double Major), Peking University, China. GPA: 3.16/4.0 
Aug. 2010 – current 
Ph.D. Candidate, Bioengineering, advised by Prof. Cheng Zhu, Georgia Institute of 
Technology, USA. GPA: 3.91/4.0 
 Use a Biomembrane Force Probe to study the binding and conformation 
dynamics of single integrins. 
 Investigate dysregulation of leukocyte integrin Mac-1 adhesion and signaling by 
a lupus-associated mutation. 
 Upgrade the Biomembrane Force Probe to study adhesion and 
mechanotransduction of platelet surface receptors GPIbα and integrin αIIbβ3. 
 Investigate the biomechanical dysregulation of platelet adhesion and activation in 
diabetes-related atherothrombosis. 
Jan. – Feb. 2014 
Visiting scholar, advised by Prof. Peter Hinterdorfer, Johannes Kepler University, 
Austria 
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 Use a High Speed Atomic Force Microscopy to observe and characterize integrin 
bending/extending conformational changes. 
Jan. – Feb. 2016 
Visiting scholar, advised by Prof. Shaun Jackson, The University of Sydney, Australia 
 Learn platelet biology, platelet mechanotransduction and mouse Type I Diabetes 
model and stroke models. 
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Graduate Research Assistant in Prof. Cheng Zhu’s lab, Coulter Department of 
Biomedical Engineering, Georgia Institute of Technology, USA 
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1. Chen Y., Lee H., Schwartz M., Zhu C., Force regulated conformational change 
of integrin αVβ3. (Accepted by Matrix Biology). Impact Factor: 4.47 
2. Elosegui-Artola A., Oria R., Chen Y., Kosmalska A., Pérez-González C., Castro 
N., Zhu C., Trepat X., Roca-Cusachs P., Mechanical regulation of a molecular 
clutch defines force transmission and transduction in response to matrix rigidity. 
Nature Cell Biology. doi:10.1038/ncb3336. (2016). Impact Factor: 19.68 
3. Ju L., Lou J., Chen Y., Zhu C., Force-induced unfolding of leucine-rich repeats of 
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glycoprotein Ibα prolongs bond lifetime with von Willebrand factor. Biophysical 
Journal 109(9):1781-4. doi: 10.1016/j.bpj.2015.08.050. (2015). Impact Factor: 
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4. Ju L., Chen Y., Zhou F., Lu H., Cruz M., Zhu C., Von Willebrand factor-A1 
domain binds platelet glycoprotein Ibα in multiple states with distinctive 
force-dependent dissociation kinetics. Thrombosis research 136(3):606-12. doi: 
10.1016/j.thromres.2015.06.019. (2015). Impact factor: 2.45 
5. Chen Y.*, Liu B.*, Ju L.*, Hong, J.*, Ji Q., Chen W., Zhu C., Fluorescence 
Biomembrane Force Probe: Concurrent Quantitation of Receptor-Ligand Kinetics 
and Binding-induced Intracellular Signaling on a Single Cell. Journal of 
Visualized Experiments (102), e52975, doi:10.3791/52975. (2015) (*Co-first 
authors). Impact factor: 1.33 
6. Rosetti F.*, Chen Y.*, Sen M., Thayer E., Azcutia V., Herter J. M., Luscinskas F. 
W., Cullere X., Zhu C., Mayadas T.N., A Lupus-Associated Mac-1 Variant Has 
Defects in Integrin Allostery and Interaction with Ligands under Force. Cell 
Reports 10, 1655-1664, doi:10.1016/j.celrep.2015.02.037. (2015) (*Co-first 
authors). Impact factor: 8.36 
7. Fiore V. F., Ju L., Chen Y., Zhu C., Barker T. H., Dynamic catch of a 
Thy-1-α5β1+syndecan-4 trimolecular complex. Nature Communications 
12;5:4886, doi: 10.1038/ncomms5886. (2014). Impact Factor: 11.47 
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1. Ju L., Chen Y., Rushdi M., Chen W., Zhu C., Two-dimensional analysis of 
cross-junctional molecular interaction by force probes. Book Title: The Immune 
Synapse: Methods and Protocols. Edited by: Cosima T. Baldari, PhD and Michael 
L. Dustin, PhD. 
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1. Chen Y., Ju L., Zhu C., Identification and Characterization of Integrin 
alphaIIbbeta3 Intermediate Affinity State Induced By Gpibalpha 
Mechanotransduction. Blood: 126 (23). (2015). 
2. Xu X., Spring C., Ju L., Wang Y., Reheman A., Yang H., Jin J., Lei X., Yang 
Yan., Reddy E., Chen Y., Chen P., Zhu G., Marchese P., Zarpellon A., Zhang H., 
She Y., Cyr T., Zhu C., Freedman J., Tso P., Sean D., Ruggeri Z. M., Ni H., 
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Endogenous Thrombosis Inhibitor: Measurement of Single-Molecular Interactions 
By Biomembrane Force Probe. Blood: 124 (21). (2014) 
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1. Chen Y., Zhu C., Observing force-regulated purified integrin bending/extending 
conformational changes. (Manuscript in preparation) 
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2. Ju L.*, Chen Y.*, Xue L., Du X., Zhu C., Cooperative unfolding of distinctive 
mechanoreceptor domains transduces force into signals. (*Co-first authors). (Under 
review by Elife) 
3. Chen Y., Ju L., Zhou F., Zhu C., Mechanical Inside-out and Outside-in Signaling 
of Integrin αIIbβ3. (Manuscript in preparation) 
4. Xu X., Wang Y., Reheman A., Ju L., Spring C. M., Jin J. W., Yang H., Chen P., 
Yang Yan., Lei X., Chen Y., Zhang H., Song J., Zhang D., Carrim N., Zhu G., She Y., 
Cyr T., Liu G., Connelly P. W., Freedman J., Tso P., Marchese P., Zhu C., Davidson 
W. S., Ruggeri Z. M., Ni H., Apolipoprotein A-IV is a novel ligand of platelet aIIbβ3 
integrin and an endogenous inhibitor of thrombosis. (Manuscript in preparation) 
 
Inventions and Technology Upgrades                                                  
1. Mar. 2016, Chen Y., Ju L., Chen W., Zhu C., Micro-space Heater and 
Temperature Controller. (Georgia Tech Invention Disclosure No. 7219) 
2. Mar. 2016, Ju L., Chen W., Liu B., Chen Y., Zhu C., Fluorescence Biomembrane 
Force Probe. (Georgia Tech Invention Disclosure No. 7232) 
 
Awards                                                        
 Oct. 2015, ASH (American Society of Hematology) Abstract Achievement 
Award 
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 2013-2014, Molecular Biophysics Senior Student Award, Georgia Institute of 
Technology 
 Nov. 2009, Outstanding Student Award, Peking University 
 Nov. 2009, Sinopec Scholarship, Peking University 
 Dec. 2008, Fuqing Yang&Yangyuan Wang Academician Scholarship, Peking 
University 
 Nov. 2007, Baosteel Scholarship, Peking University 
 
Attended Meetings                                          
 07/22-07/27/2012, 2012 Gordon Research Conferences (Hemostasis), Waterville 
Valley, USA. 
Poster presentation, Chen, Y., Ju, L., Liu, B., Cruz, M., and Zhu, C., “Two-stage 
Adhesion Kinetics of Single Platelet to VWF and Fibronectin”. 
 10/24-10/27/2012, 2012 Biomedical Engineering Society Meeting, Atlanta, USA. 
Poster presentation, Chen, Y., Chen, W., and Zhu, C., "Observing Real-time 
Bending/unbending Conformational Changes of a Single Intergrin in a Cell-free 
System". 
 01/31-02/03/2014, XVIth Linz Winter Workshop, Linz, Austria. 
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Oral presentation, Chen, Y. and Zhu, C., "Observing Real-time 
Bending/unbending Conformational Changes of a Single Intergrin in a Cell-free 
System ". 
 07/27-08/01/2014, 2014 Gordon Research Conferences (Hemostasis), Waterville 
Valley, USA. 
Poster presentation, Chen, Y., Ju, L., and Zhu, C., “Identify an Intermediate 
Affinity State of Integrin αIIbβ3 Induced by GPIbα Mechanotransduction”. 
 06/30-07/03/2015, 2015 Society for Mathematical Biology Conference. Atlanta, 
USA. 
Mini symposium talk, Chen, Y., Ju, L., Jackson, S. and Zhu, C., “Identification 
and Characterization of an Intermediate State of Integrin αIIbβ3”. 
 11/07-11/11/2015, American Heart Association Scientific Session 2015. Orlando, 
USA. 
 12/05-12/08/2015, 57th American Society of Hematology Annual Meeting. 
Orlando, USA. 
Oral presentation, Chen, Y., Ju, L., Jackson, S. and Zhu, C., “Identification of 
Integrin αIIbβ3 Intermediate Affinity State Induced by GPIbα Mechanotransduction”. 
(Abstract Achievement Award Winner) 
Poster presentation, Chen, Y., Ju, L., Lou, J. and Zhu, C., “Force-induced 
cooperative unfolding of two distinctive domains in a single GPIbα molecule”. 
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Professional Associations                                                      
 Student Member of American Heart Association 
 Student Member of American Society of Haemotology 
 
Activities                                                      
 Invited talk, Charles Perkins Centre, The University of Sydney, Australia, 
Jan. 20th, 2016 
 The student speaker of Immunoengineering Seminar Series, Georgia Tech 
and Emory, 2015 
 The student speaker of Immunoengineering Seminar Series, Georgia Tech 
and Emory, 2014 
 The student speaker of Molecular Biophysics Seminar Series, Georgia Tech, 
2014 
 The student speaker of Biomechanics Meeting, Georgia Tech, 2013 
 
Teaching Experience                                                      
 Teaching Practicum, BMED 3400, Introduction of Biomechanics, advised by 
Prof. Lena Ting, Georgia Tech, 2014 
